THE CELLULAR NUCLEIC ACID BINDING PROTEIN REGULATES THE ALZHEIMER’S DISEASE β-SECRETASE PROTEIN BACE1 by Holler, Christopher J
University of Kentucky 
UKnowledge 
Theses and Dissertations--Molecular and 
Cellular Biochemistry Molecular and Cellular Biochemistry 
2012 
THE CELLULAR NUCLEIC ACID BINDING PROTEIN REGULATES 
THE ALZHEIMER’S DISEASE β-SECRETASE PROTEIN BACE1 
Christopher J. Holler 
University of Kentucky, cjholl4@gmail.com 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Holler, Christopher J., "THE CELLULAR NUCLEIC ACID BINDING PROTEIN REGULATES THE ALZHEIMER’S 
DISEASE β-SECRETASE PROTEIN BACE1" (2012). Theses and Dissertations--Molecular and Cellular 
Biochemistry. 12. 
https://uknowledge.uky.edu/biochem_etds/12 
This Doctoral Dissertation is brought to you for free and open access by the Molecular and Cellular Biochemistry at 
UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Molecular and Cellular Biochemistry by 
an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained and attached hereto needed written 
permission statements(s) from the owner(s) of each third-party copyrighted matter to be 
included in my work, allowing electronic distribution (if such use is not permitted by the fair use 
doctrine). 
I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive 
and make accessible my work in whole or in part in all forms of media, now or hereafter known. 
I agree that the document mentioned above may be made available immediately for worldwide 
access unless a preapproved embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s dissertation 
including all changes required by the advisory committee. The undersigned agree to abide by 
the statements above. 
Christopher J. Holler, Student 
Dr. M. Paul Murphy, Major Professor 
Dr. Michael Mendenhall, Director of Graduate Studies 
 
 
 
 
 
 
 
 
THE CELLULAR NUCLEIC ACID BINDING PROTEIN REGULATES  
THE ALZHEIMER’S DISEASE β-SECRETASE PROTEIN BACE1 
 
 
 
 
________________________ 
 
DISSERTATION 
________________________ 
 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy in the  
Department of Molecular and Cellular Biochemistry 
at the University of Kentucky 
 
 
 
By 
 
Christopher John Holler 
Lexington, Kentucky 
Director: Dr. Michael Paul Murphy, Professor of Molecular and Cellular Biochemistry 
Lexington, Kentucky 
 
 
Copyright © Christopher J. Holler 2012 
 
 
 
 
 
 
 
Abstract of Dissertation 
THE CELLULAR NUCLEIC ACID BINDING PROTEIN REGULATES 
THE ALZHEIMER’S DISEASE β-SECRETASE PROTEIN BACE1 
Alzheimer’s disease (AD) is the most common neurodegenerative disease affecting the 
elderly population and is believed to be caused by the overproduction and accumulation 
of the toxic amyloid beta (Aβ) peptide in the brain. Aβ is produced by two separate 
enzymatic cleavage events of the larger membrane bound amyloid precursor protein, 
APP. The first, and rate-limiting, cleavage event is made by beta-secretase, or BACE1, 
and is thus an attractive therapeutic target. Our lab, as well as many others, has shown 
that BACE1 protein and activity are increased in late-stage sporadic AD. We have 
extended these findings to show that BACE1 is increased in the earliest stages of AD 
before the onset of significant Aβ accumulation, indicating a potential causal role in the 
disease. Interestingly, BACE1 mRNA levels are unchanged in AD, leading to reason that 
a post-transcriptional method of BACE1 regulation is altered in disease. To date, the 
mechanism for this aberrant post-transcriptional regulation has not been elucidated. This 
study has implicated the cellular nucleic acid binding protein (CNBP), a highly conserved 
RNA binding protein, as a positive regulator of BACE1 translation, with implications for 
the etiology of sporadic AD. CNBP overexpression in cultured cells or spiked into a cell-
free in vitro translation system increased BACE1 protein expression without affecting 
BACE1 mRNA levels. Knockdown of CNBP reduced BACE1 protein and mRNA 
slightly. Furthermore, CNBP associated with BACE1 mRNA in cell lysates and bound 
directly to the BACE1 5’ UTR in vitro, which confers most of the regulatory activity. 
Importantly, CNBP was increased in the progression of AD and correlated with BACE1 
expression. Cellular stressors (such as glucose deprivation and oxidative stress) that occur 
in the AD brain increase BACE1 translation and we have found that these stressors 
increased CNBP expression as well. Early experimental evidence suggests that CNBP 
may enhance BACE1 translation through a cap-independent mechanism, which is an 
alternative translational pathway activated by cell stress. These studies indicate that the 
RNA binding protein CNBP is a novel trans-acting factor important for the regulation of 
BACE1 protein production and may be a viable therapeutic target for AD. 
Keywords: Alzheimer’s Disease, BACE1, CNBP, RNA Binding Protein, Translation  
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CHAPTER ONE: Introduction 
 
Alzheimer’s Disease 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the 
most common type of dementia affecting the elderly population. Current reports estimate 
that over 5 million Americans and ~35 million persons worldwide have AD, and without 
effective therapeutic interventions those numbers could rise to over 15 million and 100 
million respectively by 2050 ([1], Alzheimer’s Disease International World Alzheimer 
Report, 2011). Such a drastic increase would bring with it an exponential rise in 
healthcare costs and additional hardships on families caring for those with AD. While 
there are currently no effective treatments for the prevention or cure of AD, significant 
advancements in understanding the underlying mechanisms of the disease have been 
made over the past 30 years that will potentially yield promising therapeutic 
breakthroughs in the near future. 
Clinically, AD is characterized by a progressive loss in memory, impairments in 
language and intellectual capacity, behavioral changes and physical deterioration that 
ultimately leads to death [2, 3]. There are two major pathological lesions in the AD brain: 
(1) intracellular neurofibrillary tangles composed primarily of the hyperphosphorylated 
tau protein and (2) extracellular neuritic plaques composed largely of the amyloid-beta 
peptide (Aβ). These two hallmarks of the AD brain are believed to be connected through 
the amyloid cascade hypothesis [4, 5], in which age-dependent accumulations of Aβ drive 
the disease process and trigger a number of downstream events including the formation 
of tangle pathology, resulting in substantial neuronal loss and cognitive impairment. As 
AD is sometimes difficult to distinguish from other dementias or even normal aging, a 
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definitive diagnosis can only be made by analyzing the post-mortem brain for the key 
pathological lesions. Familial, early-onset AD (FAD) cases are rare (<0.5% of all cases) 
[6] and result from mutations either in the precursor protein from which Aβ is derived 
(amyoid-β precursor protein; APP) [7] or the presenilins (PS1 or PS2) [8-10] which, as 
part of the γ-secretase complex, catalyze the final cleavage step of APP to generate Aβ 
[11]. The remaining AD cases are sporadic, with the same etiology as FAD; however, the 
causative agents of this form are varied and not well understood. Age is the most 
significant risk factor for sporadic AD, and aside from apolipoprotein E (APOE) 
genotype, there are few genetic clues available to assess additional risk for development 
of the disease [12]. Nevertheless, studies from FAD cases and various transgenic mouse 
models of AD (reviewed in [13]) have helped strengthen the case that Aβ is the causative 
agent of the disease and therapeutics aimed at reducing Aβ generation or accumulation 
should prove beneficial for the prevention or treatment of AD. 
APP Processing and Aβ Generation 
The Aβ peptide is excised from the large type I membrane protein APP by a series 
of membrane-bound endoprotease cleavage events [14]. APP processing occurs in two 
main pathways: non-amyloidogenic and amyloidogenic (Fig 1.1). Both of these pathways 
and the products they produce occur under normal physiological conditions; however, it 
is the increased shift towards the amyloidogenic pathway that leads to AD. The non-
amyloidogenic pathway begins with the cleavage of APP by an α-secretase (various 
metalloproteases such as ADAM9/10/17, TACE; reviewed in [15]) within the Aβ peptide 
region (Lys16-Leu17) and precludes formation of Aβ [14], instead producing a soluble 
APP fragment (sAPPα) and a membrane bound C-terminal fragment (CTFα) of 83 amino 
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acids (C83). C83 is then rapidly cleaved by the γ-secretase complex within the membrane 
to release a p3 peptide of uncertain function and the APP intracellular domain (AICD), 
which likely plays a role in signal transduction pathways [16-20]. Approximately 90% of 
APP is processed via the non-amyloidogenic pathway. However, the remaining APP may 
be cleaved first by a β-secretase, which generates sAPPβ and CTFβ (C99); C99 is then 
cleaved by γ-secretase to generate the mature 4 kDa Aβ peptide and AICD.  Recent 
studies have shown that sAPPβ can be further cleaved by an unknown protease to form a 
35kDa N-terminal fragment that is a ligand for the death receptor DR6; activation of DR6 
triggers caspase-6 mediated axonal pruning and may play a role in AD pathogenesis [21].  
The amyloidogenic pathway yields several Aβ species ranging in size from 37-43 
amino acids in length, due to the flexibility of γ-secretase cleavage within the membrane. 
The most abundant form produced is Aβ40 (~80-90%), and the most pathogenic is Aβ42 
(~5-10%) [4]. Aggregation of the more hydrophobic and fibrillogenic Aβ42 peptide 
results in deposition of insoluble, extracellular senile plaques in the brain ([22], reviewed 
by [23]). Recent advancements in the field have implicated various soluble Aβ oligomers 
as the most toxic Aβ species and are key targets for therapeutic intervention [24-26]. 
Although the normal cellular functions of APP and its various cleavage products remain 
elusive, growing evidence points to critical roles in the developing central nervous 
system (CNS) [27-29]. The role of APP in the adult brain, which remains highly 
expressed, warrants further study.  
Most emerging treatments for AD aim at minimizing Aβ production or enhancing 
Aβ clearance from the brain. As such, both β- and γ-secretase are considered prime 
therapeutic targets to combat AD [23, 30]. 
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Discovery of the Brain β-secretase: BACE1 
β-secretase, most commonly referred to as BACE1 (beta-site APP cleaving 
enzyme 1), provides the rate-limiting enzymatic activity needed to generate Aβ and was 
originally cloned by five different laboratories in 1999 using distinct isolation methods 
[31-35]. BACE1, located on chromosome 11, is an atypical, type I membrane-bound 
aspartic protease of the pepsin family (cathepsin D and E, pepsin A and C, and renin) 
[36]. Early experiments showed that BACE1 had all the characteristics of the major brain 
β-secretase. Enzymatic activity of BACE1 is highest at low pH (~4.5), consistent with 
localization to acidic intracellular compartments including endosomes and the trans-
Golgi network (TGN) and known β-secretase activity [32, 37]. Overexpression of 
BACE1 in cultured cells or transgenic animals results in a dramatic increase in Aβ 
production and APP cleavage products (sAPPβ or C99) and targeted antisense 
oligonucleotide knockdown of BACE1 reduces these products [32, 38]. In addition, 
recombinant BACE1 displays a preference for cleaving the FAD-causing Swedish 
mutation APP sequence (APPswe; β-site mutation KM  NL) over wild-type APP, 
consistent with β-secretase activity [32, 36].  
The most compelling piece of evidence proving that BACE1 is the major β-
secretase in the brain comes from BACE1 knock-out animals, generated by several 
groups [39-41]. BACE1-/- mice are devoid of any amyloid production or deposition in the 
brain, and are viable and fertile [40, 41]. BACE1-/- mice crossed with various APP 
transgenic mice have abolished amyloid pathology and improved cognitive capabilities 
[40, 42-44]. While at first BACE1-/- mice seemed normal and healthy, extensive 
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behavioral studies revealed subtle, although concerning, phenotypic abnormalities 
including increased anxiety, timidness, and mild deficits in spatial learning and memory, 
indicating that therapeutic-targeted BACE1 inhibition would not be without 
consequences [45-48]. Whether these unwanted side-effects would be reproduced in 
humans when BACE1 is inhibited remains an important question.  
A short time after BACE1 was discovered, the related enzyme BACE2, which 
maps to the obligate Down syndrome critical region of chromosome 21, was cloned [49-
51]. BACE1 and BACE2 are >65% homologous, indicating that BACE2 may be an 
alternative β-secretase [51, 52]. Indeed, BACE2 is able to cleave APP at the β-site 
(Asp+1) in vitro [53], but prefers to cleave APP within the Aβ peptide region at Phe+19 
and Phe+20 [53-55]. Additionally, while BACE1 is highly expressed in neurons [56-58], 
BACE2 is expressed at much lower levels in the brain and appeared mostly astrocytic 
[52, 56, 59]. BACE2/APP overexpressing mice do not have increased Aβ levels [60] and 
combined BACE1 and BACE2 knock-out animals have slightly enhanced morbidity over 
BACE1-/- mice [46], further indicating that BACE2 is likely a poor β-secretase candidate 
but has some essential, yet undefined roles in the CNS that may overlap with BACE1. 
While BACE2 may play a minimal, if any, role in sporadic AD, this enzyme may be of 
particular importance to individuals with Down syndrome, who harbor an extra copy of 
chromosome 21 containing both the APP and BACE2 genes [49, 51], and who invariably 
develop AD-like pathology by their early 40s [61, 62]. Altogether, extensive studies on 
BACE1 and BACE2 up to this point indicate that BACE1 is the major β-secretase 
responsible for Aβ production in the brain. 
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Synthesis, Maturation, and Trafficking of BACE1 
BACE1 is synthesized in the endoplasmic reticulum (ER) as a 501 amino acid 
pre-pro-enzyme with an N-terminal 21 residue ER-signal peptide followed by a 
prodomain from amino acids 22-45. The prodomain is cleaved by a furin-like convertase 
in the Golgi apparatus [52, 63, 64]. While studies have shown that immature BACE1 is 
able to cleave substrates [65], including APP, removal of the prodomain significantly 
increases its activity. This feature is distinct from traditional aspartic proteases in which 
the propeptide completely masks the active site of the enzyme, rendering it inactive until 
cleaved. The BACE1 catalytic domain consists of two conserved active sites (93-96 
D*SGT and 289-292 D*TGS; where * = catalytic aspartate residue) and is followed by a 
single membrane spanning region and a short C-terminal domain. The catalytic site of 
BACE1 faces the luminal side of the cellular compartments while the carboxyl terminus 
is cytoplasmic and is involved in trafficking of the enzyme. The structure of the catalytic 
active site of BACE1 has been solved [66] and there are numerous additional structures 
of BACE1 in complex with various inhibitors. A structure of the entire immature enzyme 
does not exist at this point. BACE1 likely functions as a dimer in the membrane in vivo, 
similar to its APP substrate [67-69]. Because BACE1 displays many features distinct 
from other aspartic protease family members, there is significant hope for designing 
fairly specific inhibitors against it.  
Mature, unglycosylated BACE1 has an estimated molecular weight of 65 kDa, 
while extensive modifications result in a BACE1 protein of about 75 kDa in its fully 
mature form. During maturation, BACE1 undergoes extensive post-translational 
modifications including N-glycosylation, acetylation, phosphorylation, and S-
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palmitoylation which are involved in subcellular localization and trafficking [36, 63, 64, 
70-73]. The palmitoylation of BACE1 enhances BACE1 localization to lipid rafts in the 
bilayer, which increases Aβ generation [74-76]; however subsequent studies showed that 
palmitoylated-deficient BACE1 processes APP as efficiently as raft-associated 
palmitoylated BACE1 [77].  
BACE1 is present in small quantities on the cell surface [70, 77] and is rapidly 
internalized and trafficked to endosomal compartments and the TGN, where it has 
highest activity at low pH (~4.5). BACE1 has a long half-life (8-16 hrs) [36, 70] 
compared to APP (3 hours) and may undergo numerous rounds of trafficking to the cell 
surface and back before ultimately being targeted to the lysosome for degradation [70]. 
Alternatively, BACE1 may be degraded by the proteosomal degradation pathway [78]. 
Several Golgi-localized γ-ear containing ARF (GGA) binding proteins recognize a 
dileucine (D496ISLL) motif on the carboxy terminus of BACE1 through a VHS domain 
[79]. GGA members sort various proteins, including BACE1, from the endosomes to the 
TGN and also transport ubiquitinated BACE1 to lysosomes for degradation [80-82]. 
Phosphorylation of Serine498 on BACE1 enhances the affinity of GGA proteins to 
BACE1 [83]. If the dileucine motif of BACE1 is deleted or mutated to alanines, the 
Ser498 mutated, or dominant negative GGA proteins overexpressed, BACE1 
accumulates in endosomes and results in increased Aβ generation [81, 84, 85]. In 
addition, GGA proteins (GGA1 and GGA3) are decreased in AD causing decreased 
BACE1 lysosomal degradation and increased co-localization of BACE1 with APP in 
endosomes leading to enhanced Aβ production [82, 85, 86]. GGA3 may be degraded in 
AD due to increased neuronal apoptosis, as it is a substrate for caspase-3 [82].  
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Another set of proteins, the Nogo/reticulon (RTN) family, is also involved in 
BACE1 trafficking, in this case to the endoplasmic reticulum (ER) [87, 88]. When RTN3 
is overexpressed in cells, the altered subcellular localization of BACE1 to the more 
neutral pH of the ER results in decreased BACE1 activity and Aβ production [89]. 
Monomeric RTN3 is reportedly decreased in the AD brain, reducing BACE1 ER 
localization and possibly contributing to AD pathogenesis [90]. Finally, BACE1 can be 
shed from the membrane surface through cleavage by a “sheddase” such as ADAM10 or 
TACE, which may result in decreased Aβ production since soluble BACE1 is unable to 
closely associate with the membrane-bound APP substrate [71, 91, 92]. However, in 
vitro, overexpression of soluble BACE1 can still cleave APP to produce Aβ [71], 
although the role and extent of BACE1 shedding in vivo remains unclear. Nevertheless, 
increased α-secretase activity (such as ADAM10) may reduce Aβ generation through 
cleavage of both APP and BACE1 [93]. 
   
BACE1 Substrates 
The physiological role of BACE1 is still an area of intense research and is critical 
for understanding the toxicity-based side effects that may arise by inhibiting BACE1 for 
therapeutic purposes. While APP is the most commonly studied substrate of BACE1 due 
to its role in AD, the fact that APP is a rather weak substrate for BACE1 (BACE1 prefers 
to cleave bulky residues such as Leu at the P-1 position found in the APPswe mutation) 
indicated additional BACE1 substrates likely existed. By studying similar amino acid 
sequences to that of APPswe and the phenotypes of BACE1-/- mice, many of these 
substrates are now known, which suggests an increasingly broad physiological role for 
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BACE1. These substrates include APLP1/2 (APP family members) [94-96], α-2,6 
sialytransferase (ST6Gal I) [97, 98], the P-selectin glycoprotein ligand-I (PSGL-I) [99], 
the interleukin-1 receptor type-II [100], the β-subunits of voltage-gated sodium channels 
(Navβ2) [101], the low-density lipoprotein receptor related protein (LRP-1) [102], and 
neuregulin-I/III (NRG-1, NRG-3) [103-105]. While a consensus cleavage sequence 
between known BACE1 substrates does not exist, there is a clear preference for single 
membrane-spanning substrates with a Leu or Phe at the P-1 position and a charged 
residue at the P+1 position [37, 66]. 
BACE1 cleaves APP at the β site (Asp+1) and β’ site (Glu+11) [32], both of 
which result in production of amyloid-beta peptide after cleavage by γ-secretase. 
Cleavage at the β site is most common and leads to the typical Aβ peptides of 40-42 
amino acids while cleavage at the β’ site is most commonly used in rodents (and also 
seen in vitro when BACE1 is overexpressed) and may also contribute to a significant, yet 
largely unstudied pathogenic Aβ population [106, 107]. The related enzyme BACE2 can 
also cleave APP at the β site [53, 108] but prefers to cleave within the Aβ sequence at 
Phe+20 and Ala+21, precluding pathogenic Aβ generation [53, 55, 91, 108, 109]. 
Overexpression of BACE2 can reduce Aβ [110] and since BACE1 and BACE2 can 
compete for substrate in vitro, it has been postulated that BACE2 acts as an alternative α-
secretase [54, 55, 91]. However, because BACE1 largely resides in neurons and BACE2 
in glia, it is unclear what role, if any, BACE2 has on the pathogenesis of AD in vivo. APP 
homologs APLP1/2 also undergo α, β, and γ-secretase cleavage but do not produce Aβ or 
related peptides, and the in vivo function of these products are not fully elucidated [94-96, 
111]. Cognitive and emotional deficits reported in various BACE1-/- mice appear to be 
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largely attributed to impaired APP processing, indicating key physiological roles for β-
site derived APP products [42]. 
Two other BACE1 substrates that are of particular interest are the neuregulins 
(NRG-1 and NRG-3) and the β-subunits of voltage-gated sodium channels (Navβ2). 
Neuregulins are ligand members of the Erbβ family of receptor-tyrosine kinases that have 
numerous roles in the CNS, including synaptic formation and maintenance, myelination 
of axons, and neurotransmitter expression and function [103-105]. The voltage-gated 
sodium channels regulate membrane excitability and play crucial roles in propagating 
action potentials in the CNS and peripheral nervous system (PNS). Close examination of 
the subtle phenotype of BACE1-/- mice revealed deficiencies in myelination of neurons in 
the PNS and CNS [103, 104] and alterations in the inactivation of voltage-gated sodium 
channels [46]. These events help explain some of the phenotypic abnormalities, i.e. 
hyperactivity, schizophrenic-like behavior, and epileptic symptoms of the BACE1 null 
mice [112]. Increased BACE1 expression (as in AD) or inhibiting BACE1 (as a 
therapeutic strategy) [113] both result in neurological deficits, a result of the increasingly 
broad physiological role of BACE1. Therefore, optimal BACE1 therapeutic treatments 
must focus on reducing rather than abolishing BACE1 activity in vivo, a task that has 
been challenging to this point. 
 
BACE1 Expression and Regulation in Normal and AD Brain  
BACE1 is found only in vertebrates, which was a first clue to its possible role in 
complex systems such as the brain and immune system. BACE1 is expressed in most 
tissue types, with highest levels in the CNS and lower levels in peripheral tissues [32, 
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33]. Interestingly, BACE1 is also expressed at high levels in the pancreas, where several 
largely inactive isoforms exist [114, 115]. In the brain, BACE1 is expressed primarily in 
neurons, consistent with the major Aβ-producing cell type [39], although BACE1 is 
upregulated in and around reactive astrocytes as well [116, 117]. Since astrocytes 
outnumber neurons by an order of magnitude in the brain, even a small increase in 
BACE1 in these cells could play a role in AD pathogenesis.  
BACE1 undergoes complex regulation at both the levels of transcription and 
translation (Fig 1.2). The upstream promoter region of BACE1 has been characterized 
[58, 118-120] and contains several binding sites for common transcription factors such as 
AP-1, AP-2, HSF-1, NF-κβ, PPARγ, YY1, MZF1, HNF-3β, HIF1α, STAT1/3 and Sp1 
(reviewed in [121]). Overexpression of Sp1 increases BACE1 transcription and 
knockdown of Sp1 reduces, but does not abolish BACE1 transcription, indicating 
dependence on additional transcription factors [118]. For example, NF-κβ signaling can 
repress and upregulate BACE1 transcription [122] and increasing evidence points to a 
role for PPARγ, which is involved in inflammatory response, in BACE1 regulation. 
Inflammation is an early event in the development of AD and has been a target for 
numerous AD therapeutics (reviewed in [123]). The use of certain non-steroidal anti-
inflammatory drugs (NSAIDs) potentially reduced the risk of AD in epidemiological 
studies [124] and altered amyloid metabolism in vitro [125]. NSAIDs, such as ibuprofen, 
can target PPARγ directly to suppress BACE1 gene expression in cell culture [126]. A 
selective agonist of PPARγ, pioglitazone, reduced both BACE1 mRNA and protein in 
APP transgenic mice [127]. PPARγ agonists such as pioglitazone and rosiglitazone have 
been approved for treatment of type II diabetes and produce few negative side effects, 
11 
 
indicating they may be useful in treating AD as well. The JNK/c-jun signaling pathway 
has also been implicated in BACE1 transcriptional regulation during oxidative stress 
conditions and may involve a positive feedback mechanism dependent on γ-secretase 
activity and Aβ42 production [128-130]. 
A hallmark of AD is impaired glucose metabolism [131] and BACE1 displays 
many characteristics of a stress response protein. Treatment of cells with drugs that 
impair energy metabolism led to increased levels of BACE1 and Aβ in the brain by 
approximately 2-fold [132]. In addition, BACE1 is upregulated in response to numerous 
stressor events such as hypoxia [133], ischemia [134], oxidative stress [135, 136], 
traumatic brain injury [137], cholesterol content [138, 139], viral infection [140], and 
altered calcium homeostasis [141]. A small increase in BACE1 activity is also seen in 
normal aging in rodents, monkeys, and humans [142], which may be related to these 
events. In the future, it will be important to determine which specific pathways of 
BACE1 regulation are affected in AD compared to other stress events, and how this 
influences the overall etiology of the disease process. 
The human BACE1 5’ untranslated region (UTR) is unusually large (~446 nt), 
has a high guanine-cytosine (GC) content (77%), and contains three upstream open 
reading frames (uORFs) similar to other stress response proteins - all indicators of a 
protein under tight translational regulation [143-145]. It is also highly conserved with 
other vertebrates, suggesting a critical role in regulation (Fig 1.3). The BACE1 5’ UTR 
inhibits BACE1 translation [146], likely owing to the presence of the uORFs and a high 
degree of secondary structure which may impede efficient ribosome initiation and/or 
scanning mechanisms [143-145, 147]. Although translation initiation may occur at three 
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of the four uAUGs [143-145, 148], it is unknown whether any functional peptides are 
synthesized. The 3’ UTR of BACE1 is also extremely long and is of variable length; it 
likely plays a role in stabilizing the mRNA and controlling expression through several 
microRNA binding sites [149-151]. MicroRNAs are short noncoding RNA species that 
target the 3’ UTRs of specific genes and either inhibit translation or lead to mRNA 
degradation [152]. The loss of a specific microRNA cluster led to increased BACE1 
expression, but only in a subset of AD patients [150]. In addition, a non-coding BACE1-
antisense RNA that stabilizes BACE1 mRNA was increased in AD patients [153]. 
BACE1 activity in AD may be enhanced by increased direct association with the 
lipophilic mediator molecule sphingosine-1-phosphate [154] while BACE1 half-life, and 
subsequent Aβ generation, was reported to be increased by the lipid second messenger 
ceramide, which is elevated in the brain of AD patients [155]. Alternative splicing events 
also affect BACE1 expression levels. Several BACE1 variants that display little or no 
activity exist due to alternative splicing [156]. Recently, it was reported that a G-rich 
element in exon 3 of BACE1 regulates splice site selection through formation of a G-
quadruplex (G4) structure mediated by heterogeneous nuclear ribonucleoprotein H 
(hnRNP H); knockdown of hnRNP H resulted in decreased full-length BACE1 mRNA 
[157]. These studies indicate that several post-transcriptional events likely contribute to 
the sustained increase of BACE1 in AD. 
Many groups have looked at the expression and activity of BACE1 in the AD 
brain. Compared to healthy age-matched controls, BACE1 protein and activity are 
increased in brain regions affected by AD [158-162], although others have reported no 
change [163], or decreased levels [164]. One report indicated that only ~30% of sporadic 
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AD cases had increased BACE1 levels [150], possibly owing to the fact that most 
measurements are made from end-stage AD postmortem tissue, which could differ from 
early-stage AD BACE1 levels. The increase of BACE1 in the AD brain may contribute to 
enhanced Aβ production and advancement of the disease, especially if it occurs early in 
the disease process. For example, BACE1 is also increased in the cerebrospinal fluid 
(CSF) in patients with mild-cognitive impairment, a precursor to AD [165]. BACE1 
elevation seems to occur mostly in the neurons surrounding plaque deposits and in 
reactive astrocytes [166, 167].  
Interestingly, BACE1 mRNA levels appear largely unchanged in AD, indicating 
that a post-transcriptional control process may go awry in disease, accounting for the 
increased BACE1 protein levels [57, 159, 168-170]. BACE1 is highly regulated at both 
the transcriptional and translational levels, and in particular the 5’ UTR of BACE1 
appears be the major cis-element for translational regulation. While the BACE1 5’ UTR 
keeps translation relatively low in healthy individuals, translation occurs much more 
efficiently in AD through unresolved mechanisms. This observation leads to the 
speculation that certain trans factors, such as RNA binding proteins and/or translational 
machinery components, may be altered in AD, resulting in increased BACE1 translation.  
Recently, the phosphorylation of the eukaryotic initiation factor (eIF2α-P) has 
been implicated in the increased expression of BACE1 at the translational level [170, 
171]. eIF2 is a GTP-binding protein that mediates the delivery of the initiator methionine-
tRNA (Met-tRNAi) to the ribosome to initiate protein synthesis [172]. The activity of 
eIF2 is regulated by reversible phosphorylation of its α subunit by one of four different 
stress-induced kinases [173]. When eIF2α is phosphorylated during increased cellular 
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stress, the eIF2-GDP generated after each round of initiation becomes an inhibitor of the 
guanine nucleotide exchange factor, eIF2B, and the result is a reduction in exchange of 
eIF2-bound GDP for GTP. Since eIF2-GTP is needed to bind Met-tRNAi, 
phosphorylation of eIF2α effectively inhibits recycling of eIF2 for new rounds of 
initiation; the end result is reduced global translation. Interestingly, specific mRNAs that 
encode proteins responsible for critical stress-mediated cellular functions are 
preferentially translated upon eIF2α phosphorylation [173], and BACE1 appears to be 
one of these proteins. 
In one study, energy deprivation in cultured cells and primary neurons lead to 
increased levels of BACE1 which was shown to be mediated by increased eIF2α-P [170]. 
Treatment of APP transgenic mice with energy metabolism inhibitors increased 
phosphorylated eIF2α, BACE1, Aβ, and Aβ deposition [170]. In addition, an analysis of 
postmortem human brain samples found increased levels of phosphorylated eIF2α that 
correlated with increased BACE1 and amyloid levels [170]. The increase in BACE1 
translation due to eIF2α-P was hypothesized to occur through enhanced ribosomal scan-
through of the BACE1 uORFs, allowing for more initiation events to occur at the 
authentic BACE1 start codon; however, this mechanism has not been demonstrated 
experimentally [170]. Besides glucose deprivation, hydrogen peroxide (H2O2) has also 
been shown to increase BACE1 protein post-transcriptionally in a phosphorylated eIF2α-
dependent manner [171]. Oxidative stress, implemented by H2O2 and other reactive 
oxygen species (ROS), increases in the AD brain due to mitochondrial damage and is 
thought to play a significant role in the etiology of the disease [174-176]. A recent study 
indicated that initial cell stressor events may increase eIF2α phosphorylation and BACE1 
15 
 
expression, but once a certain level of amyloid pathology is obtained (and tangle 
pathology is initiated), the events are self-sustaining and cannot be reversed with partial 
BACE1 reduction [177]. This indicates that targeting of BACE1 and/or regulating factors 
must occur early in the disease process to have the most therapeutic value. Determining 
how BACE1 translation is regulated during times of cellular stress when eIF2α is 
phosphorylated may lead to novel therapeutic treatments. 
 
CNBP: Role in Disease and Development 
The cellular nucleic acid binding protein, or CNBP, is the protein product of the 
gene commonly known as ZNF9, but more recently referred to as “CCHC-type zinc 
finger, nucleic acid binding protein” by the Human Genome Organization Gene 
Nomenclature Committee. Even though CNBP was first identified more than 25 years 
ago, very little is known about how this protein functions. CNBP is strikingly conserved 
in vertebrates and mounting evidence suggests that it is a multifunctional single-stranded 
nucleic acid binding protein involved in basic biological functions. So far, CNBP has 
been implicated in two separate biological processes: the human disease myotonic 
dystrophy type 2 (DM2) and the embryogenesis of craniofacial/forebrain structures.  
Expansion of a CCTG tetranucleotide repeat in the first intron of the human 
CNBP gene causes DM2 [178]. DM2 is an autosomal dominant disorder that presents 
clinically with a broad-range multi-systemic phenotype including myotonia, muscle 
weakness and wasting, cardiac defects, cataracts, hypersomnia, some neurological 
deficits, and endocrinological problems [179]. It is believed that DM2 is primarily caused 
by a toxic gain-of-function in which long, untranslated CCUG repeats accumulate and 
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form RNA foci in the nucleus [180]. These nuclear foci form ribonucleoprotein (RNP) 
inclusions by sequestering several RNA binding proteins involved in various RNA 
processing events including splicing, stability, transcription, and translation [181]. 
However, a growing line of evidence suggests that CNBP loss-of-function may play a 
role in the pathogenesis of DM2 as well. For example, CNBP+/- mice haploinsufficient 
for CNBP have a phenotype similar to myotonic dystrophy with multisystemic 
abnormalities that can be reversed by crossing them with CNBP overexpressing mice 
[182]. Additionally, several groups have reported that cytoplasmic levels of CNBP are 
reduced in skeletal muscle satellite cells, myoblasts, and muscle biopsies from DM2 
patients [183, 184]. A reduction in CNBP coincided with a decrease in the translation of a 
number of 5’ terminal oligopyrimidine (5’ TOP) containing mRNAs that are direct 
targets of CNBP [184]. These targets are members of the translational machinery 
apparatus and include ribosomal protein S17 (RPS17), poly-A binding protein (PABP), 
and the eukaryotic elongation factors eEF1A and EF2. The overall effect was a reduction 
in global protein synthesis that could be reversed by reintroducing CNBP ectopically to 
cultured DM2 myoblasts [184, 185]. Finally, recent evidence suggests that CCUG repeats 
themselves can cause decreased CNBP expression and this is mediated through a post-
transcriptional mechanism, likely decreased protein translation or stability [186, 187]. 
While the exact mechanism for DM2 pathogenesis remains clouded, these studies have 
shed some light on the basic cellular roles of CNBP. 
In addition to DM2, CNBP plays a prominent role in embryonic development, and 
this area of research has provided important insights into the molecular actions of CNBP. 
CNBP is ubiquitously expressed in vertebrates with high levels occurring in the testis, 
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ovary, and brain [188, 189]. Analysis of CNBP during mouse embryonic development 
showed high mRNA expression in the forebrain, midbrain, craniofacial structures, and 
limb buds; in general, the highest levels of CNBP were seen where the highest rates of 
cellular proliferation occurred [189, 190]. Studies in chicken [191] and fish embryos 
[188, 192] showed similar expression profiles and indicated a conserved mechanism. 
Complete knockout of CNBP expression in mice is embryonic lethal due to incomplete 
forebrain development and craniofacial abnormalities [189]. About 40% of the newborn 
heterozygous mice had similar phenotypes, including growth retardation, smaller 
mandible, and lack of eyes, and died shortly after birth. This suggests that a certain 
threshold level of CNBP is necessary for proper development.  
CNBP appears to influence embryonic development primarily through 
transcriptional regulation of a number of genes. The evidence that CNBP binds to the 
CT-promoter element of c-Myc and causes its upregulation [193] and that CNBP-/- mice 
lack detectable levels of c-Myc [189] suggest that CNBP plays a role in stimulating cell 
proliferation and differentiation through c-Myc induction. In support of this, 
overexpression of a dominant negative form of CNBP downregulated c-myc expression 
in a species of toad (Xenopus laevis) [194]. In the chicken, CNBP knockdown also 
downregulated other genes involved in cell proliferation which led to forebrain truncation 
[191]. Experiments using Morpholinos that specifically knockdown CNBP in zebrafish 
embryos showed that the phenotype arising from CNBP deficiency is a result of 
abnormal gene expression and reduced cell proliferation in the neural crest [192], from 
which most craniofacial cartilage is derived [195]. Additionally, increased apoptosis and 
decreased cell proliferation was seen in these CNBP Morphants where CNBP was 
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knocked down [192]. The essential role of CNBP in craniofacial development has 
outlined a basic role in embryonic development; however, CNBP remains highly 
expressed in adult tissue, such as the brain, where its cellular functions are still unknown. 
 
Nucleic Acid and Protein Interactions of CNBP 
Human CNBP was originally identified as a zinc finger protein that bound to the 
sterol regulatory element from the hydroxymethylglutaryl-coenzyme A (HMG-CoA) 
reductase gene and negatively regulated its expression [196], although follow-up studies 
could not confirm this. Subsequent studies implicated CNBP as a negative transcriptional 
regulator of the early promoter-enhancer of the JC virus [197] and the beta-myosin heavy 
chain gene [198], as well as a positive transcriptional regulator of the macrophage 
colony-stimulating factor gene in fibroblasts [199], and the CT promoter element of the 
C-MYC proto-oncogene [193]. CNBP has also been implicated as a translational 
regulator. CNBP binds a G-rich sequence downstream of 5’ TOP structures in several 
mRNAs that are part of the translational machinery apparatus, although there is still some 
discrepancy as to whether CNBP acts as a positive [184, 200] or negative [201-203] 
regulator of their translation. Several studies have now shown that CNBP and its yeast 
homolog gis2p directly interact with translating polysomes, indicating a crucial role in 
translation [204-207]. Interestingly, CNBP also binds directly to the poliovirus internal 
ribosomal entry site (IRES) to stimulate cap-independent translation [200], an alternative 
method of translation involving internal initiation that occurs when canonical cap-
dependent translation is inhibited by various cellular stressors [208]. CNBP has been 
identified as an IRES trans-acting factor (ITAF) as part of a potential complex involved 
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in the cap-independent translation of the mouse [204] and human [205] ornithine 
decarboxylase (ODC1) genes. Since CNBP binds directly to the ODC1 IRES and also 
directly associates with translating ribosomes, it may function as a bridge between 
specific mRNAs and the translational apparatus.  
Although CNBP binds single-stranded nucleic acids, it also appears to participate 
in a number of protein-protein interactions. A large-scale proteomics screen in human 
cells identified numerous candidates for CNBP-interacting proteins through mass 
spectrometry [209]. The most abundant targets found were ribosomal proteins both of the 
large and small subunits as well as several heterogenous ribonuclear proteins (hnRNPs) 
and a number of other RNA binding proteins. A separate study that used tandem affinity 
chromatography followed by mass spectrometry identified CNBP as well as many other 
RNA binding proteins and ITAFs that bound the human ODC1 IRES sequence [204]. 
These studies corroborate with previous findings that CNBP associates with the 
translation machinery and that CNBP may be a member of an RNP complex with other 
ITAFs [204], although the exact functional consequences of these protein-protein 
interactions are unknown. 
 
CNBP Gene Structure and Functional Domains 
The human CNBP gene is located on the long arm of chromosome 3 and encodes 
a protein of 177 amino acids and has a predicted molecular weight of 19 kDa [210]. The 
amino acid sequence of CNBP is strikingly conserved in human, mouse, rat, chicken, and 
toad, indicating a basic biological function (Fig. 1.4). CNBP also has orthologs in insects, 
fish, lizard, shrimp [211], and yeast [212, 213], but not in plants or bacteria. Structurally, 
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CNBP consists of seven tandem CCHC-type zinc finger motifs of 14 amino acids each 
(C-φ-X-C-G-X3-H-X4-C, where φ is an aromatic amino acid and X is any amino acid) 
[214] connected by predicted intrinsically disordered linker regions [215]. Each zinc 
finger is formed through the coordinated interaction with a single divalent cation, with 
Zn2+ providing the most stability [193]; this interaction may help maintain the overall 
structure and stability of the protein. A glycine/arginine-rich region (RGG box) is located 
between the first and second zinc fingers, which is a common feature of many RNA-
binding proteins, such as the Fragile X mental retardation protein (FMRP) [216]. An 
alternative splice site in this region results in a slightly smaller β-isoform of 170 amino 
acids that has been reported in mammals [214] and X. laevis [217, 218], but whose role is 
unclear. In addition, CNBP contains a putative nuclear localization signal, 
P(KR/KK/RK)EREQ, and a putative proteolytic PEST (Pro, Glu, Ser or Thr-enriched) 
cleavage site. CNBP is localized to the nucleus and cytoplasm in mammalian, amphibian, 
chicken, and fish cells [189, 190, 211, 219-221], while the PEST sequence allows for an 
N-terminal truncated product that has been identified in amphibians [202, 220, 222]. The 
truncated form of CNBP lacks the first zinc finger and RGG box and may possibly 
function as a dominant negative mutant with important regulatory consequences [194]. A 
single, putative cAMP-dependent protein kinase (PKA) phosphorylation site of unknown 
function exists at the C-terminus of CNBP [223]. A second putative phosphorylation site 
for casein kinase II that is missing in the CNBP β-isoform has been suggested, but not 
confirmed [218].  
CNBP consists of 5 exons, with exon 1 containing the 5’ UTR and exon 5 
containing the majority of the 3’ UTR [214]. Exons 2-5 are highly conserved in all 
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species whereas the introns are more variable, with intron 1 being the longest amongst 
invertebrates [224]. The 3’ UTR of CNBP is also highly conserved indicating a likely 
regulatory role [219]. A putative promoter region was identified in mouse CNBP within a 
3 kb proximal region upstream of the transcriptional start site that contains potential 
recognition sequences for numerous common transcription factors including Sp1, AP-1, 
GATA-1/2/3, STAT, and C/EBP among others [190]. Additionally, putative promoter 
and regulatory elements were identified in intron 1 in zebrafish [225]. Interestingly, the 
canonical sequences for a TATA- or CAAT-box may be located very far from the 
transcription start site [190, 214]. 
 
CNBP Biochemical Activities and Molecular Mechanism of Action     
CNBP binds single-stranded DNA (ssDNA) and RNA, but not double stranded 
DNA [194, 215, 226], and has been implicated in the transcriptional and translational 
regulation of various genes. Evidence of CNBP localization to the cytoplasm, ER, and 
nucleus support this claim [220-222]. In the absence of crystallographic structures of 
CNBP alone or bound to nucleic acid molecules, the different structural domains of 
CNBP have been studied experimentally in an attempt to dissect their molecular function. 
The CCHC-type zinc fingers are structurally similar to those found in retroviral 
nucleocapsid (NC) proteins and, in fact, substitution of the human CNBP zinc fingers in 
place of the two human immunodeficiency virus 1 (HIV1) NC zinc fingers preserved 
viral structure and replication ability [227]. The HIV1 NC protein primarily functions in 
the assembly of virions and packaging of the genomic RNA [228]. The zinc fingers also 
interact with ssDNA and each of the seven zinc fingers were predicted to interact with a 
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single G nucleotide of an octonucleotide probe in silico [229]. Studies in X. laevis 
indicated that the presence of the zinc fingers is required but not individually necessary 
for achieving maximal binding activity to nucleic acids [194]. However, the RGG box 
was essential for RNA-protein binding while removal of the RGG box preserved a weak 
ssDNA binding activity. Microinjection of X. laevis embryos with CNBP that lacked the 
N-terminal zinc finger and RGG region, mimicking the proteolytic form, functioned as a 
dominant negative in vivo.  
CNBP can bind ssDNA as a monomer or dimer; however, CNBP binds to RNA as 
a preformed dimer [215, 230], leading to speculation that non-interconvertable pools of 
CNBP monomers and dimers exist; exactly how CNBP dimerization occurs is unknown. 
Analysis into the biochemical and molecular features of CNBP revealed that its preferred 
targets contain unpaired guanosine-rich stretches constrained by an organized sequence 
environment [215].  Additionally, it was shown using nucleic acid melting and annealing 
assays that CNBP acts as a nucleic acid chaperone through ATP-independent binding, 
remodeling, and stabilization of nucleic acid secondary structures [215]. As an example, 
a recent study revealed that CNBP enhanced C-MYC transcriptional activity by 
promoting parallel G-quadruplex (G4) formation; however, CNBP does not actually bind 
the G4 structures [231]. The chaperone activity appears to depend on the N-terminus of 
the protein where the first zinc finger and RGG box reside [215]. Since G4 structures are 
also present in RNA, CNBP may influence translation through remodeling G-rich 
specific sequences. 
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Rationale for Study 
BACE1 is the rate-limiting enzymatic activity needed to generate the toxic Aβ 
peptide that is believed to be the causal agent of Alzheimer’s disease. Studies in our lab 
as well as others have shown that BACE1 protein and activity are increased in AD, which 
may underlie the etiology of the disease. Increased BACE1 in AD occurs in the absence 
of increased mRNA levels, indicating a change in post-transcriptional regulation. This 
raises an intriguing question about the regulatory mechanisms that govern BACE1 
translation and how they may be altered in disease states. We do not yet fully understand 
how BACE1 is translated under normal conditions, let alone during cellular stress or 
disease processes.  
Recently, our lab identified CNBP as a potential regulator of BACE1 (MPM, 
unpublished data). The purpose of this study was to determine if CNBP is a bona fide 
regulator of BACE1 expression and if so, to determine how CNBP might carry out this 
function. This study progresses the field of knowledge of both BACE1 regulation and 
CNBP molecular function, and has important implications for both Alzheimer’s disease 
and myotonic dystrophy type 2. 
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Figure 1.1 APP Processing Pathways and Aβ Generation. Top, Constitutive 
processing of APP by α-secretase (left) results in a secreted, soluble APP fragment 
(sAPPα) and a membrane-bound C-terminal fragment (C83), which is rapidly cleaved by 
the γ-secretase complex within the membrane to liberate the p3 peptide. Approximately 
90% of APP is processed by this pathway which precludes Aβ generation. However, 10% 
of APP may be first cleaved by β-secretase (right) producing sAPPβ and C99. C99 in turn 
is cleaved by γ-secretase to produce the Aβ peptide. Both pathways produce the APP 
intracellular domain (AICD) after γ-secretase cleavage. Bottom, A schematic of the Aβ 
peptide region (1-42) shows the locations of various proteolytic cleavage events at the β, 
β’, α, and γ sites. The locations where BACE1 and BACE2 cut are labeled, along with the 
Swedish mutation (NL) that enhances β-secretase cleavage in familial AD cases. 
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Figure 1.2 BACE1 is Regulated at Various Stages of Expression. BACE1 
transcription is variably regulated by its promoter region which contains binding sites for 
many transcription factors such as NF-κβ, Sp1, and PPARγ among others. BACE1 
transcription can also produce alternative splice forms which lack enzymatic activity or a 
stabilizing antisense transcript. Translation of BACE1 is highly regulated by numerous 
mechanisms including its own 5’ UTR which is extremely long, highly structured, and 
contains three upstream open reading frames (red boxes); all of which likely contribute to 
an inhibitory effect. The BACE1 3’ UTR may be variable in length and its role in 
regulating translation is largely unknown. Several microRNAs can bind to the 3’ UTR 
which results in decreased transcript stability. Under conditions of energy deprivation, 
increased phosphorylation of translation initiation factor eIF2α leads to enhanced BACE1 
translation. BACE1 protein levels may be regulated by altered subcellular localization 
through interactions with shuttling proteins or through degradation pathways. In AD, 
BACE1 protein and activity are increased without noticeable changes in mRNA levels, 
indicating that post-transcriptional regulation is altered in disease. See text for additional 
details.   
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Figure 1.3 The BACE1 5’ UTR is Conserved in Vertebrates. The BACE1 5’ UTR in 
human, mouse, and rat is long (446-nt, 428-nt, and 427-nt, respectively) with a high GC-
content (~77%, 68%, and 67%, respectively). The sequence identity between human and 
mouse or rat is 72.1 and 72.7%, respectively. Sequences highlighted in yellow indicated 
non-conserved regions between human and mouse/rat. The boxed sequences correspond 
to the three conserved uORFs, which may or may not be translated in various cell types. 
Start codons (ATG) are shown underlined in bold. There are four uATGs present; 
however, the third uATG is immediately followed by a stop codon (TAG). The last ATG 
indicate the authentic BACE1 start codon. 
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Figure 1.4 CNBP is Strikingly Conserved in Vertebrates. CNBP sequence similarity is 
>90% conserved in most vertebrates, and human CNBP sequence similarity between 
mouse and rat is 99% and 100%, respectively. Human and toad (Chaunus arenarum) 
CNBP are 94% conserved. Highlighted sequences indicate non-conserved regions. CNBP 
contains seven CCHC-type zinc fingers and an RGG region between the first and second 
zinc fingers; these regions are critical for carrying out CNBP’s interactions with ssDNA 
and RNA molecules. Full-length human CNBP is 177 amino acids in length, but an 
alternative splice site exists in the RGG region which produces a shorter CNBPβ isoform 
(170 amino acids) of unknown function. A putative PEST proteolytic cleavage site occurs 
after serine 50, which produces a truncated dominant negative protein observed in 
amphibians, but has not been found in human, mouse, or rat. A putative PKA 
phosphorylation site of unknown function exists at the C-terminus. 
 
 
 
Copyright © Christopher J. Holler 2012 
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CHAPTER TWO: General Materials and Methods 
 
Plasmids and Reagents 
The pCMV6-XL5 empty and human CNBP vectors were purchased from Origene 
Technologies. The HuSH 29-mer short-hairpin vectors (pGFP-V-RS: empty, scrambled, 
and CNBP [TAGTTTGGTAGAGGTGTTATGTATAATGC]) as well as recombinant 
full-length human CNBP protein with C-terminus DDK (i.e. Flag) tag were also 
purchased from Origene. The pCMV6-XL5 human BACE1 construct (Origene) with 5’ 
and 3’ UTRs was a kind gift from Dr. Pete Nelson (University of Kentucky; Lexington, 
KY). The pcDNA6.1-seAP vectors (with human BACE1 5’ UTR, 3’ UTR, both UTRs, or 
no UTRs) were kindly provided by Dr. Todd Golde (University of Florida; Gainesville, 
FL). The Chaunus arenarum (toad) wild-type CNBP construct (pGEX-2T GST-
CNBPWT) and recombinant proteins (GST-CNBPWT and GST-CNBP1-∆RGG) were a kind 
gift from Dr. Nora Calcaterra (National University of Rosario, Argentina). The human 
pcDNA3.1-hODC1-IRES dual luciferase vector was a kind gift from Dr. Andrew J. Link 
(Vanderbilt University; Nashville, TN). The rat BACE1 5’ UTR and null dual luciferase 
constructs (designated RP and RPh) were kindly provided by Dr. Vincent Mauro (Scripps 
University; San Diego, CA).  
To make the viral vectors, the CNBP cDNA was cloned into the XhoI / XbaI 
restriction sites in the pZac2.1 plasmid (CMV promoter driven; U Penn Viral Vector 
Core). The CNBP pZac2.1 plasmid, Adeno-helper plasmid, and rep / cap (AAV2) 
plasmids were then co-transfected using the polyethyleneimine (PEI) transfection method 
into HEK293A cells. Virus was harvested 72 hours later, either by iodixanol gradient or 
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filter kit, and reconstituted in PBS [232]. Empty vector virus was used as a negative 
control. 
 
Cell Line Cultures and Transfections 
All cell lines were purchased from ATCC. Human embryonic kidney (HEK293T 
or HEK293A), human SH-SY5Y (neuroblastoma), and mouse N2a (neuroblastoma) cells 
were cultured in Dulbecco’s Modified Eagle Media (DMEM; HyClone). Human H4 
(neuroglioma) cells were cultured in Opti-MEM media (Gibco) or DMEM. Media was 
supplemented with 10% heat-denatured fetal bovine serum (FBS; HyClone) and 1% 
Penicillin (5,000 Units/ml) / Streptomycin (5,000 µg/ml) (Pen-Strep; Lonza) unless 
otherwise specified. Cells were grown in a 37°C incubator under humidified conditions 
with 5% CO2. Plasmid transfections were performed as described in the text or figure 
legends with either FuGene 6 liposomal transfection reagent (Roche) or FuGene HD 
transfection reagent (Promega) at a 3:1 lipid:cDNA ratio. Transfections in SH-SY5Y 
cells were achieved via electroporation with an Amaxa Nucleofector using Amaxa Cell 
Line Nucleofector Kit V (Lonza) according to the manufacturer’s instructions for SH-
SY5Y cells. Pooled stable cells were made by transfecting shRNA vectors (empty, 
scrambled, or CNBP) into H4 cells and selecting for cells expressing the plasmids with 
1µg/mL puromycin (Sigma). Selective pressure was kept on the cells for approximately 
two weeks before pooling and freezing down plugs of cells. Prior to freezing, analysis of 
GFP expression by fluorescent microscopy indicated that the majority of the cells 
remaining expressed the shRNA plasmid for each cell line. 
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Primary Cell Culture and Viral Transductions   
Primary enriched cortical neuronal cultures were prepared from embryonic day 18 
Sprague-Dawley rats. Cortical tissue was dissected from the brain, washed three times in 
Minimum Essential Media (MEM; Invitrogen), and transferred to a new centrifuge tube. 
After the tissue had settled, the supernatant was removed and the tissue was washed with 
MEM two more times. Tissue was then dissociated in 0.25% trypsin (Gibco) for 7 min at 
37°C followed by repeated pipetting to aid in the process. The cells were then passed 
through a 0.22-micron nylon mesh (BD Falcon) and pelleted by centrifugation at 272×g 
for 3 min at 4°C. The supernatant was removed and the cells were resuspended in 
neurobasal (NB)/MEM (60%/40%) media (1 mL / brain). Cells were plated at the 
indicated concentrations on PEI-coated 35-mm dishes. After cells were attached (3-4 
hours later), cell culture media was replaced with fresh NB/MEM media. Half of the 
media was exchanged for fresh media every 2-3 days until experiments were started. 
Experiments began at 6 or 7 days in vitro (DIV). Cells were incubated at 37°C and 5% 
CO2 throughout. Primary astrocyte cultures were prepared the same as for neurons except 
after dissociation of cortical tissue with 0.25% trypsin, cells were diluted into 1× MEM 
(Invitrogen) and transferred to a 75 cm2 flask. Cells were grown for approximately 2 
weeks at 37°C and 5% CO2 to allow for neurons to die-off and for astrocytes to reach 
confluency. Afterwards, cells were trypsinized, counted, and grown in 10 cm dishes in 
MEM until use. 
Primary rat cortical neurons were transduced with AAV2 viral vectors according 
to published methods [233]. Briefly, approximately 1 million neurons were plated onto 
PEI-coated 35 mm dishes. On DIV 7, virus was diluted into NB/MEM media and applied 
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directly to each dish in triplicates. The starting virus concentration was estimated to be 
5×1010 genome copies / mL using QuickTiter AAV Quantitation Kit (Cell Biolabs, Inc.). 
Since we had observed some toxicity in other cell lines with high CNBP overexpression, 
we chose to use a low multiplicity of infection (MOI) of 0.1. After 4 days, 0.5 mL fresh 
NB/MEM media was added to each dish to replenish nutrients. Seven days after 
transduction, cells were harvested for biochemical analysis. 
 
Protein Extraction, SDS-PAGE, and Western Blotting  
Cells were lysed in ice cold radioimmunoprecipitation (RIPA) buffer (50 mM 
Tris-Base, pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-
100) supplemented with complete protease inhibitor (PIC) cocktail + EDTA (Amresco) 
followed by brief sonication or freeze-thaw fracturing at -80°C to enhance cell lysis. The 
lysates were cleared by centrifugation for at least 5 minutes at 20,000×g and 4°C to 
remove insoluble cellular debris. Human samples were homogenized in 1× PBS or 2% 
SDS (w/v) supplemented with protease inhibitors, unless otherwise indicated. The total 
amount of protein was determined by bicinchoninic (BCA) assay (Pierce Biotechnology).  
SDS-PAGE samples were prepared in Laemmli buffer (2% SDS, 10% glycerol, 
62.5 mM Tris-HCl, 0.002% bromophenol blue) with 10% (v/v) β-mercaptoethanol 
(BME), and heated to 70ºC for 15 minutes prior to loading. Equal protein amounts were 
loaded per lane on a range of Criterion (Bio-Rad Laboratories) or Nu-PAGE (Invitrogen) 
precast SDS-PAGE gels in MES, MOPS, or Tris-glycine running buffer and electrically 
transferred to 0.45 μm nitrocellulose or polyvinylidine fluoride (PVDF) membranes (Bio-
Rad Laboratories). For spot blots, protein extracts were diluted in 1× PBS to 20 µg/mL 
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and 50 µL (1 µg total protein) was loaded into each well of a MINIFOLD I Spot Blot 
system (Whatman). Proteins were spotted onto a 0.45 μm nitrocellulose membrane via 
vacuum filtration. Membranes were typically blocked overnight at 4°C with 1% BSA / 
2% BlockAce (Serotec) in 1× PBS, pH 7.4 (Fisher Scientific).  
Blots were incubated in the indicated primary antibody (usually 1 μg / mL) for 1-
2 hours at room temperature (RT), and in secondary antibody (1:5000 – 1:20,000 
dilution) for 30 minutes to 1 hour at RT. Primary antibodies were diluted in TBST buffer 
(1× Tris-Buffered Saline (TBS) + 0.1% Tween-20; Fisher) with 5% non-fat dried milk or 
5% bovine serum albumin (BSA; Calbiochem). Horseradish peroxidase (HRP) 
conjugated secondary antibodies (Pierce Biotechnology) were diluted in TBST + 5% 
milk. Between antibody applications, blots were washed 3 × 10 minutes in TBST buffer. 
A final wash in TBS for 5 minutes served to remove the detergent. Membranes were 
incubated with enhanced chemiluminescent detection substrate (West Dura or West Pico; 
Pierce Biotechnology) for 5 minutes followed by exposure to autoradiographic film (ISC 
Bioexpress; Fisher Scientific). Films were developed using a Kodak X-OMAT 2000A 
processor (Eastman Kodak Company). Densitometric analysis of protein bands was 
conducted using freely available Scion Image software (http://www.scioncorp.com/). 
Primary antibodies used were as follows: BACE1 was detected using mouse 
monoclonal MAB931 (BACE1 ectodomain, R&D Systems), rabbit monoclonal D10E5 
(Cell Signaling), or rabbit monoclonal EPR3956 (Epitomics). BACE2 was detected using 
rabbit polyclonal Ab5670 (amino acids 441-457; Abcam). CNBP was detected using a 
rabbit polyclonal antibody raised against the C-terminal 20 amino acids of CNBP, which 
is conserved in multiple species including human and rodents [234]. This antibody 
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recognizes one band of approximately 20-24 kDa, depending on the ladder used. β-Actin 
(AC15, Sigma), β3-Tubulin (Abcam) and GAPDH (Abcam) were detected using 
common commercial antibodies. Recombinant BACE1 or BACE2 protein (R&D 
Systems) was sometimes run as a marker for molecular weight comparison. 
 
Reverse Transcription-PCR and Quantitative Real-Time PCR 
For RNA isolation from brain, 100 mg of frozen tissue was homogenized in 
TRIzol reagent (Invitrogen) followed by phenol/chloroform extraction and ethanol 
precipitation, as per the manufacturer’s instructions. RNeasy cleanup columns (Qiagen, 
Valencia, CA) were run for each sample. Total RNA was isolated from cell cultures using 
AllPrep DNA/RNA/Protein Mini-Prep kits (Qiagen) according to the manufacturer’s 
instructions. The reverse transcriptase (RT) reaction (iScript Select cDNA Synthesis Kit; 
Bio-Rad Laboratories) used 1 µg of RNA, purified RNase H, MMLV reverse 
transcriptase, and a mixture of random hexamers and oligo dT primers, according to the 
manufacturer’s instructions. General cycling conditions for quantitative real-time PCR 
(qPCR; MJ Opticon 4 or MiniOpticon thermal cyclers; Bio-Rad Laboratories) included a 
3 minute denaturation step at 95°C followed by 40 cycles of denaturation for 15 seconds 
at 95°C and annealing/extension for 45 seconds at 60°C. Standardization was performed 
to the geometric mean of a minimum of two housekeeping genes. qPCR reactions 
contained ~20 ng of sample cDNA together with PerfeCTA SYBR green SuperMix 
(Quanta Biosciences) unless otherwise specified. A melting curve was generated 
following cycling to assess the purity of amplification as well as visual inspection of PCR 
products on an 8% Tris-Borate EDTA (TBE) polyacrylamide gel (Bio-Rad Laboratories) 
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followed by SYBR gold staining and fluorescence imaging. All primer sets (Integrated 
DNA Technologies, Inc.) used in general qPCR experiments can be found in Appendix 
Two. 
 
Aβ Enzyme Linked Immunosorption Assay (ELISA) 
Aβ measurements were carried out using a well-characterized sandwich ELISA 
procedure, the details of which, including antibodies used, have been published 
previously [235-237]. Briefly, pellets from the initial sodium acetate (NaOAc) fraction 
used for β-secretase activity measurements (see Chapter Three) were serially re-extracted 
by brief sonication in 2% SDS+PIC (w/v) or RIPA buffer + PIC, followed by 70% (v/v) 
formic acid (FA). Sample extracts were stored frozen at −80°C until time of assay. 
Formic acid extracted material was initially neutralized by a 1:20 dilution in TP buffer (1 
M Tris base, 0.5 M Na2HPO4), followed by a further dilution as needed (1:100 to 1:400, 
final) in AC buffer (0.02 M sodium phosphate buffer, pH 7, 0.4 M NaCl, 2 mM EDTA, 
0.4% Block Ace (Serotec), 0.2% BSA, 0.05% CHAPS, and 0.05% NaN3). RIPA or SDS 
soluble fractions were diluted (1:5 to 1:100) in AC buffer alone. Immunoassay plates 
(Immulon 4HBX; Nunc) were coated with 0.5 μg / well of antibody, and blocked with a 
solution of Synblock (AbD Serotec) per manufacturer’s instructions.  
Total Aβ, Aβ40 and Aβ42 measures from human samples were performed using 
monoclonal antibody Ab9 (against the amino-terminus of Aβ) for capture. Total Aβ was 
detected with biotinylated 4G8, against Aβ17-24 (Covance), Aβ40 was detected with 
biotinylated 13.1.1 (own; QED Bioscience, Inc.), and Aβ42 was detected with biotinylated 
12F4 (Covance). Oligomeric Aβ was measured using the single-site 4G8/4G8 sandwich 
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ELISA [235]. Biotinylated antibodies were detected with HRP-conjugated NeutrAvidin 
(Pierce Biotechnology). A peptide standard curve of recombinant Aβ40 or Aβ42 
(rPeptides) was run on the same plate for comparison, and standards and samples were 
run at least in duplicate. Plates were developed with TMB reagent (Kirkegaard & Perry 
Laboratories), stopped with 6% o-phosphoric acid, and read at 450 nm using a BioTek 
multiwell plate reader. Aβ values were determined by interpolation relative to the 
standard curve. 
Rodent Aβ ELISAs were performed essentially as described for the human 
samples. Briefly, media from primary neuronal cultures were collected and supplemented 
with 1 mM EDTA, pH 8.0 prior to storage at -80oC until use. Media samples were 
centrifuged briefly to remove insoluble material and loaded onto 384-well plates neat 
(100 µL per sample). For rodent Aβ ELISAs, capture was performed using 34.2.1 
(against N-terminus; QED Bioscience, Inc.) and detection was performed using 
biotinylated 4G8. Recombinant rodent Aβ42 (rPeptide) was used to generate a standard 
curve.   
 
RNA Experiments 
All RNA experiments were done using RNase-free reagents and equipment 
including buffers, tips, tubes, gloves, glassware, etc. when possible to minimize any 
spurious contamination or degradation. 
 
Statistical Analysis 
Data were analyzed using SPSS software (SPSS Inc., Chicago, IL). Simple group 
comparisons were made using either Student’s t-test, or the Mann Whitney U-test, where 
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appropriate. Group data were analyzed by a general linear model ANOVA, co-varying 
for age, gender, PMI, and loading controls when necessary, and post-hoc comparisons 
performed using Dunnett’s test. Correlations were determined using either Pearson’s r or 
Spearman’s ρ where appropriate. Specific information regarding experimental replicates 
and statistical methods used are indicated in the figure legends. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Christopher J. Holler 2012 
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CHAPTER THREE: β-Secretase Expression is Increased in Early-Stage AD 
Tables and Figures are reproduced with permission from Holler et al. [238] 
                           
INTRODUCTION 
The amyloid cascade hypothesis remains the most definitive theory outlining the 
etiology of Alzheimer’s disease, stating that the abnormal production and deposition of 
amyloid beta in the brain drives the disease process [4, 5]. Mutations that cause familial 
AD result in mismetabolism of APP and increased levels of the more fibrillogenic Aβ42 
species. The more common sporadic AD cases also show increased Aβ production, but 
the reason why is less clear. Numerous therapeutic strategies have targeted decreasing 
production and/or enhancing clearance of Aβ from the brain; however, these 
interventions need to occur very early in the disease process to have the most benefit 
(reviewed in [239, 240]). 
Since its discovery in 1999, BACE1 has been a prime therapeutic target for the 
prevention of AD (reviewed in [241]). As BACE1 is needed for the initial cleavage event 
to generate Aβ from APP, blocking this crucial step should theoretically prevent the 
disease if implemented before a threshold level of Aβ can accumulate. In support of this, 
a rare mutation in APP (A673T) was recently discovered in an Icelandic population that 
prevents cleavage by BACE1 and ultimately protects these individuals against developing 
AD [242]. The increase in Aβ production and deposition in sporadic AD cases is likely 
due to a combination of factors, but several studies have now shown that BACE1 protein 
and activity are increased in late-stage AD brain tissue compared with age-matched 
controls [158-162]. This suggests that increased BACE1 expression may be at least 
partially responsible for the development of sporadic AD. Because BACE1 is also 
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increased by various cell stresses that occur in the AD brain, an important question arises: 
is the BACE1 increase in late-stage AD a cause of the disease or a consequence that helps 
potentiate it? A more definitive conclusion could be reached by studying so-called “early-
stage” AD cases. Considerably less is known about the homologous enzyme BACE2. 
Even though BACE2 can cleave APP at the β site, it does not appear to play a significant 
role in Aβ production in AD [55, 60, 108, 110]. Nevertheless, we have previously 
observed relatively high levels of BACE2 in the brain [162], and the role of BACE2 in 
disease and its relationship to BACE1 is unresolved. 
As a progressive neurodegenerative disease, the pathophysiology of AD likely 
begins years, if not decades, before the diagnosis of dementia [243]. As such, a clinical 
continuum of AD has been used to characterize groups of individuals that can be 
considered to be in the earliest stages of AD. Mild cognitive impairment (MCI) 
represents an intermediate stage between normal cognitive decline due to healthy aging 
and the more rapid decline typical of various dementias, including, but not limited to AD 
[244]. These individuals show small but significant declines on cognition-based 
questionnaires designed to screen for signs of dementia, such as the Mini-Mental State 
Exam (MMSE), and have increased risk for developing sporadic AD with approximately 
10-15% of MCI patients progressing to AD each year. MCI is the earliest stage of clinical 
dementia and most patients have significant neuropathological changes associated with 
AD upon autopsy as well.  Even though MCI represents an early stage in the progression 
of AD, many experts believe that therapeutic intervention at this step may already be too 
late due to an extensive accumulation of pathology that results in irreversible cognitive 
decline.  
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In light of this, researchers have begun to look for an even earlier time point in the 
disease and have outlined a broad category for a stage termed pre-clinical AD (PCAD) 
[243]. PCAD encompasses asymptomatic individuals who display the pathophysiological 
changes associated with AD, but who are indistinguishable from cognitively and 
clinically normal age-matched individuals. Normally, a diagnosis of PCAD can only be 
obtained by evaluating the brain pathology upon autopsy, but recent advancements in 
neuroimaging, cerebrospinal fluid (CSF) analysis, and cellular biomarker discovery have 
begun to detect these changes in vivo. PCAD cases may display slight cognitive 
deviations from their own baseline measures, but do not yet meet criteria for MCI. Since 
these two stages represent the earliest events in the progression towards AD, determining 
what pathological changes occur in the brain during these times could shed light onto the 
underlying mechanisms of the disease. Finding biomarkers that can accurately predict a 
future diagnosis of AD could allow for early intervention therapies to prevent or delay the 
progression towards dementia. 
Little information is available on how specific the changes to BACE1 in AD are 
compared with other neurologic diseases [245]. It is conceivable that BACE1 increases in 
other neurodegenerative diseases due to cellular stress; however it is unknown if this may 
play a role in the disease process since Aβ accumulation is not typical of other dementias. 
Comparing BACE1 expression between various neurodegenerative diseases may provide 
new information on how BACE1 is regulated and its role in disease processes. 
In this chapter, we have used various biochemical assays to analyze a large set of 
post-mortem brain tissue from control (cognitively normal), PCAD, MCI, and late-stage-
AD cases, as well as several cases of frontotemporal dementia (FTD), a 
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neurodegenerative disease distinct from AD. We used tissue from two brain regions – the 
superior and middle temporal gyri (SMTG), which is heavily affected in AD; and the 
cerebellum (CB), which is largely unaffected in AD, to study changes in BACE1 and 
BACE2 expression and how they relate to each other and to Aβ. We showed that BACE1 
is increased in the progression of AD in the SMTG tissue only, which indicates a possible 
causal role in the development of AD. Furthermore, we described evidence for the 
support that increased BACE1 expression is not limited to AD, but may occur in other 
neurodegenerative diseases as well. Interestingly, BACE2 expression mirrored that of 
BACE1 in all disease states, and BACE1 and BACE2 protein and activity were strikingly 
correlated, indicating a possible shared mechanism of regulation. Finally, we confirmed 
what numerous other groups have shown, that increased BACE1 protein levels are not 
accompanied by a corresponding increase in mRNA levels, emphasizing a change in 
BACE1post-transcriptional regulation in AD.  
 
METHODS 
Subjects 
Human tissue samples (Table 3.1) were obtained from the Alzheimer’s Disease 
Center tissue repository at the University of Kentucky, Sanders-Brown Center on Aging. 
Controls (n = 9) were age-matched to disease cases (preclinical AD, or PCAD: n = 10; 
amnestic mild cognitive impairment, or MCI: n = 7; AD: n = 10). Preclinical AD cases 
(sometimes also called high pathology controls) were defined as those that met the NIA-
Reagan neuropathology criteria for likely AD, but showed no clinical signs of dementia 
([246]; NIA, 1997). Amnestic MCI was defined according to the criteria of Petersen et al. 
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[244]. We included six cases of frontotemporal dementia (FTD) as an additional 
neurodegenerative disease, and as a specificity control [247]. Aβ is not considered to play 
a significant role in FTD. The details of the recruitment, inclusion criteria, and mental 
status test battery for our normal control group have been described previously [248]. 
Human tissue collection and handling followed guidelines issued by the PHS and the 
University of Kentucky IRB. 
 
Human Tissue Collection and Processing 
Details of our collection procedures and consensus diagnosis have been described 
elsewhere [249]. Briefly, brain weights were determined and a gross neuropathologic 
evaluation carried out at the time of autopsy. Tissue samples were dissected and 
immediately frozen or fixed in 4% paraformaldehyde. For histology (Fig 3.1), paraffin 
embedded specimens were cut at 8-μm, stained with hematoxylin-eosin, and the modified 
Bielschowsky method. Braak staging [250] was performed using Gallyas stained sections 
from ventromedial temporal lobe structures and Bielschowsky-stained neocortical 
sections. Neurofibrillary tangles (NFTs), diffuse plaques (DPs), and neuritic plaques 
(NPs) were counted using Bielschowsky stained sections. Plaques were counted using a 
10× objective (field size: 2.35 mm2) in the 5 most involved fields in each section. The 
most involved fields were determined by studying the whole section and marking it. 
Plaques were classified as DPs (plaques without neurites) and NPs (plaques with 
neurites) in each region. Neurofibrillary tangles were counted with a 20× objective (field 
size: 0.586 mm2), also in the 5 most involved fields.  
Frozen samples were homogenized using a PowerMax AHS200 in five volumes 
(w/v) of sodium acetate (NaOAc) buffer (10 mM NaOAc, 1.5 mM NaCl, 0.1% Triton X-
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100, 0.32 M sucrose, pH 5.0). The buffer was supplemented with PIC+EDTA and 100 
nM pepstatin A to inhibit aspartyl proteases; BACE1 and BACE2 are not inhibited by 
pepstatin A. Whole tissue homogenate was centrifuged at 20,800×g for 30 minutes at 4°C 
to pellet insoluble material. Pelleted material was sequentially extracted in an equal 
volume (0.7 mL) of RIPA buffer with PIC+EDTA or 2% SDS with PIC+EDTA followed 
by 70% formic acid (FA) for the determination of detergent soluble and insoluble Aβ, 
respectively. In each case the pellet was extracted by brief sonication (10 × 0.5 s microtip 
pulses at 100 W; Fisher Sonic Dismembrator, Model 500; Fisher Scientific) followed by 
centrifugation to pellet insoluble material (RIPA fraction: 20,800×g for 30 minutes; FA 
fraction: 20,800×g for 1 hr; both spins were performed at 4°C). Protein content was 
determined by BCA assay relative to bovine serum albumin (BSA) standards prepared in 
the same buffer. 
 
β-Secretase Activity Assays 
We recently described and validated the assays for BACE1 and BACE2 for 
human tissue in considerable detail, including reagent specificity [162]. This method is 
similar to that of Fukumoto et al. [142, 158]. Briefly, BACE1 (MAB931, raised against 
the BACE1 ectodomain; R&D Systems) or BACE2 (Ab1, raised against amino acids 
496–511 of BACE2; EMD Biosciences) antibodies were loaded onto a 384-well black 
opaque plate (Nunc) at 0.5 μg antibody / well (in 50 µL PBS) and incubated overnight at 
4ºC. The following day, the plate was blocked (Protein Free; Pierce) for 1 hr at RT. After 
blocking, the samples extracted in NaOAc buffer (100 µL) were loaded at least in 
duplicate onto the plate. A second set of samples, loaded in absence of antibody, served 
as controls for background activity. Further validation experiments were performed on a 
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subset of samples by using a different antibody, directed against the opposite end of 
BACE1 (C-terminus, EPR3956; Epitomics) or BACE2 (N-terminus, rabbit polyclonal 
Ab2; EMD Biosciences). The plate was washed extensively (at least 5 times) with 
NaOAc buffer, and then loaded with an octameric peptide substrate (1 μM) 
corresponding to the P4’ to P4 amino acids flanking the β-secretase site in the human 
APP sequence, and containing the human Swedish APPΔNL mutation (Peptides 
International, Lousiville, KY; EDANS/DABCYL conjugate, excitation/emission: 350 
nm/490 nm). Net fluorescence was measured after 2 hours at 37ºC using a BioTek plate 
reader. 
 
RESULTS 
BACE1 and BACE2 Protein and Activity Increase in Neurodegenerative Disease 
In an earlier study, we noted that BACE2 was nearly as abundant in human brain 
as was BACE1 in a small number of cases [162]. This was also true in this larger series 
of cases (Fig 3.2; compare band intensities to 100 ng recombinant standards for both 
BACE1 and BACE2). Overall, BACE1 (F4,32 = 2.89, p<0.04) and BACE2 (F4,32 = 2.87, 
p<0.04) activities were increased in neurodegenerative disease (Fig 3.3A,B). The 
increase occurred in a disease-affected region (the SMTG) but not in a brain region 
unaffected by disease (the CB). The same increases in the SMTG but not in the CB were 
seen for BACE1 (F4,32 = 5.87, p<0.001) and BACE2 (F4,32 = 15.03, p<0.0001) proteins 
(NaOAc fraction) using Western blot analysis (Fig 3.3C,D), when examined by 
densitometry. The results were unchanged when the data were not standardized to β-
Actin as a loading control. The results were also the same when MCI and PCAD cases 
were treated as a single, combined group (the amount of pathologic disease in these cases 
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is nearly identical; see Table 3.1). As expected from earlier assay validation studies, 
BACE1 and BACE2 activities were correlated with their respective protein bands 
detected by immunoblot analysis (BACE1: R2 = 0.17, p<0.006; BACE2: R2 = 0.21, 
p<0.002). These data indicate that an increase in BACE1 and BACE2 activities and 
protein levels likely occur at an early disease stage. 
We observed a striking correlation between BACE1 and BACE2 in human brain, 
a phenomenon observed with multiple antibody combinations and assay conditions. 
Using a standard assay for BACE1 (MAB931) and BACE2 (Ab1) activities, we found 
strong correlations between the two enzymatic activities in the SMTG (R2 = 0.9, 
p<0.0001) and the CB (R2 = 0.7, p<0.001), indicating that this was unrelated to disease. 
To confirm this finding, we repeated the assay using a different method. In the validation 
test, we reversed the orientation of the assay and used different antibodies, capturing 
BACE1 at the C-terminus (using EPR3956) and BACE2 at the N-terminus (using Ab2). 
BACE1 and BACE2 activities remained highly correlated in the SMTG (R2 = 0.64, 
p<0.001) and the CB (R2 = 0.47, p<0.001) (Fig 3.3E,F). We observed similar disease-
related increases in BACE1 and BACE2 using this alternate method (Fig 3.4). Finally, 
we examined the BACE1 (using MAB931) and BACE2 (using Ab5670) relationship by 
immunoblot analysis and detected a similarly strong correlation (R2 = 0.32, p<0.001). 
The correlation was significant regardless of whether the data were standardized to β-
Actin. Hence, the strong correlations between BACE1 and BACE2 proteins and activities 
were detected using different methods. Interestingly, we also detected a significant 
increase in both BACE1 and BACE2 activity and protein in frontotemporal dementia 
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cases (Fig 3.3A-D) compared to controls in the SMTG, but not the CB, indicating that 
increased β-secretase expression is not specific to AD.   
 
BACE1 and BACE2 mRNA Levels are Unchanged in Disease  
Since we observed increases in BACE1 and BACE2 in disease, we next wanted to 
determine whether changes in the β-secretase enzymes occurred only at the level of 
protein and activity or extended down to the mRNA level. The total amount of BACE1 or 
BACE2 mRNA did not change with disease state (Fig 3.5). The amounts of BACE1 and 
BACE2 mRNA correlated with each other in the SMTG (R2 = 0.48, p<0.001) and the CB 
(R2 = 0.72, p<0.001), but in neither case did the amount of total mRNA correlate with the 
amount of BACE1 or BACE2 activity or protein. These data indicate that, in disease, 
BACE1 and BACE2 protein levels are increased through a change in post-transcriptional 
regulation. 
 
BACE1 Activity is Related to Soluble but Not Insoluble Aβ in the Brain 
 We next decided to explore the relationship between BACE1 and Aβ in greater 
detail by studying human cases in which we had access to detailed neuropathology data. 
We detected a significant increase in total Aβ only in late-stage AD cases in both the 
SMTG and CB (p<0.01) (Fig 3.6). A trend of increased total Aβ in PCAD and MCI cases 
in the SMTG was observed, but was not statistically significant. There was no 
accumulation of Aβ in FTD cases, as expected. Neither BACE1 nor BACE2 activity 
could predict the number of diffuse plaques or neuritic plaques. BACE1 (R2 = 0.12, 
p<0.03) and BACE2 (R2 = 0.13, p<0.03) activities were significantly positively related to 
the amount of Aβ in the NaOAc-soluble fraction isolated from the SMTG in this case 
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series (Fig 3.7A,B). Although these relationships were modest, we found similar results 
in the CB in these same cases (data not shown). The NaOAc fraction is the first in the 
extraction series, contains the most soluble pool of Aβ peptides, and is also where 
BACE1 activity is localized [162]. There was no relationship between either BACE1 or 
BACE2 enzymatic activities and any form of Aβ (total Aβ, Aβ40, Aβ42, or oligomeric Aβ) 
extracted in the RIPA, SDS, or FA fractions (Fig 3.7C,D; FA fraction shown). Finally, 
the amount of BACE1 protein showed a slight positive correlation with the amount of 
SDS-extractable Aβ (R2 = 0.10, p=0.05). Taken together, these data suggest that BACE1 
(or BACE2) activity and protein are not particularly strong predictors of the 
concentrations of various Aβ forms in the brain. 
 
DISCUSSION 
Increased BACE1 expression in late-stage AD has been reported by multiple 
groups, including our own. However, it has remained unclear whether this increase is a 
cause or consequence of the disease process. In this chapter, we have shown that BACE1 
is increased in early-stage AD cases, compared with healthy age-matched controls, which 
indicates that it is likely a driving factor in the progression of disease. The increase in 
BACE1 protein could not be explained by increased mRNA levels, confirming previous 
studies [57, 159, 168-170], and emphasizes an alteration in post-transcriptional regulation 
in disease. Similar expression profiles were found for the related enzyme, BACE2. 
BACE1 and BACE2 protein and enzymatic activities were highly correlated regardless of 
disease, indicating a possible shared mechanism of regulation. Since BACE2 is not 
believed to play a major role in Aβ production, further research is needed to determine 
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the consequences, if any, of increased BACE2 levels in the brain. This will likely require 
the discovery of novel BACE2 substrates. 
Few groups have looked at BACE1 in early-stage AD cases, partly due to a 
limitation in available samples. Elevated BACE1 activity and total protein levels have 
been reported in the CSF of two separate cohorts of MCI patients [165, 251] as well as 
from platelets [252], indicating that BACE1 may be considered an important biomarker 
for AD [253]. No studies had been reported from PCAD cases or from early-stage AD 
brain tissue. We did not detect a significant increase in BACE1 activity or protein in MCI 
cases compared to controls in the SMTG. This may be due to a small sample size of MCI 
cases (n=7) as we were able to detect significant BACE1 increases in PCAD cases 
(n=10), which is expected to occur before MCI on the AD clinical spectrum. 
Furthermore, MCI cases do not always progress to AD, indicating that different 
pathological processes may be a factor. 
We showed that BACE1 protein and activity were increased in the progression of 
AD in a disease affected region of the brain, the SMTG, but not in the cerebellum, which 
is largely spared from neuronal loss. Interestingly, we found high levels of BACE1 
protein and activity in the cerebellum (compare to SMTG) that were unchanged 
throughout all disease states. We also found elevated levels of total Aβ in the CB of late-
stage AD cases only. Determining why different brain regions show varying 
susceptibility to neurodegeneration could be critical for understanding the basic 
mechanisms of AD.  
Although we observed overall increases in both BACE1 and Aβ levels in late-
stage AD cases, there was not a strong correlation between BACE1 and Aβ in the brain. 
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BACE1 was weakly correlated with soluble Aβ in the NaOAc fraction, but did not 
correlate with detergent soluble or formic acid soluble Aβ, which usually correspond to 
diffuse plaques and neuritic plaques, respectively. Several studies have looked at the 
relationship between BACE1 and Aβ in the brain with varying results. An association 
between elevated BACE1 and Aβ deposition in dystrophic neurites has been reported in 
transgenic mouse models of AD [254]. Likewise, BACE1 enzymatic activity was 
correlated with Aβ plaques in the temporal cortex of AD brains [161]. Conversely, 
BACE1 or β-secretase activity has previously been shown not to correlate with Aβ-
related pathologic findings in the brain or to be a weak association [142, 158, 255]. Even 
though it has been reported that BACE1 is elevated in neurons surrounded by amyloid 
plaques, this may occur only around a subset of plaques in the AD brain [166]. We did 
note that the amount of CTFβ in the SMTG was related to the amount of Aβ in multiple 
fractions and was also related to the number of neuritic plaques (data not shown; [238]); 
this stronger relationship is likely due to CTFβ being the immediate precursor to Aβ, 
whereas BACE1 protein does not often encounter its APP substrate in the cell and thus β-
secretase activity is a step further removed [256]. Furthermore, differences in extraction 
methods and immunoassays factor into these discrepancies as well. We found that a 
better indicator of insoluble Aβ and plaques in the brain is the activity of Aβ-degrading 
enzyme neprilysin (NEP) (data not shown; [238]) and this corroborates a recent similar 
finding in frontal cortex [257]. Interestingly, a decrease in NEP activity was observed in 
AD cases in the disease-affected SMTG, but an increase in NEP activity was found in the 
cerebellum (data not shown; [238]), suggesting a possible reason for differences in brain 
region disease susceptibility. 
52 
 
We also observed an increase in BACE1 and BACE2 protein and activity in a 
limited set of FTD cases when compared to controls. FTD is a neurodegenerative disease 
distinct from AD, in which the accumulation of Aβ does not occur. FTD encompasses a 
group of related conditions caused by mutations in several genes that cause shrinking of 
the temporal and frontal lobes of the brain and results in death 7 years after diagnosis on 
average [258]. The evidence that BACE1 is increased in FTD likely indicates a 
consequence of the disease. The reason why FTD cases do not accumulate Aβ as in AD is 
unclear but may be explained by two factors: (1) cellular processes such as Aβ clearance 
mechanisms may differ between the two diseases (NEP activity was not decreased in 
FTD cases in our study) and (2) FTD patients generally die on average 20 years younger 
than AD patients (see Table 3.1), indicating that significant Aβ accumulation and 
deposition may occur had they lived longer. The evidence remains that increased BACE1 
(and BACE2) expression is not an AD-specific event and may play a role in other 
neurodegenerative diseases as well. 
While an increase in BACE1 expression early in the disease process points to a 
causal role, the evidence that levels remain high in late-stage AD cases also suggest that a 
positive feedback loop in which Aβ deposition drives β-secretase expression may be 
important, as has been suggested [130, 160, 161, 166, 170]. While this may be the case 
later in the disease process, our results indicate that the initial rise in BACE1 protein and 
activity does not depend on elevated Aβ. We showed that increased BACE1 in early AD 
cases occurred in the absence of a significant rise in total Aβ, and that FTD cases, which 
do not accumulate Aβ, have significantly elevated levels of BACE1 as well. These results 
fit in well with the current amyloid cascade hypothesis and suggest that an initial trigger, 
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possibly relating to accumulated cellular stress, increases BACE1 expression which in 
turn leads to an increase in Aβ production and deposition. The increase in Aβ production 
may cause further stress to the cell, keeping BACE1 levels chronically elevated into late-
stage AD. Once this cascade of events reaches a certain threshold of neuropathology to 
drive advancement of disease, therapeutic interventions may have little impact.  
In summary, the data presented in this chapter indicate that sustained elevation of 
BACE1 may play a causal role in the development and progression of AD and remains a 
prime therapeutic target for the prevention of AD. In addition, the increase in BACE1 
occurs through a post-transcriptional mechanism not specific to AD. How this regulation 
occurs and what factors may be involved is the primary focus of subsequent chapters. 
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Table 3.1 Case Details 
 
 
Ref # 
Age 
(y)  ApoE Sex 
Brain 
Weight (g) 
PMI 
(h) Braak  MMSE 
Last MMSE 
(y) C.O.D. Duration (y) 
Control 1066 81 3/4 Male 1410 2.00 2 30 0.46 Pulmonary Embolism N/A 
 
1069 87 3/3 Male 1230 2.42 2 29 0.52 Prostate Cancer N/A 
 
1070 82 3/4 Male 1290 2.10 1 29 1.38 Pneumonia N/A 
 
1089 74 3/3 Male 1440 4.00 1 26 0.36 Congestive Heart Failure N/A 
 
1127 91 3/4 Female 1230 1.75 2 29 0.76 Myocardial Infarct N/A 
 
1134 90 2/3 Male 1310 3.50 0 30 0.18 N/A N/A 
 
1159 86 3/3 Female 1200 3.50 0 28 1.03 N/A N/A 
 
1163 84 3/3 Female 900 3.00 1 26 0.29 Cardiac Arrest N/A 
 
1170 84 3/3 Female 1100 2.50 1 29 1.04 Breast Cancer N/A 
mean   84.3     1234.4 2.8 1.1 28.4 0.67     
s.d.   5.1     163.2 0.8 0.8 1.5 0.41     
s.e.m.   1.7     54.4 0.3 0.3 0.5 0.1     
            
FTD 1009 68 N/A Male 900 4.00 0 14 6.34 N/A N/A 
 
1078 53 N/A Female 940 4.75 2 N/A N/A Pneumonia N/A 
 
1124 48 3/3 Male 900 3.75 0 0 0.34 N/A 6 
 
1166 59 N/A Male 1230 6.00 0 17 4.28 N/A 2 
 
1183 87 N/A Female 970 4.50 0 N/A N/A N/A 6 
 
5047 51 3/4 Female 705 6.00 0 0 7.28 N/A 9 
mean   61.0     940.8 4.8 0.3 7.8 4.56   5.8 
s.d.   14.6     169.4 1.0 0.8 9.0 3.08   2.9 
s.e.m.   5.9     69.1 0.4 0.3 4.5 1.54   1.4 
            
MCI 1065 87 3/4 Male 1200 3.50 4 24 0.99 Cardiac Arrest N/A 
 
1077 87 3/3 Male 1170 2.25 3 21 0.41 Congestive Heart Failure N/A 
 
1087 82 3/3 Female 1075 2.90 3 29 0.83 Pulmonary Embolism N/A 
 
1130 99 2/3 Female 930 2.00 5 21 0.53 Congestive Heart Failure N/A 
 
1152 84 3/4 Male 1350 3.50 4 24 0.97 Congestive Heart Failure N/A 
 
1164 88 3/3 Female 1130 3.00 3 28 0.07 N/A 
 
N/A 
 
1178 96 3/3 Female 970 2.50 4 27 0.59 Colon Cancer N/A 
mean   89.0     1117.9 2.8 3.7 24.8 0.63     
s.d.   5.8     132.3 0.5 0.7 3.1 0.31     
s.e.m.   2.2     50.0 0.2 0.3 1.2 0.12     
            
PCAD 1082 84 3/3 Female 1020 2.75 4 29 0.60 N/A N/A 
 
1097 89 3/3 Female 1210 1.75 4 30 1.76 Stroke N/A 
 
1105 84 3/3 Female 1035 2.50 4 30 0.51 Congestive Heart Failure N/A 
 
1112 86 2/3 Female 1240 2.41 4 28 0.37 N/A N/A 
 
1119 87 3/3 Female 1180 2.25 4 30 0.27 Aortic Aneurysm N/A 
 
1141 84 3/3 Female 1300 3.25 4 29 1.18 Lung Cancer N/A 
 
1150 90 3/3 Female 1110 3.50 3 29 1.20 Stroke N/A 
 
1151 88 2/3 Female 1070 2.25 3 29 0.85 N/A N/A 
 
1167 77 3/4 Male 1340 2.75 4 30 1.00 Esophageal Cancer N/A 
 
1179 87 3/3 Female 1220 2.25 5 30 0.67 N/A N/A 
mean   85.6     1172.5 2.6 3.9 29.4 0.84     
s.d.   3.7     110.1 0.5 0.6 0.7 0.46     
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Table 3.1 continued 
s.e.m.   1.2     34.8 0.2 0.2 0.2 0.14     
            
AD 1084 86 N/A Female 870 3.25 6 N/A N/A Respiratory Infection N/A 
 
1086 90 3/3 Female 1090 2.75 6 11 1.91 N/A 8 
 
1116 84 3/4 Male 1090 2.75 6 18 2.55 Aspiration 8 
 
1118 83 3/3 Female 1110 3.50 6 5 0.45 N/A 9 
 
1125 74 4/4 Male 1190 3.00 6 N/A N/A Pneumonia N/A 
 
1139 86 3/3 Female 1010 2.00 6 9 7.32 Acute Respiratory Fail 15 
 
1144 85 4/4 Male 1020 2.75 6 15 1.48 Pneumonia 10 
 
1168 80 3/3 Female 1130 4.00 6 16 2.02 N/A 7 
 
1173 75 4/4 Male 1120 3.75 6 5 1.32 N/A 8 
 
1180 91 N/A Female 1110 3.00 6 1 2.40 N/A 8 
mean   83.4     1074.0 3.1 6.0 9.9 2.43   9.1 
s.d.   5.7     88.5 0.6 0.0 6.0 2.08   2.5 
s.e.m.   1.8     28.0 0.2 0.0 2.1 0.7   0.9 
 
Abbreviations: FTD = Frontotemporal Dementia; MCI = Mild Cognitive Impairment; 
AD = Alzheimer’s Disease; ApoE = Apolipoprotein E genotype; PMI = Post-Mortem 
Interval; MMSE = Mini-Mental State Exam; C.O.D. = Cause of Death; N/A = Not 
Applicable or Unavailable. 
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Figure 3.1 Histological Representations of Brain Pathologies. Examples of 
neuropathology (20× objective) in parietal cortex (Bielschowsky) and subiculum 
(Gallyas) from representative cases of amnestic mild cognitive impairment (MCI), pre-
clinical Alzheimer’s Disease (PCAD), and AD. Although the level of cognitive 
impairment varies from minimal to demented, all three disease states display the same 
basic elements of neuropathology (plaques and tangles), frequently at similar levels.  
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Figure 3.2 BACE1 and BACE2 Proteins are Abundant in Human Brain. Equal 
amounts of protein from the SMTG (25 µg) were separated by SDS-PAGE. Human 
recombinant BACE1 (100 ng; R&D Systems) or mouse recombinant BACE2 (100 ng; 
R&D Systems) were included as molecular weight comparisons. After probing for (A) 
BACE1 (MAB931) or (B) BACE2 (Ab5670), blots were stripped and reprobed for β-
Actin. Although β-Actin was broadly similar, in some cases the levels were very low. 
Comparison with recombinant protein standards indicated similar amounts of BACE1 
and BACE2 protein in human brain. Although the BACE1 band migrated close to the 
recombinant protein standard, BACE2 ran at a slightly lower apparent molecular weight. 
The lower than expected molecular weight of this band and the observed pattern of 
antibody immunoreactivity together indicate that the active form of BACE2 in the brain 
is likely BACE2∆7 (splice form C) as discussed in Holler et al. [238]. CON, control.  
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Figure 3.3 BACE1 and BACE2 are Increased in Neurodegenerative Disease. (A) 
BACE1 activity (as determined by the MAB931 capture assay) is higher in PCAD, AD, 
and FTD compared to controls. (B) BACE2 activity (as determined by the Ab1 capture 
assay) is higher in FTD and PCAD and strongly trends toward an increase in AD 
(p<0.07) compared to controls. (C) BACE1 protein is higher using Western blot analysis 
in FTD and AD (see Fig. 3.2) compared to controls. (D) BACE2 protein is higher using 
Western blot analysis in MCI, PCAD, AD, and FTD (see Fig. 3.2) compared to controls. 
Western blot analysis results were essentially unchanged when not standardized to β-
Actin, indicating that outlier cases with very low β-Actin levels had minimal effect on the 
analysis. BACE1 and BACE2 activities are highly correlated in the (E) SMTG and (F) 
CB, a phenomenon observed with multiple antibodies and assay conditions (shown: 
BACE1, EPR3956 capture assay; BACE2, Ab2 capture assay). Dunnett’s test, * = 
p<0.05, ** = p<0.01. Scale: 1000 base fluorescence units (BFU)/mg = 2.3 nmol · min-1 · 
mg-1 total protein. Error bars represent standard error of the mean (SEM).  
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Figure 3.4 BACE1 and BACE2 Activities are Replicated With Alternative Capture 
Antibodies. BACE1 (A) and BACE2 (B) enzymatic activity assays were repeated using a 
different combination of antibodies raised against opposite ends of the proteins. Overall, 
BACE1 (p<0.01) and BACE2 (p<0.05) were still higher in the SMTG from disease-
affected cases compared with controls. Using this method, the group differences by 
disease state were essentially unchanged from those of the standard MAB931/Ab1 
method (cf. Fig. 3.3). The overall significance in this second run was reduced due to 
slightly lower power because this was a subset of cases. PCAD (BACE1, t9 = 
3.24, p<0.01; BACE2, t9 = 2.40, p<0.03) and AD (BACE1, t11 = 1.86, p<0.05) were the 
only groups that showed differences versus the control group. We observed marginally 
lower BACE2 activity (p<0.05) in the CB in disease-affected cases with this combination 
of antibodies; this finding was inconsistent with the first data set and was possibly 
spurious. * = p<0.05, ** = p<0.01, Dunnett's test. Error bars represent SEM. Scale is 
same as in Fig. 3.3.   
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Figure 3.5 BACE1 and BACE2 mRNA Levels Are Unchanged in the Progression of 
AD. The mean total mRNA levels (ie., all splice forms) for BACE1 (A) and BACE2 (B) 
did not show consistent alterations across multiple disease states in either the SMTG or 
CB (all comparisons, p>0.2). Values were standardized to the geometric mean of 
GAPDH and TPT1. Error bars represent SEM.  
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Figure 3.6 Total Aβ Levels are Increased in AD, Similar in MCI and PCAD Cases, 
and Minimal in FTD Cases. Total Aβ showed a disease-related increase in the SMTG 
(F4,32 = 16.38, p<0.001) and the CB (F4,29 = 30.14, p<0.001), although the overall amount 
of Aβ was far lower in the CB (however, two data points in the AD group that were ∼20-
fold higher than the group mean were dropped from the CB analysis; this did not affect 
overall significance). Total Aβ in MCI and PCAD cases in the SMTG were similar and 
trended towards being increased compared to controls. ** = p<0.01, Dunnett's test. Error 
bars represent SEM.  
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Figure 3.7 BACE1 and BACE2 Enzymatic Activities are Related to Soluble, but Not 
Insoluble, Aβ in the Brain. BACE1 (A) and BACE2 (B) enzymatic activities were 
significantly correlated with the amount of Aβ solubilized in the NaOAc fraction, which 
contains the most soluble pool of peptide. Neither BACE1 (C) or BACE2 (D) enzymatic 
activities were correlated with less-soluble forms of Aβ, such as the pool extracted with 
70% formic acid, FA. Scale: 1000 base fluorescence units (BFU)/mg = 2.3 nmol · min-1 · 
mg-1 total protein.  
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CHAPTER FOUR: CNBP is a Positive Regulator of BACE1 Translation 
 
INTRODUCTION 
BACE1 is highly regulated at the level of transcription and translation. However, 
in the progression of AD, BACE1 protein levels are increased with no concomitant 
increase in mRNA, indicating that a post-transcriptional mechanism is responsible for 
this rise. The BACE1 5’ UTR appears to be the main cis-element responsible for BACE1 
translational regulation and has all the characteristics of an mRNA under tight 
translational control: it is extremely long (~446 nt), highly structured (77% GC content), 
and contains three uORFs (four uAUGs). Each of these features likely contributes in 
some way to the repressive nature of the BACE1 5’ UTR, although exactly how has been 
debatable. For example, Lammich et al., concluded that the high GC content and 
secondary structure of the BACE1 5’ UTR was the main factor in repressing BACE1 
translation [146]. Other groups have done extensive mutagenesis studies on the 5’ UTR 
and have suggested that the various uAUGs have differing effects on translation through 
ribosome shunting [144] or leaky scanning and reinitiation events [143, 145]. These 
conflicting results illustrate that we still do not fully understand how BACE1 is translated 
under normal conditions. The questions of how and why BACE1 translation is enhanced 
in the progression of AD remain unanswered, but may hold the key to promising new 
therapeutic strategies. 
BACE1 protein expression is maintained at relatively low levels under 
physiologically normal conditions and this is reflective of its role in the brain. The list of 
BACE1 substrates is growing and suggests BACE1 may carry out protective functions 
(reviewed in [241]). This is evidenced by its role in cleaving members of the neuregulin 
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family, a process needed for re-myelination after nerve injury (reviewed in [259]). 
Indeed, increased BACE1 expression has been observed after traumatic brain injury 
(TBI) [137]. In addition, physiological cleavage of APP (reviewed in [260]) and the 
related APLP1 and APLP2 proteins [94, 95] appears to be important for cell-cell 
signaling, synaptic function, and memory. Furthermore, BACE1 is increased in response 
to various cell stresses such as glucose deprivation [170] and oxidative stress [171]. 
While brief, transient increases in BACE1 may be neuroprotective, it is the sustained 
elevation seen in the progression of sporadic AD that underlies its pathogenic role. 
Determining what factors contribute to sustained BACE1 elevation is an important 
question in the AD field that has yet to be elucidated.  
A number of RNA binding proteins have been implicated in the control of 
complex brain functions and have been linked to several neurodegenerative diseases 
(reviewed in [261]). These RNA binding proteins usually have broad cellular functions 
including RNA processing, transport, stability, and translational regulation. For example, 
APP translation was shown to be modulated by the competing interactions of the RNA 
binding proteins FMRP and heterogeneous nuclear ribonucleoprotein C (hnRNP C) 
[262]. These proteins exhibited negative or positive regulation, respectively, and affected 
the subcellular localization of APP. Additionally, mutations in RNA binding proteins 
such as FMRP, FUS (fused in sarcoma), and TDP-43 (TAR DNA-binding protein 43) 
lead to neurodegenerative diseases, highlighting their importance in cellular functions 
(reviewed in [263]). To date, no trans-acting RNA binding proteins have been 
implemented in BACE1 translational regulation. 
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Previously, members of our lab conducted a targeted gene knockout study in 
Chinese hamster ovary (CHO) cells stably overexpressing human APP to look for 
disrupted genes that caused alterations in Aβ metabolism (MPM, unpublished data).                                                                                                                                                                                                                                                                                                                            
One cell line displayed a down-regulation of BACE1 expression and a decrease in Aβ 
production that could not be attributed to changes in APP or the γ-secretase complex. The 
knocked-out gene linked to the down-regulation of BACE1 was identified as ZNF9, 
which encodes the cellular nucleic acid binding protein, or CNBP. Initial experiments 
identified CNBP as a positive regulator of BACE1 expression, but this had not been 
confirmed. Nor was it known whether CNBP affected BACE1 expression at the level of 
transcription or translation. Although not much is known about CNBP’s cellular function, 
it has been implicated as an RNA binding protein and translational regulator of several 
seemingly unrelated mRNAs [184, 202, 204]. 
In this chapter, we have used both cell culture and cell-free systems to show that 
CNBP acts as a positive regulator of BACE1 expression and this occurs at the level of 
translation. Furthermore, we show that CNBP interacts with BACE1 mRNA in cell 
lysates and likely regulates BACE1 translation through direct interaction with its 5’ UTR. 
Finally, we present evidence that CNBP is increased in AD-affected brain tissue, as well 
as early-stage AD cases and that CNBP expression is highly correlated with BACE1 
expression in the brain. Taken together, these results implicate CNBP as an important 
trans-acting factor in the regulation of BACE1 translation. 
 
METHODS 
Human Tissue 
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Human autopsy samples were obtained from the University of Kentucky 
Alzheimer’s Disease Research Center. Frozen tissue from a disease affected (SMTG) or 
unaffected (CB) region was homogenized in 2% SDS or PBS (both with PIC+EDTA), as 
described in Chapter Two. Controls (n = 19, 6M/13F; 86.0 ± 1.4 years) were age-matched 
to AD cases (n = 22, 6M/16F; 83.0 ± 1.3 years). A second set of controls (n = 19, 
6M/13F; 85.0 ± 4.3 years, MMSE score = 28.9 ± 1.2) included 10 cases that met 
neuropathologic criteria of likely AD [246] but showed no clinical signs of dementia 
(MMSE score = 29.4  ± 0.7); this group was compared to 7 cases of amnestic mild-
cognitive impairment (MCI; 89.0 ± 6.2 years; MMSE score = 24.8  ± 3.1), the earliest 
recognized clinical precursor of AD [244]. Post-mortem intervals (PMI) were short for 
both set one (2.8 ± 0.2 hours) and two (2.7 ± 0.6 hours). Controls had no history of 
dementia. Obtaining of informed consent, human tissue collection and handling followed 
guidelines issued by the PHS and was approved by the University of Kentucky 
Institutional Review Board (IRB). 
 
Subcellular Fractionation 
Primary rat cells (neurons, DIV=7 and astrocytes, DIV=28) were lysed and 
separated into nuclear and non-nuclear (referred to as cytoplasmic) fractions using the 
NE-PER kit (Pierce) according to the manufacturer’s instructions. Tissue from aged rat 
brain (4 animals; 20 months old) was harvested and separated into cytoplasmic and 
nuclear fractions as described previously [264]. Total protein was measured by BCA 
assay. 
 
Recombinant CNBP Purification  
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Recombinant CNBP was purified from E. coli in order to generate enough protein 
to use in these studies. First, the pGEX-2T plasmid vector containing wild-type Chaunus 
arenarum CNBP with an N-terminal GST fusion tag (GST-CNBPWT) was transformed 
into One Shot Max Efficiency DH5α-T1R (Invitrogen) chemically competent cells 
according to the manufacturer’s instructions and plated on LB agar supplemented with 50 
µg/L carbenicillin (Sigma). Transformed colonies were selected and plasmid was purified 
using Qiagen mini-prep kit. The purified plasmids were digested with BamH1 and EcoR1 
(New England Biolabs) restriction enzymes to verify the presence of the 541-nt CNBP 
insert. Fresh cultures (100 mL) were induced with 0.5 mM IPTG (Fisher) overnight. 
Bacterial cells were harvested by centrifugation for 10 min at 2150×g and 4ºC in 50 mL 
tubes (BD Falcon). The pellet was washed with 50 mL of 25 mM Tris-HCl, pH 8.0, 
centrifuged to remove wash buffer, and stored at -20ºC until use.  
The GST-CNBPWT batch purification protocol was provided by Dr. Nora 
Calcaterra (National University of Rosario, Argentina) and is based on previous 
published reports for purification of GST-fusion proteins [265]. Briefly, GST-agarose 
(Genscript) was equilibrated in Buffer TEN (50 mM Tris-HCl, pH 8.0, 1 mM EDTA, 200 
mM NaCl). Bacterial pellets in 50 mL conical tubes were resuspended in 3 mL Lysis 
Buffer (Buffer TEN + 5 mM DTT, 0.5% Triton X-100, PIC+EDTA). Cell lysis was 
enhanced by brief sonication (10 pulses of 0.5 sec each at 100 W). 1 mL aliquots of 
bacterial lysates were transferred to 1.5 mL eppendorf microfuge tubes and centrifuged 
for 30 min at 4oC and 20,800×g and the supernatants were transferred to new tubes. Next, 
175 µL of pre-equilibrated GST-agarose slurry (about 100 µL beads) was added to each 1 
mL of cleared lysate and the tubes were incubated with end-over-end rotation for 1 hr at 
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4oC to allow GST-CNBPWT to bind to the resin. After incubation, the beads were pelleted 
by brief centrifugation and washed several times with 1 mL Wash Buffer (Buffer TEN, 5 
mM ATP). Proteins were eluted from the beads in 100 µL Elution Buffer (Buffer TEN, 
15mM glutathione, pH 7.4) by incubation at 4ºC for 1 hr with gentle agitation. After 
elution, the beads were pelleted by centrifugation at 100×g at 4ºC for 10 min. The 
supernatants were collected and pooled to get a final volume of about 3.5 mL which was 
then dialyzed into CNBP EMSA binding buffer (final concentration of 50 mM Tris-HCl, 
pH 7.5, 1 mM MgCl2, 50 mM KCl, 0.5 mM DTT, 5% glycerol). This fraction was then 
concentrated using centrifugal concentrators (Pierce; MWCO = 20 kDa) and total 
concentrated protein was measured by BCA assay. Aliquots of protein were run on SDS-
PAGE and purity was judged to be greater than 90% by Coomassie stain while Western 
blot confirmed the presence of mostly GST-CNBPWT monomers (~45.7 kDa) and some 
SDS-stable multimers (~100, 150, 200 kDa) of the expected size. Aliquots of the 
recombinant GST-CNBPWT protein were stored at -80oC until use. 
 
RNA Immunoprecipitation (RIP) 
RIP experiments were based on a previously published protocol [266] and 
Millipore’s MagnaRIP kit instructions. Approximately 18×106 H4 cells or 100 mg mouse 
brain (from postnatal day 2-4 pups) tissue was lysed in polysome lysis buffer (PLB; 10 
mM HEPES, pH 7.0, 100 mM KCl, 5 mM MgCl2, 0.5% NP40) supplemented with PIC 
(without EDTA; Calbiochem) and 200 U/mL RNase inhibitor (RNasin Plus RNase 
Inhibitor, Promega). Cells were pipetted repeatedly and mouse brain tissue was 
homogenized with a Dounce homogenizer to aid extraction. Raw extracts were frozen at -
80ºC until use to complete the lysis process. Thawed extracts were centrifuged at 
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20,800×g and 4ºC for 15 minutes to pellet insoluble material. Supernatants were saved 
for RIP experiments.   
Equal amounts of Protein A and Protein G agarose beads (Pierce) were 
equilibrated in NT2 buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM MgCl2, 
0.05% NP40). Approximately 20-50 µL of beads resuspended in NT2 buffer were used 
for each RIP sample. To the beads, antibody was added either against a specific protein 
of interest or as an isotype specific control. Antibodies used were rabbit polyclonal 
antisera (CNBP; C-terminus last 20 aa; own), pre-CNBP rabbit serum, rabbit polyclonal 
anti-PABP (Abcam), mouse monoclonal anti-PABP 10E10 (Abcam), rabbit IgG 
(Millipore), and mouse IgG (Millipore). Equal amounts of antibody were added to sample 
and control tubes (10 µg for CNBP and pre-immune sera, 5 µg for anti-PABP and IgG) 
and the antibody-bead mixture was incubated overnight (~16 hours) at 4ºC with end-
over-end rotation. After incubation with antibody, the samples were centrifuged at 
2,000×g to pellet the beads and the supernatant removed. The beads were then washed 4× 
with ice-cold NT2 buffer and resuspended in NT2 buffer with 200 U/mL RNase inhibitor 
and 20 mM EDTA (to disrupt polyribosomes) followed by addition of 100 µL sample 
extract. A 10 µL aliquot of sample extract was saved for total RNA extraction. Extracts 
were incubated with the antibody-bead complexes for 2-4 hours at 4ºC with end-over-end 
rotation. Samples were then pelleted by centrifugation at 2,000×g and the supernatant 
was removed. The beads were then washed at least five times (5 minutes each at 4ºC) 
with either ice-cold NT2 buffer (H4) or 1× RIPA (mouse brain, for a more stringent 
wash). An aliquot of the final washed beads was saved for IP / Western blot analysis to 
confirm pull-down of CNBP. The beads were pelleted by centrifugation and resuspended 
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in NT2 buffer with 10% SDS and 30 µg of proteinase K. Samples were heated at 55ºC for 
30 minutes with agitation to digest protein complexes. 
RNA was extracted with phenol/chloroform/isoamyl alcohol (125:24:1, pH 4.3, 
Fisher) followed by ethanol precipitation overnight at -80ºC. Glycogen (20 µg; Roche) 
was added to each sample to enhance RNA precipitation. Precipitated samples were 
centrifuged at 20,800×g for 30 min at 4oC and the pelleted RNA was resuspended in 
nuclease-free water. Equal volumes of RNA (usually 2 µL) were reverse transcribed 
using Verso cDNA synthesis kit (Fisher) according to the manufacturer’s protocol. The 
RNA samples were heated to 70ºC for 5 min prior to the RT reaction to remove 
secondary structure. cDNA samples (2 µL) were then analyzed by quantitative real-time 
PCR on a Bio-Rad Mini-Opticon using iScript reagent (Bio-Rad) and gene-specific 
primers designed against intron-exon splice site junctions (Integrated DNA Technologies, 
Inc.). Cycling parameters used were: Heat activation 90ºC for 30 sec, then 40-45 cycles 
of 95ºC for 3 sec, 60ºC for 30 sec, 72ºC for 30 sec, followed by a final extension step of 
72ºC for 5 min. The C(t) values for each sample were used to calculate the fold 
enrichment of the target of interest. After amplification, an aliquot of the product was run 
on a 2% agarose gel and visualized with SybrGreen stain to ensure correct product size. 
The procedure for crosslinked RIP experiments was similar and based on a 
previously published protocol [267]. One 15-cm dish of H4 cells (~16 million cells) were 
trypsinized, washed once with 10 mL Opti-MEM media (with 10% FBS), washed twice 
with 10 mL sterile PBS, and then resuspended in 10 mL sterile PBS. Formaldehyde (AR 
grade, from a 37% HCHO/10% Methanol stock; Fisher) was added to the cells at a final 
concentration of 1% and cells were incubated at room temperature for 10 minutes with 
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slow mixing to induce crosslinking. The crosslinking reaction was quenched by the 
addition of 2.5 M glycine (pH 7.0) to a final concentration of 0.25 M followed by a five 
minute incubation at room temperature. The cells were then centrifuged at ~800×g for 
four minutes followed by two washes with ice-cold PBS. The fixed cell pellet was 
resuspended in 2 mL of 1× RIPA buffer containing PIC without EDTA and 200 U/mL 
RNase inhibitor. The cells were then sonicated for three rounds of 20 sec each at 100 W. 
Samples were incubated on ice for 2 minutes between each round of sonication. The 
lysates were then centrifuged at 20,800×g for 10 min at 4ºC to remove insoluble material. 
The supernatant was saved for RIP experiments. Antibodies were incubated with Protein 
A and G beads for 2 hours at 4ºC, and lysates were incubated with antibody-bead 
complexes for 1 hour at 4ºC, both with end-over-end rotation. RIPA buffer was used in 
place of PLB buffer and a high stringency RIPA buffer (50 mM Tris-HCl, pH 7.5, 1% 
NP-40, 1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 M NaCl, 1 M urea) was 
used for washing. Protein-antibody-bead complexes were resuspended in 100 µL of 
resuspension buffer (50 mM Tris-HCl, pH 7.0, 5 mM EDTA, 10 mM DTT, 1% SDS) and 
heated at 70ºC for 45 minutes to reverse crosslinks. RNA was extracted using TRIzol 
followed by phenol/chloroform and ethanol/glycogen precipitation. RNA pellets were 
resuspended in sterile water. RT and qPCR steps were done as described above. UV-
crosslinking experiments were performed the same as for formaldehyde crosslinking 
except H4 cells grown in 10 cm dishes were irradiated once with a Stratalinker 1800 
(Stratagene) at 120 mJ/cm2 at 254 nm in 1× PBS prior to lysis. No heating step was 
performed prior to RNA purification. 
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 All primer sets (Integrated DNA Technologies, Inc.) used in RIP qPCR 
experiments can be found in Appendix Two. 
 
In Vitro Transcription / Translation (IVTT) Assay 
IVTT assays were carried out using the TnT Coupled Reticulocye Lysate System 
(Promega) according to the manufacturer’s protocol. This system does not require capped 
mRNA. Briefly, reactions were assembled in nuclease free 1.5 mL microfuge tubes with 
0.5 µg of vector (pCMV6-XL5 BACE1 or pcDNA6 seAP vectors; all with T7 promoters) 
and indicated amounts of recombinant GST-CNBPWT in the presence of 2 µL 35S-
cystein/methionine (1175 Ci/mmol; Perkin Elmer) in a final reaction volume of 25 µL. 
Samples were incubated at 30ºC for 1.5 h. After incubation, a 5 µL aliquot was mixed 
with SDS loading buffer and heat-denatured for 15 min at 70ºC. Proteins were separated 
by SDS-PAGE on a Criterion polyacrylamide gel. After electrophoresis, the gel was dried 
and exposed on a PhosphorImager. Bands were quantified by densitometry using Scion 
Image. 
 
Electrophoretic Mobility Shift Assays (EMSA) 
Given the length and structural complexity of the BACE1 5’ UTR, we first 
attempted binding using   short 5’-biotin labeled RNA probes (Integrated DNA 
Technologies, Inc.) for L4 (5’-GUGGCCGCUGUGGAGAAGCAGCGAGGAGAUG-3’) 
and BACE1 (5’-GCCGCCGCCGUGCCGAUGUAGCGGGCUCCGG-3’). The L4 probe 
contained most of the 5’ UTR of the ribosomal protein L4 which is a direct target of 
CNBP [202, 230]. This region of the BACE1 5’ UTR (210 – 240) was identified by 
alignment in Vector NTI as the most likely match with L4 (58% sequence identity). 
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Probes were resuspended in nuclease free water and stored at -80ºC until use. 
Biotinylated 31-nt probes were detected with the Pierce Lightshift chemiluminescent 
EMSA kit according to the manufacturer’s instructions. 
To generate the BACE1 5’ UTR probe used in electrophoretic mobility shift 
assays, the pCMV6-XL5 BACE1 vector was first linearized with EcoN1 (New England 
Biolabs) which cuts the vector only once at 370-nt inside the BACE1 coding region. The 
choice of restriction enzymes were limited to ones that only cut the vector once, that 
would avoid leaving a 3’ overhang, and that would generate the entire 5’ UTR of 
BACE1, thus leaving EcoN1 as the best option. Following digestion, one-twentieth 
volume 0.5 M EDTA was added to stop the reaction, followed by sodium acetate and 
ethanol precipitation. The digested DNA pellet was resuspended in Tris-EDTA (pH 7.4) 
buffer to a concentration of 0.5 µg/uL. Ambion MEGAscript kit (Applied Biosystems) 
was used to generate unlabeled or 35S-UTP (120 µCi/sample, Perkin Elmer) labeled 
nucleotide probes according to the manufacturer’s protocol. Ambion MEGAclear kit 
(Applied Biosystems) was used to purify, concentrate, and recover the generated RNA 
probes. Following purification, the probes were checked for concentration and purity 
using a UV-Vis spectrophotometer (260/280 nm ratio) and by agarose gel electrophoresis 
to confirm estimated product size of approximately 835-nt.  Radiolabeled and unlabeled 
probes were stored at -80ºC until use.  
EMSA reactions were carried out in 1.5 mL nuclease free microcentrifuge tubes. 
Briefly, RNA probes were incubated in the absence or presence of varying amounts of 
recombinant CNBP in EMSA binding buffer (50 mM Tris-HCl pH 7.5, 1 mM MgCl2, 50 
mM KCl, 0.5 mM DTT, 5% glycerol + 10U RNase Inhibitor) for 30 minutes at room 
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temperature in a final volume of 20 µL, unless otherwise specified. Some samples were 
subjected to UV-crosslinking using a Stratalinker 1800 at 254 nm (5-cm below bulb) for 
5 minutes on ice after binding. CNBP concentrations ranged from 0.25 to 10 µM, and the 
35S-UTP labeled BACE1 5’ UTR was used at 10-100 nM. The reactions were then 
separated on a Criterion 5% TBE gel (Bio-Rad Technologies) in 0.5× TBE running buffer 
(Bio-Rad). Gels were dried and exposed on a PhosphorImager. Bands were quantified by 
densitometry using Scion Image. 
 
RESULTS 
CNBP is Mostly Cytoplasmic and Found in Neurons and Astrocytes in the Brain 
CNBP localizes to the cytoplasm, ER, and nucleus in a variety of tissues and 
species during development [220-222]. However, the subcellular localization of CNBP in 
the adult brain has not yet been reported. It was also unknown if CNBP expression is 
largely neuronal or extends to other cell types. To study this, we first lysed embryonic rat 
cortical neurons or astrocytes and looked at CNBP expression via Western blot. We 
found that both neurons and astrocytes express CNBP at comparable levels (Fig 4.1A). It 
is interesting to note that BACE1 expression is absent in rat primary astrocytes even 
though CNBP is highly expressed. It has been reported recently that a translational block 
of BACE1, but not BACE2, occurs in these cells [268]. We next looked at the subcellular 
localization of CNBP in primary rat neurons. CNBP was found at high levels in both the 
nuclear and cytoplasmic fractions (Fig 4.1A). This was not unexpected, as CNBP has 
been reported to localize to the nucleus of various cell types in embryonic development, 
where it plays a critical role in transcriptional processes [190, 220].  
78 
 
To see if CNBP localization in the brain changed with age, we separated nuclear 
and cytoplasmic fractions from aged rat brain tissue followed by Western blot for CNBP. 
We found that CNBP was located exclusively to the cytoplasm in four different aged rat 
brains (Fig 4.1B), the same compartment where BACE1 was located. Overall, these 
results indicate a primary role for CNBP in the cytoplasm in adult brain tissue, consistent 
with a role in translation. 
 
CNBP Positively Regulates BACE1 Protein Levels 
Preliminary findings from our lab in CHO cells indicated that CNBP may be a 
positive regulator of BACE1 expression (MPM, unpublished data). In order to confirm 
this, we transfected several human cell lines with either a full-length untagged human 
CNBP expression vector or an empty vector and then analyzed CNBP and BACE1 
protein levels via Western blot. BACE1 protein was significantly increased when 
HEK293T cells were transiently transfected with CNBP, as detected by immunoblot (Fig 
4.2A). Increasing the amount of CNBP cDNA used in the transfection increased the 
amount of both BACE1 and CNBP (Fig 4.2A), and BACE1 and CNBP expression were 
positively correlated (ρ = 0.31, p<0.05). To confirm our findings, we overexpressed 
CNBP in DIV=7 rat primary cortical neurons using adeno-associated virus (AAV2) 
vectors. CNBP overexpression caused an increase in BACE1 protein and in the amount 
of secreted Aβ peptide (Fig 4.2B). We observed no effects of CNBP overexpression on 
β-Actin or β3-Tubulin protein levels, and adjusting band densities to either of these as 
internal loading controls did not alter the results.  
79 
 
Finally, we evaluated the effect of CNBP on BACE1 expression in a cell-free in 
vitro transcription / translation system to ensure that the observed effects on BACE1 were 
directly related to CNBP and not caused by non-specific cellular events such as increased 
stress due to protein overexpression. The addition of spiked recombinant CNBP protein 
significantly increased 35S-cysteine/methionine labeled BACE1 protein in a dose 
dependent manner in the cell-free system (Fig 4.2C). The increase in BACE1 occurred 
via a post-transcriptional mechanism as we did not detect an increase in BACE1 mRNA 
with increased CNBP added to the system. Taken together, these data clearly indicate that 
CNBP is a positive regulator of BACE1 expression and that this regulation is conserved 
across multiple cell types and species. 
 
CNBP Knockdown Reduces BACE1 Protein Levels Variably 
Since CNBP overexpression increased BACE1 protein levels, we next wanted to 
determine if the reverse was true. Does knocking down CNBP decrease BACE1 protein? 
To do this, we first transiently transfected H4 cells with CNBP shRNA or control shRNA 
(empty or scrambled) vectors for 72 hours, followed by Western blot for protein 
expression. We found that transient expression of CNBP shRNA significantly reduced 
CNBP protein levels and also reduced BACE1 protein levels by a similar amount when 
compared to the scrambled control shRNA (Fig 4.3A). Results were similar when 
comparing knockdown levels to an empty vector control. 
Because we could not achieve any higher knockdown of CNBP with transient 
transfection (transfection efficiency was usually less than 50%), we created pooled stable 
H4 cell lines that expressed the shRNA constructs (empty vector, scrambled shRNA, or 
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CNBP shRNA). We then repeated our knockdown analysis using expression data 
grouped from the pooled stable cells and from transiently transfected cells. Surprisingly, 
even though CNBP levels were significantly reduced in the CNBP shRNA cells 
compared to the control shRNA cells, BACE1 levels were not significantly reduced in 
this larger analysis (Fig 4.3B). This may indicate that BACE1 reduction in response to 
sustained CNBP knockdown is less robust than the increases observed with 
overexpression. Alternatively, we may have simply selected for a population of cells that 
were more resistant to decreases in BACE1 expression in our pooled stable cells. 
Transient overexpression of CNBP in the CNBP shRNA pooled stable cell line resulted 
in a significant increase in BACE1 protein, indicating that this mechanism of regulation 
was still viable (Fig 4.3B). Altogether, these results imply that a reduction in CNBP can 
cause a variable decrease in BACE1 protein levels in cultured cells.  
 
CNBP Expression Levels Differentially Affect BACE1 mRNA 
To determine if overexpression or knockdown of CNBP had an effect on BACE1 
mRNA levels, we transiently transfected HEK293T, H4, or SH-SY5Y (neuroblastoma) 
cells with CNBP (24 hr transfection) or CNBP shRNA (72 hr transfection) along with 
appropriate negative controls, followed by RNA extraction, purification, and analysis 
using real-time quantitative PCR. We were able to significantly overexpress CNBP in all 
three cell types as indicated by increased CNBP mRNA levels; however, CNBP 
overexpression did not significantly increase BACE1 mRNA levels in any of the three 
cell lines tested (Fig. 4.4, top). This indicates that CNBP regulation of BACE1 likely 
occurs post-transcriptionally, as we suspected. Interestingly, knockdown of CNBP 
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decreased BACE1 mRNA levels slightly, although this reduction was only significant in 
SH-SY5Y cells (Fig. 4.4, bottom).  
To confirm that CNBP overexpression did not increase BACE1 protein or mRNA 
half-life, other members in our lab carried out steady-state metabolic labeling or pulse-
chase experiments in H4 or HEK293T cells, followed by BACE1 protein or RNA 
analysis (MPM and RLW, unpublished data). The results indicated no obvious effect of 
CNBP overexpression on BACE1 protein or mRNA half-life. Taken together, our 
expression data indicate that an increase in CNBP likely regulates BACE1 through 
enhanced translation. 
 
CNBP Associates with BACE1 mRNA 
CNBP is an RNA binding protein and we suspected that it may interact with 
BACE1 mRNA to exert its translational regulation. In order to study this, we used RNA 
immunoprecipitation (RIP) to determine if CNBP associated with BACE1 mRNA at 
endogenous concentrations from cell lysates. Preliminary RIP experiments were done in 
whole cell lysates of H4 cells or whole tissue lysates from mouse pup brain. Poly-A 
binding protein (PABP) and β-Actin mRNA were used as a positive control for the RIP 
experiment to ensure the overall experimental conditions were sufficient. The PABP/β-
Actin combination is used as a positive control in several commercially available RIP kits 
(Millipore, Sigma-Aldrich). We found that BACE1 mRNA was enriched in H4 or mouse 
brain lysates immunoprecipitated (IP) with our CNBP polysera compared to samples 
immunoprecipitated with negative control pre-immune serum (Fig 4.5A). Western blots 
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were run from the various IP fractions to confirm that only the CNBP polysera, and not 
the pre-immune serum, immunoprecipitated endogenous CNBP (Fig 4.5B).  
RIP experiments carried out using whole cell lysates are routinely used for 
detecting interactions between protein and target mRNA but may result in non-
physiological false positives due to compartment mixing once the cells are lysed [269]. In 
addition, weak or transient interactions between an RNA binding protein and its RNA 
targets may be missed. Thus, we wanted to determine if the CNBP/BACE1 mRNA 
interaction was confirmed when cells were crosslinked before lysing. Crosslinking of 
cells provides a “snapshot” of events that are taking place at any given time in the cell 
and can indicate interactions between two molecules that are in extremely close 
proximity [267]. We attempted two types of crosslinking: (1) crosslinking with 
formaldehyde that can be reversed by heating, and (2) irreversible crosslinking with UV 
irradiation that creates permanent covalent bonds between proteins and RNA molecules. 
We obtained similar results from both crosslinking experiments and thus pooled the data 
together for our crosslinked RIP analysis. Our results confirmed the association between 
CNBP and BACE1 mRNA and also identified some additional mRNAs that may be 
targets of CNBP as well (Fig 4.5C). Along with BACE1, we found that β-Actin, small 
ribosomal protein 17 (RPS17), bridging integrator (BIN1), and ODC1 mRNAs were all 
enriched in CNBP pull-down samples compared to negative control pull-down samples. 
Conversely, tau (MAPT), APP, GAPDH, and CNBP mRNAs were not 
immunoprecipitated by CNBP. 
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The BACE1 5’ UTR Mediates CNBP Translational Regulation 
Translational regulation of BACE1 is largely mediated by its 5’ UTR which is 
long, highly structured, and contains several uORFs. Therefore, we hypothesized that 
CNBP mediates its interaction with BACE1 mRNA through the BACE1 5’ UTR. The 
BACE1 3’ UTR is also extremely long, but does not appear to affect expression [146]. To 
determine the effect of the BACE1 UTRs on CNBP-mediated protein translation, we 
expressed four different secreted alkaline phosphatase (seAP) reporter constructs in a 
cell-free, in vitro transcription / translation system (IVTT) with or without recombinant 
CNBP spiked in. The seAP vectors contained the seAP gene flanked by either the human 
BACE1 5’ UTR, 3’ UTR, both UTRs, or no UTRs driven by a T7 promoter.  
Expression of these constructs in the IVTT system yielded several protein 
products (Fig 4.6A). Several of these bands may be truncated proteins but are produced 
from all four vectors and indicate de novo protein synthesis in this system. Comparison of 
band intensities by eye between constructs containing the BACE1 5’ UTR with those 
lacking it illustrated the inhibitory nature of the BACE1 5’ UTR as described previously 
[146] (Fig 4.6A). When recombinant GST-CNBPWT was added to the system, an increase 
in protein expression was observed and this effect was most prominent when the BACE1 
5’ UTR was present (Fig 4.6A,B). We chose to highlight one band as a representative of 
the others to illustrate that the BACE1 5’ UTR appears critical for the CNBP-mediated 
increase in translated product (Fig 4.6B,C). These results imply that although the 3’ UTR 
of BACE1 may be important for other regulatory mechanisms, CNBP likely exerts its 
translational regulation through the 5’ UTR. As a result, we chose to focus the remainder 
of our studies on this region of the BACE1 mRNA. 
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CNBP Binds Directly to the BACE1 5’ UTR 
Our results from the RIP studies showed that CNBP is associated with BACE1 
mRNA in cell lysates, but those experiments could not indicate whether the interaction is 
direct or indirect. Because CNBP is an RNA binding protein, we suspected that CNBP 
would bind directly to the BACE1 5’ UTR. In order to test this, we used electrophoretic 
mobility shift assays (EMSA) using recombinant CNBP and various RNA probes. EMSA 
experiments are widely used to determine if a protein binds directly to a specific nucleic 
acid sequence (eg. an RNA probe), which is detected by running the complex on a 
polyacrylamide gel [270]. RNA that is bound to protein will migrate slower through the 
gel compared to free RNA, indicated by a shift in the bands. 
Because the entire BACE1 5’ UTR is long and complex, we first tested CNBP 
binding to a short, 31-nt region of the BACE1 5’ UTR that was most similar in sequence 
and GC content to the 5’ UTR of the X. laevis L4 ribosomal protein. The L4 probe was 
also 31-nt in length and contained the entire 5’ UTR (plus start codon) of L4 minus the 5’ 
TOP sequence; CNBP directly binds this segment [202]. We obtained consistent shifts 
with the L4 probe and CNBP under a variety of assay conditions (Fig 4.7B,C); however, 
we never observed binding of CNBP to the 31-nt BACE1 probe (Fig 4.7D). CNBP binds 
to regions of unpaired G residues constrained by a structured environment [215] and an 
analysis of the predicted secondary structures of the two 31-nt probes using the mfold 
web server ([271]; http://mfold.rna.albany.edu/?q=mfold) revealed that the L4 probe 
contained more unpaired Gs than the BACE1 probe, even though they are predicted to 
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have a similar hairpin-like structure (Fig 4.7A); this likely accounts for the differential 
binding observed. 
Next, we created a longer, radiolabeled RNA probe containing the entire human 
BACE1 5’ UTR as well as a portion of the N-terminal BACE1 ORF using in vitro 
transcription. Combining this probe with increasing amounts of recombinant CNBP 
resulted in direct binding of CNBP to the probe as indicated by EMSA (Fig 4.8). This 
was achieved with both GST-CNBPWT and with recombinant human CNBP containing a 
C-terminal DDK tag (Origene). Several previously published reports showed that GST 
alone did not bind various RNA probes in EMSA experiments [194, 215, 226]. 
Furthermore, a mutant CNBP protein (GST-CNBP1-∆RGG), which lacks the RGG region 
important for RNA binding [194], failed to bind the probe. These results indicated that 
CNBP bound directly to an RNA probe that contained the BACE1 5’ UTR in vitro and 
further suggested that this region is a likely site for CNBP-mediated translational 
regulation. 
 
CNBP Increases in AD and Correlates with BACE1 
We next sought to establish if CNBP was increased in the AD brain, which could 
account for the changes in BACE1. We examined a disease affected (the superior and 
middle temporal gyri; SMTG) and unaffected (the cerebellum; CB) region of the brain 
from a cohort of AD cases and age-matched controls for CNBP and BACE1 protein 
expression (Fig 4.9A). In both regions, the amount of CNBP and BACE1 protein were 
positively correlated (Spearman’s ρ: SMTG = 0.423, p<0.01; CB = 0.316, p<0.05; Fig 
4.9C). We next performed an analysis of CNBP and BACE1 protein levels using age, 
86 
 
post-mortem interval, and GAPDH or β-Actin levels (the loading controls) as covariates, 
and including gender as a variable. In the SMTG, both CNBP (F1,34 = 9.29, p<0.005) and 
BACE1 (F1,34 = 11.43, p<0.005) were increased in the AD cases (Fig 4.9B). In contrast, 
in the CB, both CNBP (F1,34 = 4.30, p<0.05) and BACE1 (F1,34 = 8.03, p<0.01) were 
decreased (Fig 4.9B). Neither CNBP nor BACE1 mRNA changed significantly in the 
disease, although CNBP mRNA trended towards the changes observed in protein levels 
(Fig 4.10).  
We also examined a small number of MCI cases, looking for changes in CNBP in 
the earliest stages of disease. We detected a significant increase in CNBP in MCI cases 
(F1,20 = 5.65, p<0.03) (Fig 4.11, left). Although BACE1 was not increased in these cases, 
CNBP and BACE1 were correlated (p<0.001) (Fig 4.11, right). Others in our lab found 
no relationship between CNBP and age, or CNBP and Aβ, in either the human or mouse 
brain, indicating that CNBP does not likely increase as a consequence of normal aging 
(MPM, unpublished data). Together, these data show that CNBP increases from an early 
stage of the disease process, and that this increase likely precedes significant increases in 
BACE1. 
 
DISCUSSION 
The BACE1 5’ UTR appears to be the main cis-acting element regulating BACE1 
translation, resulting in inefficient translation under normal, physiological conditions. It 
may be that certain trans-acting factors play a significant role in enhancing BACE1 
translation, as seen during the progression towards AD. The experiments described in this 
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chapter implicate the RNA binding protein, CNBP, as an important and novel trans-
acting factor in the regulation of BACE1 translation.  
Our results indicate that CNBP protein is expressed at high levels in both primary 
cortical astrocytes and neurons from rat brain. The evidence that BACE1 translation is 
inhibited in primary rat astrocytes by an unknown mechanism [268] indicates that CNBP 
does not positively regulate BACE1 translation in this cell type, at least during early 
development. It also suggests that BACE1 translation is differentially regulated in various 
cell types and at different ages, possibly through other mechanisms such as noncoding 
RNAs. Because BACE1 in reactive astrocytes may play an important role in AD 
(reviewed in [116]), determining if there are significant differences in BACE1 
translational regulation between neurons and astrocytes needs to be further studied.  
Subcellular fractionation of primary cortical rat neurons indicated that CNBP 
exists in both the cytoplasm and nucleus, consistent with its role in transcriptional 
processes during development, and possibly suggests a shuttling mechanism for CNBP. 
Shuttling of CNBP between the nucleus and cytoplasm has been observed in the 
embryogenesis of the toad species Bufo (Chaunus) arenarum [220]. Alternatively, 
various pools of CNBP monomer and dimer may exist in different cellular locations; 
indicative of its binding activity [215]. The role of CNBP in translational regulation 
during development has not been investigated. Other members of our lab have looked at 
CNBP expression in young rodent brain using immunohistochemistry and found that 
CNBP was mainly localized to the cytoplasm; however, distinct staining could be 
detected in the nucleus as well (MPM, unpublished data). Interestingly, subcellular 
fractionation of aged whole rat brain tissue showed CNBP localization only in the 
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cytoplasmic fraction. This indicates a shift in CNBP to a mostly cytoplasmic function in 
the adult brain, consistent with a primary role in translation. With a molecular weight of 
around 20 kDa, CNBP is small enough to pass through the nuclear pore complex by 
simple diffusion [272]; however, our results suggest this may not happen readily in the 
aged brain. CNBP contains a conserved putative PKA phosphorylation site at its C-
terminus and it is tempting to speculate that it could be involved in regulating shuttling 
between the nucleus and the cytoplasm. Additionally, specific cellular conditions in the 
aged brain may be conducive for CNBP to form large ribonucleoprotein complexes, 
keeping it largely localized to the cytoplasm.  
CNBP is a translational regulator of several seemingly unrelated mRNA targets 
and we have shown in this chapter that CNBP is a trans-acting regulator of BACE1. 
Overexpression of CNBP in cultured cells or in primary neurons increased BACE1 
protein production and knocking down CNBP had the opposite effect, indicating that 
CNBP is a positive regulator of BACE1 expression. Although overexpression of CNBP 
seemed to have no effect on BACE1 mRNA levels or stability, decreased CNBP 
expression below physiological normal levels reduced BACE1 mRNA expression. This 
pattern indicates that a threshold level of CNBP may be needed for the stability of its 
target transcripts and is characteristic of other RNA binding proteins, such as TDP-43, 
which sustains the normal levels of its target RNAs [273, 274]. Since under normal 
circumstances these proteins may be sufficiently bound to their cellular targets to affect 
stability, overexpression will not necessarily lead to further increases in RNA target 
abundance. 
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An observed increase in protein levels post-transcriptionally can only occur 
through enhanced mRNA or protein stability (i.e. increased half-life or decreased 
degradation) or through increased translation. Only one group has suggested changes in 
BACE1 degradation in AD via increased BACE1 half-life mediated through the lipid 
second messenger ceramide [155]. However, we detected no changes in BACE1 protein 
or mRNA half-life (MPM, RLW unpublished data) or in total BACE1 mRNA with 
CNBP overexpression, confirming that CNBP most likely enhances BACE1 translation. 
We have replicated our expression findings in various cell types (human embryonic 
kidney, neuroglioma, neuroblastoma, primary neurons) and from different species 
(hamster, rat, human), indicating that this method of regulation is highly conserved.  
We found that CNBP associated with BACE1 mRNA at endogenous 
concentrations in cellular lysates through RNA immunoprecipitation studies. Besides 
BACE1, our RIP analysis identified several additional potential mRNA targets of CNBP, 
including β-Actin, BIN1, RPS17, and ODC1. Both RPS17 [184] and ODC1 [204] 
mRNAs have previously been shown to be direct targets of CNBP and served as positive 
controls to validate our results. Although we did not see any changes in β-Actin 
expression in cell culture experiments with CNBP modulation, we have noted changes in 
its expression in several in vivo experiments (MPM and RLW, unpublished data), 
indicating that it may be a bona fide target of CNBP regulation. BIN1 is involved in 
endocytosis [275] and membrane curvature [276] and has been implicated as the second 
highest genetic risk factor, behind ApoE4, for the development of sporadic AD [277, 
278]. Currently, its role in AD pathogenesis is unknown. BIN1 has also been implicated 
in DM2 through alterations in splicing patterns [279]. Thus BIN1 is a particularly 
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interesting target that links CNBP to both DM2 and AD. Additional expression studies 
will be needed in order to validate β-Actin and BIN1 mRNAs as functional CNBP 
targets.  
CNBP failed to bind mRNAs for GAPDH, APP, MAPT, BACE2, or CNBP itself. 
GAPDH is an abundant protein that exclusively uses cap-dependent translation and has 
been previously used as a negative control in CNBP RNA immunoprecipitation 
experiments [204]. APP and MAPT are critical AD-related proteins and interestingly 
both have been suggested to contain IRES elements in their 5’ UTRs [280, 281]. Thus, it 
was anticipated that one or both would be enriched in our RIP experiments. The 
observation that neither was immunoprecipitated by CNBP may indicate that CNBP’s 
interaction with IRES elements is selective and/or requires other regulatory proteins. We 
have shown in Chapter Three that BACE1 and BACE2 activities and proteins are highly 
correlated in the progression of AD, and this is suggestive of a shared mechanism of 
regulation. We speculated that CNBP might be this common regulator, but our RIP 
results indicated that CNBP does not bind BACE2 mRNA. Although this finding is 
interesting, it is not altogether surprising, given that the BACE1 and BACE2 transcript 
sequences are widely dissimilar except for their coding regions [282]. Finally, other RNA 
binding proteins, such as FMRP [283], TDP-43 [284], and PABP [285], have been shown 
to bind their own mRNAs, but according to our results this may not be the case with 
CNBP.  
While these RIP experiments provided new and interesting information about 
possible CNBP targets, they should be evaluated with caution due to the inherent 
limitations of the experiment. RIP experiments, both native and crosslinked, may lead to 
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false-positives and/or false-negatives. The success of the RIP experiment is affected by 
the structural and sequence complexity of the binding sites and the accessibility of the 
protein to its target mRNAs. In addition, the choice of buffer may not accurately reflect 
the physiological conditions needed for binding, which may include formation of multi-
protein complexes [286]. For example, in our studies we included EDTA, which is 
important for reducing background and gaining access to epitopes by disrupting 
ribosomes from mRNP complexes [266]. Since CNBP interacts with the translation 
machinery [204-207], we wanted to minimize this interaction. However, because the 
CNBP zinc fingers enhance interactions with RNA [194], chelators such as EDTA likely 
reduce CNBP binding activity, possibly causing us to miss some targets. The antibody 
binding site may also affect RIP efficiency; our polyclonal CNBP antibody recognizes 
the last 20 amino acids of the C-terminus which partially overlaps the last CCHC zinc 
finger and also the putative PKA phosphorylation site. Masking of these regions could 
severely hinder CNBPs ability to effectively bind target mRNAs, resulting in low 
immunoprecipitation efficiency. We did try a RIP experiment with a commercial N-
terminal CNBP antibody (Abcam), but did not get pull-down of native CNBP from a cell 
extract. Thus, optimization of experimental conditions is required to obtain the most 
accurate results and any identified targets must be validated by secondary methods.   
Our RIP experiments indicated that CNBP associated with BACE1 mRNA, and 
we showed that this interaction is direct through EMSA experiments. CNBP was able to 
bind the RNA probe containing the BACE1 5’ UTR, which is the most likely site for 
translational regulation. However, because the probe contained a portion of the BACE1 
coding region, we cannot rule out that important interactions are limited to the 5’ UTR. 
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Similarly, although we showed that CNBP likely exerts its translational effects through 
the BACE1 5’ UTR in our seAP IVTT assays, we cannot rule out that CNBP may 
functionally bind to portions of the BACE1 3’ UTR as well. Further studies will be 
needed to address these questions.  
The results from our human tissue analysis suggest that CNBP is increased in a 
disease-affected region of the brain (SMTG) and is highly correlated with BACE1 
expression. Interestingly, both CNBP and BACE1 were decreased in the disease-
unaffected cerebellum in this set of samples, which could underscore important 
pathogenic discrepancies in different brain regions. Neither BACE1 nor CNBP mRNA 
levels significantly changed in AD, although CNBP mRNA trended towards explaining 
protein levels. Finally, and most importantly, we found that CNBP was increased early in 
the disease process as we would expect if it plays a role in increasing BACE1 translation 
in AD. 
Overall, we have shown in this chapter that CNBP positively regulates BACE1 
translation, but determining how this regulation occurs and what causes CNBP to 
increase in AD are still unanswered questions. In the next chapter, we will begin to 
explore these questions in order to better understand the mechanism of CNBP 
translational regulation of BACE1 in the brain and its consequences for disease. 
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Figure 4.1 CNBP Expression and Localization in the Brain. (A) Approximately 8 µg 
of total protein was separated by SDS-PAGE followed by Western blotting. CNBP was 
present in high levels in whole cell lysates from both rat primary cortical astrocytes and 
neurons (left). A translational block of BACE1 occurs in primary rat astrocytes [268]. 
Subcellular fractionation of rat primary cortical neurons (right) revealed that CNBP was 
located in both the cytoplasm and nucleus in developing neurons. The presence of some 
BACE1 (D10E5) in the nucleus may represent partial carry over from the cytoplasmic 
fraction but did not account for the large portion of CNBP found in the nucleus. (B) Four 
20-month old rat brains were fractionated into cytoplasmic and nuclear pools and 
evaluated for protein expression. Each lane was loaded with 8 µg of total protein. CNBP 
was found exclusively in the cytoplasm consistent with BACE1 localization. For these 
blots, β-Actin was used as a loading marker. 
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Figure 4.2 CNBP Increases BACE1 Protein Expression. (A) Transient overexpression 
of CNBP with increasing amounts of CNBP cDNA lead to corresponding increases in 
BACE1 expression (EPR3956) in HEK293T cells. CNBP (F2,27 = 6.46, p<0.005) and 
BACE1 (F2,27 = 14.89, p<0.001) cDNA dose response (3 experiments, n = 8-11 replicates 
/ dose); Dunnett’s test vs. control, * = p<0.05, ** = p<0.01, *** = p<0.001; vs. 0.5 µg 
CNBP, # = p<0.05. (B) Overexpression of CNBP in rat primary cortical neurons using 
AAV2 increased both BACE1 (D10E5) and total Aβ (t-test, ** = p<0.01). The sample 
size (n = 3) was too small to obtain significance in protein levels, although the virus had 
similar effects on human neuroblastoma cells (not shown). (C) CNBP significantly 
increased BACE1 protein production (t-test, ** = p < 0.01; n = 3 independent replicates) 
in a cell-free in vitro transcription / translation rabbit reticulocyte lysate system. The 
increase in BACE1 was dependent on the amount of CNBP added up to 10 µg; higher 
concentrations of CNBP (15 µg; n = 1, not shown) appeared to have no additional effect 
on BACE1 protein levels. BACE1 protein was normalized to BACE1 mRNA levels 
extracted from each sample, which showed a slight decrease in mRNA with increasing 
amounts of CNBP protein. Error bars represent SEM. 
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Figure 4.3 CNBP Knockdown Reduces BACE1 Protein Variably. (A) Transient 
shRNA knockdown of CNBP with an shRNA directed against its 3’ UTR (Origene 
HuSH) in H4 neuroglioma cells lead to a reduction in BACE1 (EPR3956) (t-test, * = 
p<0.05; ** = p<0.01). (B) In pooled stable H4 cell lines, CNBP can be knocked down 
and then replaced by cDNA complementation (left). In the overall evaluation of 
knockdown experiments (right), the BACE1 reduction only trended lower (p<0.13) when 
CNBP was knocked down, even though the increase was substantial when CNBP was 
overexpressed (3 experiments, n = 9-12 replicates / construct; combined pooled stables 
and transient transfection; Scheffe test for multiple pairwise comparisons, ** = p<0.01, 
relative to scrambled shRNA). This could indicate that BACE1 reduction in response to 
CNBP knockdown may be less robust than the increase observed in response to 
overexpression. All knockdown results were the same when compared to an empty vector 
control. Error bars represent SEM. AU, arbitrary units. 
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Figure 4.4 CNBP Overexpression or Knockdown Differentially Affects BACE1 
mRNA Levels. CNBP overexpression (top row) in HEK293T, H4, or SH-SY5Y cells did 
not increase BACE1 mRNA expression. CNBP knockdown (bottom row) using shRNA 
trended towards a reduction in BACE1 mRNA levels overall and may indicate a 
threshold level of CNBP is needed for target mRNA stability. Geometric means were 
normalized to expression levels of β-Actin and GAPDH and compared to controls; t-test, 
* = p<0.05, ** = p<0.01. Results are the average of three individual experiments. Error 
bars represent SEM. 
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Figure 4.5 CNBP Associates with BACE1 mRNA in Cell Lysates. (A) RNA 
immunoprecipitation (RIP) followed by RT-qPCR from H4 whole cell lysate or whole 
mouse brain lysate showed that CNBP associated with BACE1 mRNA at endogenous 
concentrations. PCR products were run on a 2% agarose gel to confirm correct product 
size and enrichment in the specific protein pull-down sample (PABP or CNBP) compared 
to the negative control pull-down sample (IgG or pre-CNBP). PABP/β-Actin was used as 
an overall positive control for the RIP experiment. RPS17 (human) or rpL32 (mouse), 
both identified mRNA targets of CNBP, were used as positive controls for CNBP pull-
down. (B) IP-Western blots confirmed the immunoprecipitation of CNBP protein by 
CNBP polyserum (α-CNBP) and not by the pre-immune serum (Pre-CNBP). UB = 
unbound fraction, W = wash fraction, IP = immunoprecipitated fraction. (C) Examination 
of select mRNAs (of varying abundance) from RIP crosslinking experiments in H4 cells 
showed that in addition to BACE1 and RPS17, CNBP was able to pull down mRNAs for 
β-Actin, BIN1 and ODC1, but not BACE2, MAPT, APP, GAPDH or the mRNA for 
CNBP itself (Mann-Whitney Test, adjusted for multiple comparisons: * = p<0.05, ** = 
p<0.01, *** = p<0.001; 3-4 independent experiments, 3 – 11 replicates / target mRNA). 
Fold enrichment represents the signal above background level and was calculated as 
2^[Ct(mock) – Ct (IP)], where Ct represents the cycle threshold. 
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Figure 4.6 The BACE1 5’ UTR Mediates CNBP Translational Regulation. (A) seAP 
vectors containing various combinations of BACE1 UTRs or no UTRs were translated in 
a cell-free lysate with or without recombinant GST-CNBPWT spiked in; protein products 
were  radiolabeled with 35S-cysteine/methionine and detected by SDS-PAGE and 
autoradiography. The same several protein products were produced from all four vectors 
used (compare to No Vector control, relocated from blot directly to the left of the protein 
lanes). The constructs containing the BACE1 5’ UTR display a striking inhibition of 
overall protein production compared to the vectors lacking the BACE1 5’ UTR, 
consistent with its described inhibitory nature. (B) A single protein band was further 
analyzed for expression levels with or without recombinant CNBP added to the system. 
(C) Densitometric quantification of this single band illustrated that CNBP increased 
protein expression only in vectors containing the BACE1 5’ UTR when compared with 
the vector containing no UTRs. The BACE1 3’ UTR had little effect on protein 
production in the presence of excess recombinant CNBP. This same general effect was 
observed for each individual band or when all bands were combined, implicating the 
BACE1 5’ UTR as the most likely site of CNBP translational regulation. 
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Figure 4.7 Identification of EMSA Binding Conditions for CNBP. (A) A known 
CNBP target (X. laevis L4 ribosomal protein RNA) was used to develop binding 
conditions, along with its closest in silica match (a 31-nt site with 58% identity, at 
position 210-240 in the BACE1 5’ UTR). The predicted secondary structures (mfold 
program) for the two 31-nt oligos at their most favorable free energies (L4: ΔGº = -11.7 
kJ, BACE1: ΔGº = -11.3 kJ) indicated similar hairpin structures. (B) CNBP bound the L4 
probe most favorably at room temperature (RT) compared to 4°C or 37°C. Binding 
reactions were carried out in 1× binding buffer (10 mM Tris, pH 7.5, 50 mM KCl, 1 mM 
DTT, 10% glycerol, 10U RNase inhibitor) for 30 minutes with 50 ng (~100 nM) of 
recombinant human CNBPWT-DDK and 0.5 ng (50 fmol; 2.5 nM) of L4 oligo. (C) 
Several buffer conditions (#1, 2, 4, 5, and 6) were reasonable for CNBP binding the L4 
test probe; CNBPWT-DDK: 50 ng (~100 nM); L4 oligo: 0.5 ng (50 fmol; 2.5 nM). (D) 
The most similar region of the BACE1 5’ UTR compared to the L4 probe did not bind 
CNBP under the most favorable EMSA conditions. This indicated that the binding region 
for CNBP is not specific to this region, but likely binds a more generic motif such as 
structured G-rich regions with an adequate number of unpaired guanines [215, 231]. 
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Figure 4.8 CNBP Binds Directly to the BACE1 5’ UTR. Electrophoretic mobility shift 
assays showed that CNBP (both GST-CNBPWT and human CNBPWT-DDK) bound 
directly to the labeled BACE1 5’ UTR (6.14 ng; 1.08 nM per lane). Binding was blocked 
by an excess (300×) of unlabeled UTR competitor; a CNBP mutant (GST-CNBP1-∆RGG) 
missing the RGG box (critical RNA recognition motif [194]) showed no binding and 
indicated the GST tag was not responsible for binding.  
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Figure 4.9 CNBP Increases With BACE1 in AD. (A) Human case statistics used for 
Western blot analysis. (B) Left, representative Western blots for BACE1 (Epitomics, 
EPR3956) and CNBP protein in AD-affected (the SMTG) and unaffected (the CB) 
regions. Right, in AD, CNBP and BACE1 were significantly higher in the SMTG, and 
significantly lower in the CB. (C) CNBP and BACE1 levels were significantly and 
positively correlated in both the SMTG (p<0.01) and the CB (p<0.05). * = p<0.05, ** = 
p<0.01. Error bars represent SEM. AU, arbitrary units. 
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Figure 4.10 BACE1 and CNBP mRNA Levels are Unchanged in AD. BACE1 (top) 
and CNBP (bottom) total mRNA levels were not significantly different between Control 
and AD cases in either the SMTG or CB (BACE1: p>0.2; CNBP: p>0.4). The mRNA for 
CNBP trended towards an increase in the SMTG and a decrease in the CB, mirroring 
protein levels. mRNA data was only available for a subset of the cases, (10 AD, 9 
control; BACE1 values were standardized to the geometric mean of GAPDH and TPT1. 
CNBP values were represented as a ratio of the CNBP/TPT1 standard curves; no effect 
was observed for alternative methods of standardization). Error bars represent SEM. 
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Figure 4.11 CNBP is Increased in Early-Stage AD. PBS extracts from a set of human 
tissue (SMTG region; Control, low pathology: n = 9; Control, high pathology (PCAD): N 
= 10, mild cognitive impairment (MCI): n = 7) were run on spot blots and probed for 
CNBP, BACE1 (Epitomics, EPR3956), or β3-Tubulin (Abcam). Three blots were run for 
each protein (9 total blots) for consistency and to avoid potential problems with 
incomplete stripping and re-probing of the same membrane. Protein spots were quantified 
by densitometry using Scion Image and the median value for each sample was used. β3-
Tubulin values did not vary significantly across all samples or blots. Control cases (low 
pathology and high pathology) were grouped and compared to MCI cases. CNBP was 
increased in MCI (left), widely considered the earliest clinical stage of AD; BACE1 and 
CNBP were also significantly correlated (right) in this case series. * = p<0.05. Error bars 
represent SEM. AU, arbitrary units. 
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CHAPTER FIVE: CNBP is Induced by Cellular Stress and Increases 
Cap-Independent Translation of BACE1 
 
INTRODUCTION   
We have shown in Chapter Four that CNBP regulates translation of BACE1 and 
that this may play an important role in the etiology of sporadic Alzheimer’s disease. 
CNBP is a positive regulator of BACE1 expression and increases early in the disease 
process. These results lead to two additional interesting questions: (1) how is CNBP 
expression regulated and (2) how might CNBP enhance BACE1 translation? This chapter 
will begin to address those two questions with the goal of discovering more about the 
functional role of CNBP in the brain and how it may regulate translation of its targets, 
specifically BACE1.  
Impaired energy production in the brain has been suggested to play a major role in 
the development of sporadic AD. Positron emission tomography imaging studies revealed 
lower glucose utilization in AD brains compared to age-matched controls [131, 287-289]. 
Reduced brain glucose metabolism has also been reported in patients with MCI, 
indicating one of the earliest events that may occur in the brain leading to disease [290-
292]. Importantly, inhibiting energy metabolism in vitro increases amyloidogenic APP 
processing [293-296]. Recently, it was shown that energy inhibition increases translation 
of BACE1 via the phosphorylation of the eukaryotic initiation factor eIF2α (eIF2α-P) 
[132, 170], although the mechanism of how this occurs is still unclear. 
In addition to glucose deprivation, oxidative stress is another hallmark of the AD 
brain (reviewed in [297]). Oxidative stress occurs from an imbalance in the production 
and neutralization of reactive oxygen species (ROS), which are produced during energy 
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metabolism reactions. The accumulation of ROS in the form of free radicals and 
peroxides cause damage to DNA, RNA, protein, and lipid molecules in the cell and 
disrupt normal cellular signaling processes (reviewed in [298]). It is unclear what causes 
an increase in ROS in AD, but increased oxidative damage occurs in individuals with 
MCI [299, 300], and suggests a causal role in the disease. Oxidative stress may increase 
BACE1 expression transcriptionally ([136], reviewed by [301]) or through a post-
transcriptional mechanism [171]. Furthermore, a feedback loop between Aβ production, 
oxidative stress, and secretase (α, β, γ) functions has been proposed [301] which may be 
evolutionarily conserved [302]. 
Most transcripts, including BACE1, are believed to be translated in the canonical 
5’ cap-dependent manner under normal cellular conditions. Cap-dependent translation is 
achieved through the recognition and binding of the 7-methylguanylate cap by a number 
of eukaryotic initiation factors and the small (40S) ribosomal subunit which combine to 
form a 43S pre-initiation complex. This complex then scans the transcript in a 5’ to 3’ 
direction in search of the first AUG start codon, where the large ribosomal subunit (60S) 
is recruited to form the 80S ribosomal complex and initiate translation. However, cap-
dependent translation is impaired when cells undergo various forms of stress (reviewed in 
[303] and [304]). Cells often respond to physiological and pathophysiological stress (eg. 
nutrient deprivation, oxidative stress, viral infection, apoptosis, unfolded protein 
response, cell cycle transitions) by downregulating global protein synthesis to conserve 
energy and resources; this is achieved in part by the phosphorylation of eIF2α [304, 305].  
Paradoxically, certain transcripts are preferentially translated during stress 
conditions and BACE1 appears to be one of these. These mRNAs encode proteins that 
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carry out crucial functions during times of cellular stress and many rely on alternative 
methods of translation initiation. The most commonly studied method is a cap-
independent process that involves direct recruitment of the 40S ribosome close to the 
initiator start codon through an internal ribosome entry site (IRES) (Reviewed in [305]). 
IRESs are cis-acting structured elements that are usually located in the 5’ UTR and were 
first discovered in picornaviruses, but have since been characterized in other viruses as 
well as a growing number of eukaryotic cellular mRNAs (reviewed in [306] and [307]). 
IRES sequences are highly variable and form complex structures, and their presence must 
be individually verified experimentally. It is unclear how IRES elements directly recruit 
ribosomes, but it has become apparent that a number of non-canonical initiation factors 
called IRES trans-acting factors (ITAFs) are involved in IRES-mediated translation 
(reviewed in [308] and [309]). Although there has been no evidence to suggest that the 
BACE1 5’ UTR can support cap-independent translation through an IRES, it displays 
many features (extremely long, high GC content, multiple uORFs, activated by stress) 
common amongst other cellular transcripts that do contain proposed IRES elements 
[303]. Thus, further study is warranted to determine whether BACE1 can support cap-
independent translation, especially during times of cellular stress. 
To date, there have been no studies on how various cellular conditions affect 
CNBP expression, although several lines of evidence suggest that CNBP may be 
involved in stress-induced translational regulation. CNBP has been implicated in the 
translational regulation of two seemingly unrelated types of mRNAs: 5’ TOP containing 
mRNAs and mRNAs harboring an IRES. However, both of these types of mRNAs are 
highly regulated by stress conditions which may be a common characteristic of CNBP 
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targets. In two separate studies, CNBP was described as an ITAF that promoted the 
IRES-mediated cap-independent translation of ODC1 [204] and also as a nucleic acid 
chaperone that could catalyze the rearrangement of nucleic acid secondary structures 
[215]. Interestingly, many other ITAFs have been shown to possess RNA chaperone 
activity ([310, 311] and reviewed in [312]). These clues indicate that CNBP could be 
broadly involved in stress-induced translational regulation. 
In this chapter, we carried out a set of experiments to probe the possible 
mechanism for the observed enhanced translation of BACE1 by CNBP. We first used 
several different cell lines to show that various cellular stresses stimulate CNBP 
expression. We then used nuclease-EMSAs and circular dichroism (CD) to study 
properties of RNA structure upon CNBP binding and showed that it is unlikely CNBP 
enhances translation of BACE1 by decreasing global RNA secondary structure. Finally, 
we used various dicistronic reporter constructs in both cell culture and cell-free systems 
to show that increased levels of CNBP may mediate translation of BACE1 via a cap-
independent mechanism. 
 
METHODS 
Nuclease EMSA 
EMSAs were done essentially as described in Chapter Four, with some important 
additions. For nuclease treated samples, RNase T1 (1 U, Fermentas; for the L4 T1 
experiment, the concentration was 20 U to ensure complete digestion), RNase A (1 U, 
Promega), or RNase V1 (0.1 U, Ambion) were added to the binding reactions for the last 
5 minutes to allow nuclease digestion to occur. Samples were run on a non-reducing 5% 
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TBE polyacrylamide gel. Recombinant GST-CNBPWT was added at a 100:1 
(CNBP:probe) molar ratio unless otherwise specified.   
 
Circular Dichroism (CD) Spectroscopy 
The entire unlabeled 5’ UTR of BACE1 was generated by in vitro transcription as 
described in Chapter Four. Recombinant GST-CNBPWT (10 µM) was added to BACE1 5’ 
UTR RNA probe (50 nM) in a total volume of 200 µL EMSA binding buffer and allowed 
to incubate for 15 minutes at room temperature prior to CD spectroscopy. CD spectra 
were recorded over a wavelength range of 250-350 nm with a Jasco-810 
spectrapolarimeter using a quartz cell of 1-cm optical path length, and an instrument 
scanning speed of 50 nm/min with a response time of 8 s. The reported CD spectrum of 
each sample represented the average of four accumulations taken at room temperature. 
Blank cuvette and buffer background CD spectra were generated and determined to be 
free of noise. The spectral contribution of GST-CNBPWT (10 µM) alone was subtracted 
from the bound spectra. 
 
Stress Experiments (Glucose Deprivation or H2O2 Treatment) 
H4, HEK293T, or N2a cells were grown in 6-well or 12-well plates to 60-80% 
confluence as described in Chapter Two. For glucose deprivation experiments, media was 
removed from all wells and replaced with DMEM media containing 4500 mg/L D-
glucose (referred to as high glucose in figures; Gibco) or no glucose (referred to as no 
glucose, low glucose, or glucose deprivation in figures; Gibco). The plates were 
incubated at 37ºC for the indicated amount of time, after which the media was removed, 
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cells were washed with 1× PBS, and lysed in 1× RIPA with PIC+EDTA, followed by 
brief sonication. Lysates were cleared by centrifugation and total protein was measured 
using BCA assay. For glucose deprivation experiments in primary cells, rat cortical 
neurons were harvested as described in Chapter Two and plated in 35 mm dishes at 1.35 
million cells / dish. At 7 DIV, neurons were treated for 8 hr in 0.45-µM filter sterilized 
Locke’s solution (5 mM HEPES, pH 7.4, 154 mM NaCl, 5.6 mM KCl, 1 mM MgCl2, 3.6 
mM NaHCO3, 2.3 mM CaCl2) with or without 20 mM D-glucose (Sigma) [170, 313] and 
then harvested as described previously for biochemical analysis. 
To induce oxidative stress, H4 cells were treated with 0, 50, 100, 200, 300 or 500 
µM hydrogen peroxide (H2O2; Sigma, 30% stock) in fresh DMEM media (no sodium 
pyruvate, no FBS; Gibco) for 10 minutes at 37ºC. Afterwards, the media was removed 
and replaced with fresh DMEM media containing no H2O2 followed by an additional 
incubation for 1 hour at 37ºC. At the endpoint, cells were lysed and processed as 
described above for biochemical analysis.  
 
Dual Luciferase Assay 
H4 or HEK293T cells were grown in 6-well plates to 50-70% confluence and 
transfected with the human ODC1-IRES [205], RP-null, RPh-null, RP-BACE1, or RPh-
BACE1 dual luciferase constructs [144] along with pCMV6-XL5 empty vector or 
pCMV6-XL5 CNBP using FuGene HD as described in Chapter Two. Cells were 
harvested after 24 hours and dual luciferase assays (DLR Reporter Assay System; 
Promega) were performed in white opaque 96-well microplates (Costar) according to the 
manufacturer’s instructions using a BioTek Synergy HD plate reader set to monitor 
luminescence. In vitro transcription / translation assays were carried out as described in 
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Chapter Four (0.5 µg of plasmid and 10 µM GST-CNBPWT were used) and 5 µL of each 
cell lysate reaction was used for dual luciferase assays. Results were presented as a ratio 
of Firefly luciferase activity to Renilla luciferase activity compared to appropriate 
negative controls.  
 
RESULTS 
Cellular Stress Increases CNBP Expression 
We first sought to answer the question of why CNBP expression may increase in 
the early AD brain. Since CNBP has been implicated in the translation of two different 
sets of stress-regulated mRNAs (5’ TOP- and IRES-containing) and since BACE1 
translation is regulated by various cellular stresses, we hypothesized that cellular stresses 
common to AD may increase CNBP expression as well. To test this, we performed 
studies in multiple cell lines and primary neurons grown under conditions of low glucose, 
mimicking the state of energy deprivation in the AD brain [170]. Glucose deprivation for 
2-8 hours and in several cell types lead to a robust increase in both CNBP and BACE1 
expression overall (Fig. 5.1A-C), and this effect was partially blocked by a shRNA 
directed against CNBP (Fig. 5.2). A breakdown of the results indicated that all cell lines 
showed increased CNBP and BACE1 expression (clearly visible on Western blots) with 
glucose deprivation, but only HEK293T (set 2) and primary neurons reached statistical 
significance (Fig. 5.1D). These results reflected inconsistencies in Western blot data, 
even within the same samples run multiple times, resulting in a large variance. A larger 
set of samples with more replications would likely result in significant increases for all 
cell types. It is important to note that BACE1 and CNBP protein levels remained highly 
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correlated in these experiments as well (Fig. 5.1E). Although brief H2O2 exposure was 
also able to induce CNBP expression by up to 2-fold at 500 µM (Fig. 5.3), we did not 
observe a corresponding increase in BACE1 under these conditions. Nevertheless, these 
results propose a mechanism for increased CNBP levels observed in AD and indicate that 
prolonged cellular stress, as seen in the progression of AD, may be linked to a pathogenic 
role of CNBP. 
 
CNBP Does Not Alter BACE1 5’ UTR Global Secondary Structure 
The high degree of stable secondary structure in the BACE1 5’ UTR has been 
proposed to inhibit BACE1 translation by impeding ribosome scanning [146]. Since 
CNBP can rearrange nucleic acid secondary structure through its nucleic acid chaperone 
activity, we first considered the possibility that CNBP may improve BACE1 translation 
by reducing the global secondary structure of the BACE1 5’ UTR. This would likely 
require CNBP to “coat” the RNA molecule when present in excess quantities, a 
characteristic that has been attributed to other RNA chaperone proteins [314]. Coating of 
the RNA molecule by CNBP could theoretically allow for more efficient ribosomal 
scanning in order for the translational machinery to reach the authentic AUG codon and 
may also explain why CNBP increased BACE1 protein expression in a dose-dependent 
manner.  
We first evaluated the ability of CNBP to bind the BACE1 5’ UTR probe in the 
presence of various RNA nucleases using EMSA. RNase T1 cuts only after unpaired G 
nucleotides, RNase A cuts only after unpaired C or U nucleotides, and RNase V1 cuts 
only double stranded RNA (dsRNA). Since CNBP binds unpaired G nucleotides, we 
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hypothesized that CNBP should partially protect these sites of the from RNase T1 
activity, preserving a shift using EMSA. On the other hand, RNase A was expected to 
freely digest the RNA regardless of CNBP binding. Finally, if CNBP plays a role in 
reducing RNA secondary structure by coating the mRNA (binding to most unpaired Gs), 
then CNBP should retain partial binding ability to the BACE1 5’ UTR in the presence of 
RNase V1.  
We first showed that CNBP offered some RNA protection in the presence of 
RNase T1 using the L4 31-nt probe (Fig. 5.4A). Next, we performed EMSAs using the 
radiolabeled BACE1 5’ UTR probe along with recombinant CNBP and RNase T1, A, or 
V1. Just as with the L4 probe, CNBP was able to partially protect the BACE1 5’ UTR 
from digestion by RNase T1, presumably through binding unpaired G residues (Fig. 
5.4B). Alternatively, RNase A was able to fully digest the RNA probe, even with CNBP 
bound, as expected (data not shown). Finally, CNBP-bound BACE1 5’ UTR RNA was 
not protected from RNase V1 digestion (Fig. 5.4C), indicating that CNBP does not likely 
unfold global secondary structure of the BACE1 5’ UTR at high concentrations.  
We attempted to confirm this result through CD spectroscopy measurements of 
the unlabeled BACE1 RNA probe alone or bound to CNBP, looking for drastic changes 
in the CD spectra between the two which might indicate a global change in secondary 
structure. Our results indicated that the CD spectras of free probe and CNBP-bound probe 
were largely identical (Fig. 5.4D), further suggesting that a global unfolding of the RNA 
molecule is unlikely upon the presence of excess quantities of CNBP. 
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CNBP Enhances Cap-Independent Translation of BACE1 
Recent studies indicated that CNBP directly binds the ODC1 IRES to mediate 
cap-independent translation, possibly as part of a larger complex of ITAFs [204, 205]. 
We designed a set of experiments to test the possibility that CNBP regulates cap-
independent translation of BACE1 using dicistronic luciferase reporter constructs (Fig. 
5.5). Dicistronic reporter constructs contain two non-overlapping ORFs separated by a 
stop codon immediately after the 5’ cistron and a linker region (the sequence to be tested) 
preceding the 3’ cistron, and are considered good models to test for cap-independent 
translation [315]. A hairpin placed at the 5’ end of a dicistronic construct inhibits cap-
dependent translation of the upstream cistron and is often used to confirm that any 
activity of the downstream cistron results from cap-independent initiation. The rat 
BACE1 5’ UTR sequence in these constructs is highly similar to the human BACE1 5’ 
UTR [58, 144, 146] and has been confirmed to not contain a cryptic promoter, nor is it 
cleaved into two monocistronic transcripts [144, 147] which could result in false-positive 
readings of cap-independent luciferase activity.  
Insertion of the BACE1 5’ UTR between the two luciferase genes enabled cap-
independent translation of firefly luciferase when expressed in HEK293T cells (Fig. 
5.6A). Importantly, BACE1 5’ UTR mediated firefly luciferase expression increased 
under conditions of glucose deprivation (Fig. 5.6B), and when CNBP was overexpressed 
(Fig. 5.6C). We were able to replicate the effect of CNBP on the dual luciferase reporters 
in an in vitro transcription / translation assay (Fig. 5.6E). As a positive control for these 
experiments, we included a dual luciferase construct containing a portion of the ODC1 5’ 
UTR that contains an IRES [205] in place of the BACE1 5’ UTR and showed that CNBP 
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overexpression enhanced cap-independent translation comparable to that observed with 
the BACE1 constructs. CNBP was overexpressed to similar levels in these experiments, 
as confirmed by Western blot (Fig. 5.6D). Finally, CNBP overexpression did not affect 
cap-dependent translation of Renilla luciferase (Fig. 5.7). Taken together, these results 
suggest that CNBP enhances cap-independent translation of BACE1 possibly through a 
previously undiscovered IRES element, and that this regulation may be dependent on 
CNBP protein levels, which are increased by cellular stress. 
 
DISCUSSION 
In this chapter, we showed that CNBP can be induced by cellular stressors 
designed to mimic some aspects of the environment in the AD brain, such as glucose 
deprivation and oxidative stress. We observed similar results in several cell lines and in 
primary neurons, indicating a conserved mechanism of regulation. In the glucose 
deprivation experiments, we did not detect a significant increase in CNBP prior to 
BACE1 over several time points; pulse-chase experiments over shorter time frames may 
be useful in determining a more detailed expression profile. Also, even though we 
showed that H2O2 exposure could increase CNBP expression, we did not detect a 
corresponding increase in BACE1 expression as had been reported previously [171]. The 
discrepancies between results may be explained by differences in experimental methods 
(cell lines, treatment conditions, antibodies used) and requires further study.  
It is not surprising that CNBP may be involved in stress-induced translational 
regulation. Numerous RNA binding proteins are involved in important cellular activities 
under stressed conditions. These include the previously identified ITAFs heterogeneous 
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ribonucleoprotein (hnRNP) I/PTB (polypyrimidine tract binding protein; [316]), hnRNP 
E2/PCBP2 (poly r(C) binding protein 2; [317]), La autoantigen [318, 319], and unr 
(upstream of N-ras; [320]) as well as proteins involved in neurodegenerative diseases 
such as FMRP [321] and TDP-43 (reviewed in [322]) among others. The roles of these 
proteins vary from transcriptional and translational regulation to mRNA localization and 
splicing. CNBP has already been linked to La [202, 230] and PCBP2 [204] in 
translational regulation and may function as part of a complex of proteins needed for 
coordinated response to cellular stress. In addition, an analysis of the mouse CNBP 
promoter [190] indicated several putative binding sites for transcription factors that have 
been implicated in neuronal stress response such as Sp1 [323], AP-1 (reviewed in [324]), 
and CHOP-C/EBP [325], which indicate that CNBP transcription may be upregulated by 
stress. Although we only evaluated protein expression in these stress experiments, RNA 
analysis from our human tissue experiments in Chapter Four at least hinted that CNBP 
transcription may change in the AD brain. 
CNBP has recently been characterized as a nucleic acid chaperone protein [215]. 
Nucleic acid chaperones bind single-stranded DNA or RNA and catalyze the 
rearrangement of secondary structures in an ATP-independent manner, influencing 
cellular processes such as transcription, translation, splicing, and stability (reviewed in 
[314]). A role for CNBP chaperone activity in c-Myc transcription has recently been 
described, in which CNBP was shown to catalyze the formation of G-quadruplex (G4) 
structures through rearrangement of ssDNA bases [231]. This process used the DNA 
melting and annealing activities of CNBP; it may be that CNBP could also rearrange the 
secondary structure of RNA molecules to influence translational regulation.  
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It has been suggested that RNA chaperone proteins, in excess quantities, may 
“coat” a nucleic acid target, thereby destabilizing global secondary structure (reviewed in 
[314]). Helix destabilizing assays utilizing various RNA nucleases are typically used to 
test for this activity. Our nuclease-EMSA and CD results indicated that it is unlikely 
CNBP reduces global secondary structure of BACE1 mRNA, although it may be that 
numerous CNBP proteins may associate with the mRNA, depending on the amount of 
unpaired G’s available and the surrounding structured environment. These results do not 
rule out the possibility that certain cellular conditions or additional cellular factors may 
be needed to see a global rearrangement of secondary structure, or that CNBP may be 
involved in rearrangement of local secondary structures to influence translational 
regulation. 
Our results indicated that the BACE1 5’ UTR facilitates cap-independent 
translation and that this activity is enhanced when CNBP levels are increased either 
directly (by CNBP overexpression) or indirectly (by glucose deprivation). We observed 
an increase in cap-independent translation by CNBP both in cell culture and in a cell-free 
system. The ODC1 IRES was used as a positive control for CNBP-mediated cap-
independent translation and we saw comparable results with previously published data 
[204, 205] as well as with our own results for CNBP-mediated cap-independent 
translation of BACE1. It is interesting to note that ODC1, which provides the rate-
limiting activity in polyamine synthesis, is increased after CNS injury [326] and is also 
increased in AD brain tissue [327, 328] where it shifts to a more cytoplasmic localization 
[329]. Thus in AD, increased ODC1 may be mediated by CNBP as well. 
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The results from our dual luciferase experiments makes it tempting to speculate 
that the BACE1 5’ UTR contains a true IRES element. There has been no evidence to 
support the idea that the BACE1 5’ UTR harbors an IRES to support cap-independent 
initiation of BACE1 translation, although only two groups have looked. Rogers et al. 
reported no evidence of cap-independent translation from a dicistronic luciferase 
construct containing the rat BACE1 5’ UTR expressed in cultured rat cells; however, they 
did not show any data to support their claim [144]. De Pietri Tonelli et al. expressed 
BACE1 discistronic vectors in SK-N-BE (human neuroblastoma) or HeLa cells and 
found no evidence of cap-independent translation either, but once again no data was 
shown [148]. This group also used an MVA-T7pol vaccinia virus system to express their 
reporter constructs which allows for transcription to occur solely in the cytoplasm; 
however, it has recently been suggested that a “nuclear experience” may play a role in 
BACE1 translation, suggesting that cytoplasmic expression systems may not be 
physiologically relevant [147]. Importantly, both of these studies only looked for cap-
independent translation under normal cellular conditions in which cap-dependent 
translation predominates. Although we did observe cap-independent expression of our 
BACE1 constructs in unstressed cells, this may be attributed to cell type specific factors 
or standardization methods. The most important result is that we observed an increase in 
cap-independent expression above control levels under stressed conditions and when 
CNBP was overexpressed. It is interesting to note that some limited evidence indicates 
that the 5’ UTRs of both APP [280] and MAPT [281] may contain IRES elements, but 
CNBP did not bind either of these mRNAs in our RIP experiments (Chapter Four). 
Although this does not prove the absence of a BACE1 IRES, it does suggest that CNBP 
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probably does not bind indiscriminately to all IRES elements. Propensity to bind and 
regulate certain IRES elements but not others is a common trait amongst ITAFs and is 
most likely dictated by the formation of specific RNP complexes to allow for greater 
combinatorial control (reviewed in [307]). It is important to note that cap-independent 
translation and IRES-directed translation initiation are not synonymous. It has recently 
been proposed that some cellular mRNAs may employ cap-independent translation that is 
5’ end- and scanning-dependent in the absence of a 5’cap or an IRES, or when eIF4E, 
which binds the 5’ cap and is required for cap-dependent initiation, is inhibited (reviewed 
in [330]). Therefore, it is plausible that CNBP could direct cap-independent translation of 
BACE1 in an IRES-independent fashion. 
Although the data presented in this chapter begins to describe how CNBP might 
regulate the translation of BACE1 during the progression of AD, many details are still 
left unanswered. The next, and final chapter, will serve to provide an overall conclusion 
to this body of work as well as to discuss some of the interesting questions generated by 
this study, including specific recommendations for future experiments. 
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Figure 5.1 Glucose Deprivation Increases Both CNBP and BACE1 Expression. 
Representative Western blots of CNBP and BACE1 (D10E5) expression in (A) cultured 
cells (H4, HEK293T, N2a) and (B) primary cortical rat neurons over various time points 
under conditions of glucose deprivation (low glucose) (HG = high glucose, LG = low 
glucose). (C) Overall, there was a significant increase in both CNBP (F1,64 = 17.0, p<0.1) 
and BACE1 (F1,64 = 6.4, p<0.02) expression in cultured cells subject to glucose 
deprivation up to 8 hours. (D) Breakdown of effects of glucose deprivation in multiple 
cell types (5 independent experiments; replicates in brackets, ½ grown in high glucose 
conditions): H4 (n = 8), HEK293T (experiment 1, n = 8), HEK293T (experiment 2, n = 
36), N2a (n = 8), rat primary neurons (n = 6); Baseline = high glucose measurements. 
Dunnett’s test, * = p<0.05, ** = p<0.01. (E) CNBP and BACE1 were also strongly 
correlated in these experiments. Results were unchanged when standardized to loading 
control (β-Actin, GAPDH, β3-Tubulin) levels. Error bars represent SEM. AU, arbitrary 
units. 
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Figure 5.2 CNBP May Mediate Stress-Induced BACE1 Protein Expression. Stable 
expression of a shRNA directed against CNBP in H4 cells at least partially blocked the 
effects of glucose deprivation (2 hour glucose deprivation) on BACE1 expression relative 
to the control shRNA vector (n = 3); t-test, * = p<0.05. HG = high glucose, NG = no 
glucose (glucose deprived). Error bars represent SEM. 
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Figure 5.3 H2O2 Increases CNBP Protein Expression. Brief (10 minute) exposure to 
H2O2 followed by a 1 hour incubation lead to increased CNBP expression (F5,12 = 4.3, 
p<0.02) in H4 cells (n = 2-5 replicates / concentration) in a dose-dependent manner, 
although we did not detect a change in BACE1 in this cell type under these conditions; 
Dunnet’s test, * = p<0.05. Error bars represent SEM. AU, arbitrary units. 
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Figure 5.4 CNBP Binding has Minimal Effects on Global BACE1 RNA Secondary 
Structure. (A) Digestion of bound and unbound L4 probe (the CNBP positive binding 
control) with RNase T1 indicates partial protection of the probe (Lane 1, L4 probe; Lane 
2, T1 digested L4 probe; Lane 3, L4 bound to CNBP; Lane 4, partially protected L4 
probe; Lane 5, CNBP added after digestion does not bind the L4 probe; Lane 6, CNBP 
treated with excess EDTA (*) reduces binding to the L4 probe; Lane 7, heat denatured 
CNBP (#) reduces binding to the L4 probe). Molar ratio of CNBP:probe was 100:1. (B) 
BACE1 5’ UTR similarly shows partial protection from RNase T1 digestion (note 
increase in % uncut with increasing CNBP added); this is consistent with CNBP binding 
regions of unpaired G’s [331]. Molar ratios of CNBP:probe were 20:1, 150:1, and 750:1. 
CNBP binding did not offer any protection against RNase A digestion (RNase A cuts 
after C/U; not shown). (C) CNBP binding does not protect against RNase V1, which 
digests dsRNA (* = EDTA and heat treated CNBP); this suggests that CNBP binding 
does not significantly reduce the amount of dsRNA within the BACE1 5’ UTR. Molar 
ratio of CNBP:probe was 100:1. (D) CNBP binding did not have a striking effect on the 
CD spectra of the BACE1 RNA. 
  
130 
 
 
Figure 5.5 Schematic of Dual Luciferase Constructs. Dual luciferase constructs [144] 
contained an SV40 promoter with (RPh) or without (RP) a 5’ hairpin to block cap-
dependent translation, and with or without the BACE1 5’ UTR inserted between the two 
luciferase genes. Since a STOP codon follows the Renilla luciferase gene, and since the 
BACE1 5’ UTR remains intact and does not contain a cryptic promoter [144, 147], the 
Photinus (Firefly) luciferase can only be translated into active enzyme via a cap-
independent mechanism. In these constructs, the rat BACE1 5’ UTR is used, which is 
427-nt long with four uAUGs (three uORFs) and is highly conserved with the human 
BACE1 5’ UTR [58, 144, 146], indicating a conserved regulatory role. 
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Figure 5.6 CNBP Drives Cap-Independent Translation of BACE1. (A) The BACE1 
5’ UTR showed cap-independent translation compared to the null constructs (since cap-
dependent translation is partially blocked in the RPh-BACE1 construct, the relative 
increase in expression is larger). (B) Glucose deprivation further increased the relative 
magnitude of cap-independent expression. (C) CNBP overexpression caused a similar 
increase in RP-BACE1 cap-independent translation as compared to a known positive 
control, the ODC1 5’ UTR. (D) CNBP overexpression in panel C was comparable for all 
constructs by Western blot. (E) CNBP increased relative cap-independent translation (F:R 
= Firefly:Renilla expression) of the BACE1 RPh vector and the hODC1-IRES vector in 
an in vitro transcription / translation system in a concentration dependent manner. t-test, * 
= p<0.05, ** = p<0.01; # = p<0.01, relative to RP-BACE1. In panels A, B, and C, the F:R 
expression ratios are shown for each construct standardized to RP-BACE1 which was set 
to 100. In panel E, F:R ratios are shown standardized to the 0 µg CNBP samples. Error 
bars represent SEM. AU, arbitrary units. 
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Figure 5.7 Renilla Activity is Not Affected by the BACE1 5’ UTR or CNBP. As 
expected, the 5’ hairpin was an exceptionally strong suppressor of cap-dependent Renilla 
expression (t46 = 19.1, p<0.0001). Insertion of the BACE1 5’ UTR in between the Renilla 
and firefly luciferase genes had no impact on overall expression (p<0.7). CNBP 
overexpression (insert: blot indicating matched levels of expression) also had no effect 
on the Renilla expression from any of these constructs (p<0.3), indicating that CNBP did 
not have a generic effect on cap-dependent translation (2 independent experiments were 
performed in HEK293T cells, n = 6 replicates / construct, ½ with CNBP overexpression). 
Firefly luciferase expression (see Fig 5.6) was determined from the same experiments. 
Data are shown standardized to RP-BACE1, set to 100. Error bars represent SEM. RFU, 
relative fluorescent units. 
 
Copyright © Christopher J. Holler 2012 
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CHAPTER SIX: Summary and Future Directions 
  
SUMMARY 
In Chapter Three, we evaluated the expression of BACE1 and the related enzyme 
BACE2 in the brain tissue of a cohort of human cases ranging from early AD (PCAD, 
MCI), to late-stage AD, as well as several FTD cases. We showed that BACE1 protein 
and activity are increased in the earliest stages of AD, indicating a possible causal role in 
the development of disease. These changes occurred in a disease affected region (the 
SMTG) of the brain, but not in a disease unaffected region (CB). An increase in BACE1 
preceded significant accumulation of Aβ in the progression of AD, and we observed 
increased BACE1 in FTD cases as well which do not accumulate Aβ; this initial rise in 
BACE1 may be a response to enhanced cellular stress. We found similar results with 
BACE2 and showed that BACE1 and BACE2 expression are highly correlated in disease, 
suggesting a possible shared mechanism of regulation. A role for BACE2 in AD is 
currently unknown. In this study, BACE1 was weakly correlated with soluble Aβ 
measures and may not be a good predictor for amyloid load. Importantly, we verified that 
BACE1 protein is increased in the absence of changes to mRNA levels, suggesting that a 
post-transcriptional method of regulation is altered in disease. 
Previously, our lab identified the RNA binding protein, CNBP, as a potential 
regulator of BACE1 expression (MPM, unpublished data). In Chapter Four, we presented 
evidence that confirmed CNBP is a positive regulator of BACE1. Overexpression of 
CNBP in cell culture models and in primary neurons increased BACE1 protein; 
knockdown of CNBP decreased BACE1 protein levels variably, possibly through 
decreased transcript stability. We were also able to stimulate BACE1 translation in a cell- 
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free system using coupled in vitro transcription / translation by spiking in recombinant 
CNBP; these results indicated direct regulation by CNBP. Interestingly, in both cell and 
cell-free systems, CNBP increased BACE1 protein levels in a concentration-dependent 
manner. We showed that CNBP overexpression did not increase BACE1 transcription, 
further suggesting a primary role in translation. This was verified by checking for 
alterations in BACE1 mRNA or protein half-life after CNBP overexpression; in these 
experiments no changes were observed (MPM, RLW; unpublished data).  
The results from our RNA immunoprecipitation experiments showed that CNBP 
associated with BACE1 mRNA at endogenous concentrations and that CNBP bound 
directly to the BACE1 5’ UTR in vitro using EMSA. Furthermore, the BACE1 5’ UTR 
seemed to be necessary for an increase in CNBP-mediated protein production in an in 
vitro transcription / translation system. These studies further indicated that direct binding 
of CNBP to the BACE1 5’ UTR may be needed to carry out its regulation. Finally, we 
looked at CNBP and BACE1 expression in the brain in a cohort of AD and age-matched 
control cases. Both proteins were increased in AD in the SMTG, but decreased in the CB. 
No significant changes in BACE1 or CNBP mRNA levels were observed between control 
and AD cases; however, CNBP mRNA levels trended towards predicting protein levels. 
We extended our studies to several early-stage AD cases and found that CNBP protein 
levels were significantly increased in MCI cases; significant BACE1 elevation was not 
observed in these cases, indicating that increased CNBP levels in the brain likely precede 
increased BACE1 levels, as we would predict. Importantly, in all of our human cases, 
CNBP and BACE1 proteins were significantly positively correlated. 
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In Chapter Five, we asked the question of why CNBP expression might increase 
in the progression of AD. Since BACE1 translation is increased by cellular stress and 
since known CNBP mRNA targets also tend to be regulated in this fashion, we 
speculated that cellular stresses common to AD might increase CNBP as well. Indeed, we 
found that both glucose deprivation and H2O2 exposure (to induce oxidative stress) 
increased CNBP expression in cell cultures and in primary neurons. This indicated that 
CNBP might be a critical regulator of BACE1 protein translation during times of 
enhanced cellular duress. 
Finally, we wondered how CNBP might enhance BACE1 translation. Since little 
was known about how CNBP regulates translation of any of its targets, this was a 
daunting task. However, it was recently discovered that CNBP binds to an internal 
ribosome entry site in the ODC1 5’ UTR to activate cap-independent translation [204]. 
Cap-independent translation is often employed by stress response proteins during times 
of heightened cellular strain when traditional cap-dependent translation is inhibited. 
Although cap-independent translation had never been observed for BACE1 before, its 5’ 
UTR is typical of other cellular transcripts that do support this alternative method of 
translation initiation, usually through an IRES element. We tested the ability of the 
BACE1 5’ UTR to support cap-independent translation in HEK293T cells using dual 
luciferase reporter constructs. Our results indicated that the BACE1 5’ UTR could 
support cap-independent translation and most importantly that this activity was increased 
by CNBP either directly (through CNBP overexpression) or indirectly (through glucose 
deprivation). The BACE1 5’ UTR also mediated cap-independent translation in a CNBP 
concentration dependent manner in a cell-free in vitro transcription / translation assay. 
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Taken together, these results indicate that cellular stress may increase CNBP protein 
levels which in turn enhance cap-independent translation of BACE1. 
The goal of this project was to determine if the RNA binding protein, CNBP, is a 
regulator of the Alzheimer’s disease β-secretase protein, BACE1, and if so, how this 
regulation might occur. The results presented in this thesis, as a whole, begin to shape a 
compelling story for the involvement of CNBP as a novel translational regulator of 
BACE1 with important implications for the development of sporadic AD (Fig 6.1). The 
data presented in this thesis complement previously published literature in the fields of 
BACE1 expression and CNBP molecular function, yet also propose interesting and novel 
insights that advance both fields of research. Although much has been learned from these 
studies, many questions remain to be answered. 
 
CONCLUSIONS and FUTURE DIRECTIONS 
CNBP Interactions with the BACE1 5’ UTR 
In Chapter Four, we showed that CNBP associated with BACE1 mRNA at 
endogenous concentrations in cell lysates through RNA immunoprecipitation 
experiments and that CNBP bound directly to the BACE1 5’ UTR using EMSA and in 
vitro transcription / translation experiments. These studies indicated that direct binding of 
CNBP to the BACE1 5’ UTR may be needed to carry out its regulation. Future 
experiments will be conducted to try and discern the exact location or locations where 
CNBP functionally binds to the BACE1 5’ UTR. Since CNBP may bind to numerous 
unpaired Gs along the 5’ UTR, truncated 5’ leader sequences linked to a reporter gene 
could be used to determine which regions are necessary for CNBP-mediated translational 
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regulation. Alternatively, constructs in which the various uAUGs have been mutated 
could be used in the same manner. Many of these constructs have already been made by 
other labs and may be available for future studies [143-146]. 
CNBP is the first known trans-acting protein implicated in regulating BACE1 
translation through the BACE1 5’ UTR. Given the length and structural complexity of the 
BACE1 5’ UTR, it is surprising that no one has reported other proteins that interact with 
this region. In the future, it will be important to determine if CNBP acts as part of a 
complex of proteins, as expected, to regulate BACE1 translation. Tandem affinity 
chromatography followed by mass-spectrometry analysis may be used to determine other 
RNA binding proteins that interact with the BACE1 5’ UTR. In this manner, the BACE1 
5’ UTR could be used to “fish” out interacting proteins from a tissue or cellular extract, 
which could then be identified using mass spectrometry methods. A similar method was 
used to identify CNBP and PCBP2 bound to the ODC1 IRES element [204]. It would be 
particularly helpful if a narrow functional CNBP binding region of the BACE1 5’ UTR 
was identified first. 
 
CNBP and the Phosphorylation of eIF2α  
It has been reported that phosphorylation of eIF2α (eIF2α-P) increases BACE1 
translation after glucose deprivation [170] or oxidative stress [171]. We have shown that 
CNBP is involved in the stress-induced translational regulation of BACE1 and this 
suggests a link between CNBP and eIF2α-P (Fig. 6.2). Our results indicate that cellular 
stress increases CNBP protein levels and enhances cap-independent translation of 
BACE1, possibly through an IRES. IRES-mediated translation of some transcripts 
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requires phosphorylation of eIF2α [332], but can be active independent of eIF2α-P as 
well [333]. Therefore, it is tempting to speculate that upon phosphorylation of eIF2α 
during stress conditions, increased levels of CNBP enhance cap-independent translation 
of BACE1. CNBP could accomplish this by direct recruitment of ribosomes to the 
mRNA as part of an ITAF complex or through rearrangement of local secondary 
structures using its RNA chaperone activity. We did notice a potential block in the stress-
induced increase of BACE1 in our CNBP shRNA pooled stable cells, indicating that 
CNBP may be critical for this process. However, in order to definitively determine if 
CNBP is a required trans factor responsible for increasing BACE1 translation during 
cellular stress, we would need to inhibit or completely knock out CNBP expression in 
vivo. Under these conditions, induction of cellular stress and eIF2α-P should not cause an 
increase in BACE1 protein. Unfortunately, there are no known inhibitors of CNBP and 
CNBP knockout cells do not exist, making this hypothesis difficult to test. It has been 
proposed that CNBP mutants lacking the RGG region act as dominant negatives in vivo 
[194]; these mutants could be useful for studying specific CNBP molecular functions in 
the future. 
The phosphorylation of eIF2α, and subsequent reduction in levels of the eIF2-
GTP/Meti-tRNA pre-initiation complex, has been proposed to enhance ribosomal bypass 
of BACE1 uORFs through decreased reinitiation events [170]. Thus, a higher proportion 
of small ribosomal subunits may reach the authentic BACE1 start codon to initiate 
translation. It may be that CNBP plays a role in this hypothesis by enhancing ribosomal 
read-through of uORFs upon eIF2α-P (Fig 6.2). This could occur after cap-dependent or 
cap-independent initiation. In this model, CNBP may interact directly with the small 
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ribosomal subunit to enhance scan-through of uORFs; this may be mediated by CNBP’s 
RNA chaperone activity which could remove impeding secondary structures. 
Alternatively, CNBP may simply act as a tether, keeping the 40s subunit associated with 
the mRNA longer. The evidence that CNBP associates with both RNA and proteins of 
the ribosomal subunits strengthens this proposed model. Finally, increased CNBP levels 
may mask sites near the uAUGs, allowing for more efficient ribosomal scan-through. In 
these hypothetical models, CNBP may be critically important for scanning and 
reinitiation events of BACE1 and other targets with uORFs. Much more work will be 
needed to clarify the link between CNBP and eIF2α-P during cellular stress and whether 
they are involved in the same mechanism of translational regulation or separate 
mechanisms altogether. 
  
Additional CNBP Molecular Targets – RNA and Protein     
A secondary aim of this project was to discover other mRNAs that may be 
functional targets of CNBP, either in muscle or in brain, with implications for 
involvement in myotonic dystrophy type 2 (DM2) or neurodegenerative disease, 
respectively. RNA purification followed by high-throughput sequencing analysis (RNA-
Seq) is the most current and advanced method for analyzing a specific pool of RNAs 
(reviewed in [334]). RNA-Seq has been used to identify targets of other RNA binding 
proteins including TDP-43 [284, 335] and polycomb proteins [336]. RNA-Seq allows for 
the identification of individual RNA (mRNAs and non-coding RNAs) targets as well as 
providing specific sequence information which may shed light on consensus binding 
regions [337]. Our results indicate that RNA immunoprecipitation of CNBP may be 
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feasible for carrying out a RNA-Seq analysis if the experimental conditions can be 
further optimized. Ultimately, we anticipate that CNBP should pull down a large pool of 
mRNA targets given its broad binding site requirements; any interesting targets would 
need to be validated by expression studies.  
There has been one published report of identified targets and a consensus binding 
site for the yeast protein Gis2p, an ortholog of human CNBP, using tandem affinity 
purification followed by DNA microarray analysis (RIP-Chip) [206]. This study 
identified hundreds of mRNAs with stretches of G(A/U)(A/U) trinucleotide repeats 
associated with Gis2p that included ribosomal RNA processing factors and muscle-
related genes. We looked for this consensus sequence in the BACE1 5’ UTR but were 
unable to find a match. It is important to note that Gis2p lacks the RGG domain between 
the first and second zinc fingers, which plays a major role in RNA binding [194]. 
Therefore, CNBP likely recognizes an overlapping set of targets with Gis2p, but possibly 
many more.  
We selectively evaluated several transcripts as potential binding targets of CNBP 
using crosslinked RIP followed by real-time quantitative PCR. Along with several 
positive controls (RPS17, ODC1) and BACE1, we identified β-Actin and BIN1 mRNAs 
as potential targets of CNBP. Like BACE1, neither β-Actin nor BIN1 are known to 
harbor an IRES or 5’ TOP structure in their 5’ UTRs, and indicate that CNBP’s 
recognition of mRNA targets may be much broader than initially thought. BIN1 is an 
especially interesting target given that it has been linked to both AD [277] and DM2 
[279]. Preliminary experiments in our lab have indicated that BIN1 expression and/or 
splicing may be altered in AD (CJH, unpublished data). Future experiments should be 
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carried out to determine if CNBP affects BIN1 expression. In addition to RNA 
immunoprecipitation strategies, our lab is currently trying to identify CNBP targets 
through targeted overexpression or knockdown of CNBP in vivo in mouse brain and/or 
muscle using proteomics and RNA-Seq strategies. 
Along with identifying mRNA targets of CNBP, it will be critical to learn more 
about proteins that interact with CNBP in order to determine whether it primarily 
functions as part of a larger RNP complex, as suspected. Thus far, there have been few 
studies that have identified possible CNBP-interacting proteins. A large-scale study of 
protein-protein interactions in human cells using a mass spectrometry-based approach 
identified some 40 proteins that interact with CNBP [209]. Among them were numerous 
ribosomal proteins (both small and large subunit), heterogeneous ribonucleoproteins 
(hnRNP C, A3, R, UL1), other RNA binding proteins (PURA, SYNCRIP), and various 
factors involved in RNA processing. The Saccharomyces Genome Database (SGD), 
which compiles data from large-scale yeast interactome analyses, suggests that Gis2p 
interacts with at least 28 other RNA binding proteins including translation initiation 
factors (Ygr054p; ortholog of eIF2A), cytoplasmic ATP-dependent RNA helicases 
(Dbp1, Dbp2, and Dhh1), and Lsm1 and Lsm6, which associate with the Pat1 decapping 
enzyme and the Xrn1 exoribonuclease involved in mRNA degradation [206]. A more 
focused study using tandem affinity purification identified CNBP and the previously 
characterized ITAF, PCBP2, as direct, functional binding partners of the ODC1 IRES 
sequence [204]. This study also identified many other ITAFs and RNA binding proteins 
as possible CNBP-interacting proteins, but none have been validated. Taken together, 
these studies suggest that CNBP is likely involved in various layers of post-
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transcriptional regulation and may function in a complex combinatorial fashion with 
numerous other proteins.  
 
Dual Roles of CNBP Translational Regulation 
 CNBP appears to control translation of a diverse set of mRNAs. These targets are 
involved in global protein translation (5’ TOP-containing mRNAs) as well as specialized 
translation (IRES-containing mRNAs). In our studies, we did not observe a consistent 
striking alteration in total protein levels when CNBP was overexpressed or knocked 
down (CJH, unpublished data). In general, overexpression slightly reduced total protein 
levels and knockdown slightly increased total protein levels. A common theme amongst 
CNBP targets may be stress-induced regulation. Interestingly, amino acid starvation 
causes sequestration of 5’ TOP mRNAs to stress granules [338], where translation is 
arrested at the initiation step, keeping global protein synthesis low [339]. Conversely, 
many IRES-containing mRNAs are preferentially translated during times of cellular 
stress (reviewed in [340]). Based on these data, it is tempting to speculate that during 
normal cellular conditions, CNBP mediates cap-dependent translation of one set of RNAs 
(e.g. 5’ TOP mRNAs), but when cells become stressed, CNBP shifts to a primary role in 
cap-independent translation of a separate set of mRNAs (IRES-containing). Future 
studies focused on these two sets of mRNAs may confirm this hypothesis. 
 
CNBP Structure and Function 
There is still much to be learned about the CNBP protein itself. For example, what 
post-translational modifications does it undergo? Is it phosphorylated, and if so, what are 
the functional consequences? What is the significance of CNBP binding to RNA as a 
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dimer, as has been suggested [215], and do preformed pools of CNBP monomer and 
dimer exist? What are the important domains that mediate protein-protein interactions? 
Also, does CNBP get proteolytically cleaved at the PEST site in human tissues as 
described for other species, and how would this affect CNBP’s cellular functions? 
Answering these questions will help shape our understanding of how CNBP functions in 
the cell and how it may contribute to human diseases such as myotonic dystrophy type 2 
or Alzheimer’s disease. 
 
Altered CNBP Expression Levels as a Contributing Factor to Disease 
CNBP has already been implicated in DM2 [178], and the results from our studies 
now suggest that CNBP may be involved in the development of sporadic AD as well. 
Interestingly, these two diseases may be linked to the expression level of CNBP, albeit in 
opposite directions. In DM2, haploinsufficiency of CNBP protein may play a role in the 
phenotype of the disease [182]. Our CNBP knockdown studies indicate that CNBP may 
be required at a threshold concentration for target transcript stability, as was indicated 
with BACE1. Further experiments are needed to see if CNBP knockdown decreases 
BACE1 mRNA half-life, which would help confirm a role in target transcript stability. 
Currently, our lab is working on expressing CNBP shRNA constructs in mouse 
quadriceps and gastrocnemius muscles using a lentiviral delivery system with the goal of 
discovering potential CNBP targets.   
The results from this study indicate that an overexpression of CNBP may have 
pathogenic consequences as well. CNBP likely regulates the expression of many proteins 
and has been implicated in the control of cell proliferation and cell death (reviewed in 
145 
 
[224]). Thus, sustained elevated levels of CNBP, as we predict occurs in the progression 
of AD, could have dire consequences on global protein expression. Determining what 
proteins are altered upon CNBP overexpression will be critical in determining the extent 
to which CNBP may play a role in disease processes. These results, as a whole, imply 
that drastic perturbations in CNBP protein from normal levels may have pathogenic 
consequences for both DM2 (decreased levels) and AD (increased levels). 
 
CNBP Mouse Model 
 We have clearly showed that CNBP affects BACE1 translation and this may have 
implications for sporadic AD. However, a more definitive way to link CNBP to a causal 
role in the development of AD would be to carry out experiments using a transgenic 
mouse model. For example, crossing a mouse line that overexpresses CNBP specifically 
in neurons with a well characterized mouse model of AD (for instance, the Tg2576 
mouse model, which expresses the APP∆NL mutation [341]) would allow us to 
determine if CNBP overproduction increases Aβ production and deposition in vivo, 
presumably through increased BACE1 expression, but possibly through other unknown 
mechanisms as well. There are no mouse models that overexpress CNBP at this time; 
however, our lab has tried to overexpress CNBP in the brain of newborn mice using 
various viral delivery systems. Thus far, we have been unsuccessful in achieving CNBP 
overexpression in vivo (RLW, unpublished data); it may be that CNBP expression is 
tightly regulated at this stage since it has such critical functions in development. Thus, an 
inducible expression model may be necessary to overexpress CNBP at later ages. 
 
Therapeutic Implications 
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 We observed a moderate increase in CNBP protein levels in the progression of 
AD which may be linked to pathogenic consequences. Our results suggest that targeted 
knockdown of CNBP would be needed as a therapy for AD; however, reduction of CNBP 
by as little as 50% results in numerous problems associated with a DM2 phenotype [182]. 
Therefore the best strategy would be to employ a partial knockdown of CNBP, with an 
aim in returning protein concentrations to near basal levels. We have observed 20-30% 
knockdown of CNBP levels in cell culture using a lentiviral shRNA construct against 
CNBP (MPM, unpublished data); this may be sufficient to test as a therapy in vivo. We 
still need to learn more about CNBP’s targets and its molecular functions in the cell in 
order to determine if it could be a suitable therapeutic target.  
Another possible therapeutic intervention would be to block the interaction 
between CNBP and BACE1 mRNA. Of course, this would require the identification of a 
specific region or sequence that CNBP binds to, such as an IRES element, if one exists. 
Specifically, this strategy could prevent cap-independent translation of BACE1 (but 
possibly many other stress response proteins as well). Translational regulation is already 
a major therapeutic target in cancer [342, 343] and inhibition of cap-independent 
translation may be a novel avenue for the treatment or prevention of AD. In support of 
this, there is evidence that the predominant Alzheimer’s disease drug, memantine, may 
act as an inhibitor of IRES-mediated translation initiation [344] which could help block 
the expression of APP, tau, and potentially BACE1. At this time, we are still a ways off 
from determining if CNBP and/or its molecular pathways could be suitable therapeutic 
targets for treatment of AD, but our results indicate that it is a an intriguing possibility. 
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Figure 6.1 Model of CNBP’s Proposed Role in AD. In this generalized model, various 
AD risk factors such as age, diet and metabolism, ApoE4 genotype, or traumatic brain 
injury lead to gradual impairment in brain energy utilization beginning years or decades 
before onset of disease. Over time, reduced energy availability in the brain activates the 
stress response pathway in cells which upregulates CNBP expression and also causes the 
phosphorylation of eIF2α. This combination of events might work in tandem to enhance 
BACE1 translation though an unresolved mechanism. A transient increase in stress 
response proteins, such as BACE1, likely has neuroprotective effects. However, if 
stressed conditions persist, BACE1 levels may become chronically elevated. Over many 
years during the progression to AD, even a small increase in BACE1 could have 
significant impact on amyloid production. Increased Aβ levels may contribute to a 
feedback mechanism in which cells are further stressed and more BACE1 is generated. 
These events, coupled with impairments in amyloid clearance and degradation, lead to 
enhanced Aβ deposition and plaque formation in the brain. At some point, a threshold 
level of Aβ accumulation is reached that initiates downstream pathology including tau 
hyperphosphorylation, tangle formation, and neuronal loss, eventually leading to sporadic 
Alzheimer’s disease. 
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Figure 6.2 Possible mechanisms of how CNBP regulates BACE1 translation. (A) 
Under normal cellular conditions, BACE1 translation is very inefficient due to a high 
degree of secondary structure (red loop; for simplicity) and three uORFs (blue numbered 
boxes) in the BACE1 5’ UTR which impede the ribosome (pink ovals) from reaching the 
authentic BACE1 start codon. Since eIF2α is largely unphosphorylated, multiple rounds 
of translation reinitiation and dissociation may occur at uORFs. Low or basal levels of 
CNBP may transiently or weakly interact with the BACE1 5’ UTR (for simplicity, no 
CNBP is shown bound) to influence transcript stability, but BACE1 translation is 
unaffected. (B) During cellular stress, CNBP levels (yellow ovals; shown bound as a 
dimer) are elevated and BACE1 translation is enhanced through several possible 
mechanisms. CNBP may recruit ribosomes directly near a start codon (uAUG or 
authentic), possibly through an undiscovered IRES element, to activate cap-independent 
translation. Since eIF2α-P levels are high, it is believed that enhanced ribosomal scan-
through of the 5’ UTR occurs due to a decrease in reinitiation events at uAUGs. CNBP 
may play a role in this by tethering the small ribosomal subunit (single pink oval) to the 
mRNA after termination of a uORF, keeping it associated with the transcript longer as it 
scans downstream. Additionally, CNBP may play a role in masking upstream uAUGs. In 
all scenarios considered, CNBP might use its RNA chaperone activity to alter local 
secondary structures which may be needed for direct recruitment of the ribosome or more 
efficient ribosomal scanning. The green circle indicates the 5’ cap structure. 
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APPENDIX ONE: List of Abbreviations 
 
5’ TOP 5’ terminal oligopyrimidine 
AAV Adeno-associated virus 
Aβ Amyloid-beta 
AD Alzheimer’s disease 
ADAM A disintegrin and metalloprotease 
APLP APP-like proteins 
APP Amyloid precursor protein 
APPswe APP Swedish mutation (∆NL) 
AICD APP intracellular domain 
APOE Apolipoprotein E 
ATP Adenosine triphosphate 
BACE(1/2) β-site APP cleaving enzyme (1/2) 
BCA Bicinchoninic acid 
BIN1 Bridging integrator 1 
BME β-mercaptoethanol 
BSA Bovine serum albumin 
cAMP Cyclic adenosine monophosphate 
CB Cerebellum 
CD Circular dichroism 
cDNA Complementary DNA 
CNBP Cellular nucleic acid binding protein 
CNS Central nervous system 
CSF Cerebrospinal fluid 
CTF(α/β) C-terminal fragment 
DIV Days in vitro 
DM2 Myotonic dystrophy type 2 
DMEM Dubelcco’s modified eagle medium 
DNA Deoxyribonucleic acid 
DR6 Death receptor 6 
DTT Dithiolthreitol 
eEF(1A/2) Eukaryotic elongation factor (1A/2) 
eIF2α Eukaryotic initiation factor 2 alpha 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
EMSA Electrophoretic mobility shift assay 
ER Endoplasmic reticulum 
FAD Familial Alzheimer’s disease 
FBS Fetal bovine serum 
FMRP Fragile-X mental retardation protein 
FTD Frontotemporal dementia 
G4 G-quadruplex 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
Gis2p GIg suppressor 2 protein 
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APPENDIX ONE continued 
GFP Green fluorescent protein 
GGA Golgi-localized γ-ear containing ARF 
GST Glutathione-S-transferase 
H2O2 Hydrogen peroxide 
HIV Human immunodeficiency virus 
hnRNP Heterogeneous nuclear ribonucleoprotein 
HRP Horseradish peroxidase 
IgG Immunoglobulin G 
IP Immunoprecipitation 
IPTG Isopropylthio-β-galactoside 
IRES Internal ribosome entry site 
ITAF IRES trans-acting factor 
IVTT In vitro transcription / translation 
LRP Low density lipoprotein receptor-related protein 
MAPT Microtubule associate protein tau 
MEM Minimum essential medium 
MCI Mild cognitive impairment 
MES 2-(N-morpholino)ethanesulfonic acid 
MMSE Mini-mental state examination 
MOI Multiplicity of infection 
MOPS 3-(N-morpholino)propanesulfonic acid 
mRNA Messenger RNA 
Nav-β2 β-subunits of voltage-gated sodium channels 
NB Neurobasal 
NC Nucleocapsid 
NRG Neuregulin 
NSAID Non-steroidal anti-inflammatory 
ODC1 Ornithine decarboxylase 
ORF Open reading frame 
PABP Poly-A binding protein 
PAGE Polyacrylamide gel electrophoresis 
PBS(T) Phosphate buffered saline (+ Tween) 
PCAD Preclinical AD 
PCR Polymerase chain reaction 
PEI Polyethyleneimine 
PEST Pro, Glu, Ser or Thr-enriched 
PKA Protein kinase A 
PLB Polysome lysis buffer 
PMI Postmortem interval 
PS(1/2) Presenilin (1/2) 
PSGL-I P-selectin glycoprotein ligand-I 
PVDF Polyvinylidene fluoride 
qPCR Quantitative real-time PCR 
RGG box Glycine/arginine rich region 
RIP RNA immunoprecipitation 
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APPENDIX ONE continued 
RIPA Radioimmunoprecipitation assay 
RNA Ribonucleic acid 
RNA-Seq RNA-high throughput sequencing  
RNP Ribonucleoprotein 
ROS Reactive oxygen species 
RPS17 Human small ribosomal subunit 17 
Rpl32 Rodent large ribosomal subunit 32 
RTN Reticulon 
RT-PCR Reverse transcription PCR 
sAPP(α/β) Soluble APP (α/β) 
SDS Sodium dodecyl sulfate 
seAP Secreted alkaline phosphatase 
SEM Standard error on the mean 
SMTG Superior middle temporal gyri 
ssDNA Single-stranded DNA 
ST6Gal I Alpha-2,6-sialyltransferase 
TACE TNF-alpha converting enzyme 
TBI Traumatic brain injury 
TBS(T) Tris-buffered saline (+Tween) 
TDP-43 TAR-DNA binding protein 43 
TGN Trans-Golgi network 
TPT1 Tumor protein, translationally controlled 1 
uAUG Upstream AUG 
uORF Upstream open reading frame 
UTP Uridine triphosphate 
UTR Untranslated region 
UV Ultraviolet 
VHS domain Vps-27, Hrs and STAM domain 
WT Wild-type 
ZNF9 Zinc-finger protein 9 
 
Symbols 
Alpha, α 
Beta, β 
Gamma, γ 
Kappa, κ 
Mu, μ 
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APPENDIX TWO: PCR Primers 
Primers Used for General qPCR Experiments 
Gene Symbol Primer Identifier Sequence (5’ to 3’) 
β-site APP 
Cleaving Enzyme 
1 
BACE1 
(Human) 
BACE1 Forward TATCATGGAGGGCTTCTACGTTG 
BACE1 Reverse GTCCTGAACTCATCGTGCACAT 
β-site APP 
Cleaving Enzyme 
2 
BACE2 
(Human) 
BACE2 Forward 
(3’ UTR) 
GCAACCATGAACTCAGCTATTAAGAA 
BACE2 Reverse 
(3’ UTR) 
AGAAAGCGCCACCATCGA 
Cellular Nucleic 
Acid Binding 
Protein 
CNBP 
(Human) 
CNBP Forward TCCTTCATGCAGGGTTCTGTCAGT 
CNBP Reverse GACAAGGTTGGAATGTGCACAGCA 
β-Actin 
β-ACTIN 
(Human) 
ACTIN Forward ACCAACTGGGACGACATGGAGAAA 
ACTIN Reverse TAGCACAGCCTGGATAGCAACGTA 
Glyceraldehyde-
3-Phosphate 
Dehydrogenase 
GAPDH 
(Human) 
GAPDH Forward ACCACAGTCCATGCCATCAC 
GAPDH Reverse TCCACCACCCTGTTGCTGTA 
Tumor Protein 
Translationally 
Controlled 1 
TPT1 
(Human) 
TPT1 Forward GATCGCGGAACGGGTTGT 
TPT1 Reverse TTCAGCGGAGGCATTTCC 
 
Primers Used for RIP qPCR Experiments 
Gene Symbol Primer Identifier Sequence (5’ to 3’) 
β-Actin 
β-ACTIN 
(Human) 
ACTIN Forward ACCAACTGGGACGACATGGAGAAA 
ACTIN Reverse TAGCACAGCCTGGATAGCAACGTA 
Glyceraldehyde-3-
Phosphate 
Dehydrogenase 
GAPDH 
(Human) 
GAPDH Forward ACCACAGTCCATGCCATCAC 
GAPDH Reverse TCCACCACCCTGTTGCTGTA 
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APPENDIX TWO continued 
Ribosomal Protein 
S17 
RPS17 
(Human) 
RPS17 Forward ATGAAGCGAATTCAGAGAGGCCCA 
RPS17 Reverse AGTGACCTGAAGGTTGGACAGACT 
Amyloid β-
Precursor Protein 
APP 
(Human) 
APP Forward (Exon 3) AACCAGTGACCATCCAGAAC 
APP Reverse (Exon 4) ACTTGTCAGGAACGAGAAGG 
Microtubule- 
Associated Protein 
Tau 
MAPT 
(Human) 
MAPT Forward 
(Isoform 6) 
ATTACTGCCAACAGTTTCGGCTGC 
MAPT Reverse 
(Isoform 6) 
TAAGAAGGCCCATGGTGCTGAAGA 
Ornithine 
Decarboxylase 1 
ODC1 
(Human) 
ODC1 Forward CTGCTTGATATTGGCGGTGGCTTT 
ODC1 Reverse ATGCAACATAGTATCTGCCGGGCT 
β-site APP 
Cleaving Enzyme 
1 
BACE1 
(Human) 
BACE1 Forward TGCAGTCAAATCCATCAAGGCAGC 
BACE1 Reverse TGATGCGGAAGGACTGGTTGGTAA 
β-site APP 
Cleaving Enzyme 
2 
BACE2 
(Human) 
BACE2 Forward  
GCAACCATGAACTCAGCTATTAAGA
A 
BACE2 Reverse AGAAAGCGCCACCATCGA 
Cellular Nucleic 
Acid Binding 
Protein 
CNBP 
(Human) 
CNBP Forward TCCTTCATGCAGGGTTCTGTCAGT 
CNBP Reverse GACAAGGTTGGAATGTGCACAGCA 
Bridging Integrator 
1 
BIN1 
(Human) 
BIN1 Forward 
(Isoform 1) 
AGAGAACAACGACCTGCTGTGGAT 
BIN1 Reverse 
(Isoform 1) 
TTGGCAATGCGTGACTTGATGTCG 
β-Actin 
β-Actin 
(mouse) 
Mouse β-actin 
Forward 
TTGCTGACAGGATGCAGAAGGAGA 
Mouse β-Actin 
Reverse 
ACTCCTGCTTGCTGATCCACATCT 
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APPENDIX TWO continued 
Ribosomal Protein 
L32 
rpl32 
(mouse) 
Mouse rpl32 Forward TCTGGTGAAGCCCAAGATCGTCAA 
Mouse rpl32 Reverse GGGTTTCCGCCAGTTTCGCTTAAT 
β-site APP 
Cleaving Enzyme 
1 
Bace1 
(mouse) 
Mouse Bace1 Forward ATGTTGCCACTCTGCCTCATGGTA 
Mouse Bace1 Reverse TGAGCAGGGAGATGTCATCAGCAA 
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